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ABSTRACT 
 
Deirdre K. Tucker: Morphological, cellular, and molecular effects of bisphenol A (BPA) and 
bisphenol alternatives in the mouse mammary gland 
(Under the direction of Suzanne E. Fenton) 
 
 
 Bisphenol A (BPA) is an industrial chemical used in manufacturing of epoxy resins and 
polycarbonate plastics that are in many consumer products, including canned foods, plastic 
bottles, and water supply pipes, thus increasing human exposure. The effects of early life 
exposure to BPA have been extensively documented in several tissues of multiple species. 
Animal studies have been critical in identifying morphological and transcriptional changes in the 
mammary gland, at human relevant BPA exposures (≤0.05 µg/kg bw/d). These studies have 
prompted increasing public concerns surrounding the use of BPA in consumer products and have 
warranted the implementation of alternative analogues, including the fluorinated and sulfonated 
derivatives, BPAF and BPS. Estrogenicity screenings of these analogues have revealed either 
enhanced or comparable properties to BPA, indicating their endocrine potential which may 
impact the mammary gland. This research investigates the potential effects of early life exposure 
to the bisphenol analogues, BPAF, BPS, and BPA on pubertal development and adult mammary 
gland alterations, as well as cellular and molecular pathways that are associated with these 
changes.  
 Disposition studies were performed in pregnant CD-1 dams exposed once to BPA (50 
mg/kg), BPAF (5 mg/kg), or BPS (5 mg/kg) to confirm transplacental transfer and to determine 
serum and urinary pharmacokinetics. This information was used to establish a proper dosing  
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schedule for future developmental exposures. Dams had similar serum, urinary and fecal half-
lives that were all ≤ 8 hr for all analogues. Urinary recovery was greatest for BPS whereas BPAF 
recovery was greater in the feces. All chemicals were confirmed to cross the placenta. Pregnant 
mice were then exposed to BPA (0.5-50 mg/kg) or BPAF and BPS (0.05-5 mg/kg) during the 
fetal period when rudimentary mammary placodes are forming (GD 10-17). Pubertal mammary 
glands from offspring exposed to every chemical exhibited accelerated development that 
included increased terminal end buds, branching density and longitudinal growth. The incidence 
of inflammation and proliferative epithelial lesions significantly increased in adult glands and 
produced adenocarcinomas at less than 12 mos. in chemically treated groups, with the highest 
occurrence in BPAF 5 mg/kg and BPS 0.5 mg/kg. Mammary transplants from digested FACS 
sorted mammary glands (PND 19-56) prenatally exposed to these two chemicals/concentrations 
revealed that neither BPAF nor BPS increased mammary repopulating unit frequency, changed 
expression of stem cell maintenance and differentiation genes, or altered total epithelial cell 
counts from pubertal mammary glands even though morphological changes at these time-points 
suggested that they would. Genome-wide analysis and RT-PCR validation of RNA from pubertal 
mammary glands revealed BPAF altered immune pathways, whereas BPS altered circadian 
rhythm and mitochondrial dysfunction pathways. Many gene changes occurred during early 
puberty (PND 20) and others continued into late puberty (PND 55). Neither chemical altered 
genes associated with apoptosis or from the nuclear receptor estrogen family except Errg 
(BPAF), but they did cause changes in Evi5 and Tsc22d1, two genes that are influential in 
epithelial cancers and adenocarcinomas. Together these data suggest that prenatal exposure to 
BPAF and BPS can morphologically alter the pubertal mammary gland in ways that persist into 
adulthood and encourage neoplasia formation. 
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CHAPTER 1 
Introduction 
BACKGROUND 
 Breast cancer remains the most commonly diagnosed cancer amongst females in the 
United States and is estimated to affect 1 in 8 women over the course of their lifetime [1]. As a 
result of better screening and detection methods and better targeted therapies, the number of 
deaths attributed to this disease has significantly reduced. However, the number of breast cancer 
diagnoses remains the same or is increasing in premenopausal women [2]. Heritable risks 
account for approximately 15% of breast cancer cases, whereas the remaining cases are 
associated with risk factors that cannot be altered, such as sex, age, race, age at menarche and 
menopause and breast density as well as factors that may be controlled. These can include 
lifestyle and environmental factors that include but are not limited to parity, physical activity or 
the use of contraceptives [2]. Extensive research in rodents has shown that environmental 
chemicals can induce tumors in the mammary gland, but proving causation in human populations 
is difficult and only a small handful of examples exist (i.e. dioxin, DDT, DES and nuclear 
radiation) [3-7]. There is a need for understanding how chemicals modify mammary gland 
development and risk for later disease so that prevention of breast cancer may be increased 
through improved risk assessment on chemical classes and regulatory steps that reduce 
environmental exposures. Understanding the chemical classes that may modify breast cancer risk 
will also increase public awareness and lead to modified lifestyle choices, especially in the most 
susceptible populations. 
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Mammary gland growth occurs at a rate similar to other organs and tissues in early life. 
Once puberty begins, the gland undergoes exponential growth that includes increased terminal 
end buds (TEBs), ductal elongation and lateral branching. The TEBs contain highly mitotic cells 
that are vulnerable to chemical insults including endocrine disruptors. Endocrine disruptors 
(EDs) are chemicals that can alter hormonal homeostasis to produce adverse effects on 
development, metabolism, behavior, or reproduction. Rodent studies investigating various EDs 
and their effects on the mammary gland during critical windows of exposure (i.e. in utero, 
neonatally or perinatally) demonstrated their ability to alter normal tissue development and the 
epigenome and transcriptome that are responsible for mammary gland patterning [8, 9]. During 
each stage of development, the mammary gland relies on signaling from multiple hormones 
(Figure 1-1), therefore, it may be at an increased risk for altered growth and function following 
ED exposure, especially to those EDs whose mechanisms are facilitated through the estrogen 
receptor (ER) or happen during critical periods of development. The ER is abundant throughout 
the gland (i.e. epithelial and mesenchymal cells after weaning and mesenchymal cells in 
fetus/newborn) and can be directly and indirectly responsible for cellular proliferation in the 
gland as well as tumor promotion [10-12]. 
BPA is an established ED that is used in the production of polycarbonates and epoxy 
resins. Under normal and elevated temperatures this chemical has been shown to leach into food 
and beverage containers.  Capable of binding to ERα, BPA is considered a weak estrogen in 
comparison to estradiol, but in several instances has been shown to elicit adverse effects on the 
developing mammary gland. Defining the mechanisms involved in these changes has not been an 
easy task, and the emergence of other bisphenol replacements that are structurally and 
estrogenically similar to BPA, such as the fluorinated and sulfated derivatives Bisphenol AF 
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(BPAF) and Bisphenol S (BPS), adds to this difficulty. Therefore, the overarching goal of this 
research is to evaluate the effects of BPA, BPAF, and BPS on the developing mammary gland 
and investigate potential modes of action for observed changes to determine how they may relate 
to human health. A detailed literature review on the mammary gland, BPA, BPAF and BPS 
follows and will provide the necessary background information to gain a better understanding of 
why this project was undertaken.  
 
Life Stages of Normal Mammary Gland Development 
Mice  
Mammary gland morphogenesis is a unique and intricate process that requires extensive 
crosstalk between endocrine, paracrine, autocrine, and cellular networks. There are many 
documented similarities between human and rodent mammary development, however, due to the 
limitations of acquiring normal tissues from humans, similarity of some of the genes and 
pathways have yet to be determined. During embryogenesis in the mouse, rudimentary placodes 
arise from the ectoderm. Maternal hormones and epithelial-mesenchymal crosstalk then promote 
the formation of a primary ductal tree that is present before birth [13]. Following birth, the gland 
grows isometrically with the body until puberty when the hypothalamic-pituitary-gonadal (HPG) 
axis becomes activated. Both estrogen and growth hormone (GH) are released and signal to 
receptors located on epithelial and/or stromal cells. Binding of estrogen to the ER-α in the fetal 
mammary stroma induces hepatocyte growth factor (HGF), which is required for epithelial 
branching [14]. Secretion of GH from the pituitary gland stimulates insulin growth factor 1 
(IGF1) production within the mammary stroma [15]. As a result a bi-layered duct forms, 
comprised of an inner luminal compartment and an outer monolayer of cap cells that eventually 
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develops into the myoepithelial layer [16]. At the time of birth, the mammary glands consist of 
rudimentary epithelial stalks. Growth remains constant with development until puberty.   
During puberty, highly proliferative structures known as terminal end buds (TEBs) are 
prominent. The TEBs are tear-drop shaped structures located at the end of the extending ducts of 
the gland, and contain 4-6 layers of cuboidal epithelial cells, and cap cells on the basal surface, 
just below the basal lamina [17]. Cap cells exhibit poor apical-basal polarity, are incapable of 
forming cell junctions, and do not contain a highly organized cytoskeletal element [17]. These 
cells are thought to have pluripotent characteristics and will form into both luminal and 
myoepithelial compartments. Evidence suggests that TEBs are packed with luminal cells that 
undergo apoptosis to create the lumen space [18]. As lumen are being created, ductal elongation 
is also taking place as a result of end bud pressure through the stromal compartment [19]. As 
new cells are added to the TEB, the extracellular matrix (ECM) begins to constrict which allows 
for elongation. Matrix metalloproteinase 14 (MMP14) is particularly integral in this process and 
was elevated in the cells surrounding the TEBs [20]. While collagen has been shown to play an 
essential role in tubulogenesis, it can also bind to the ECM to help in creating mammary cell 
shape. The combination of fibroblast growth factor (FGF) and ECM remodeling by MMP2 and 
MMP3 causes TEBs to bifurcate, leading to epithelial branching [16, 21]. ECM remodeling also 
promotes angiogenesis and increased vascular endothelial growth factor (VEGF) expression 
during puberty. Adipocytes express an estrogen response element in their VEGF promoter that 
encourages communication between endothelial cells, epithelial cells, and adipocytes [22]. 
Binding of estrogen to ERα in the epithelium also induces amphiregulin (AREG), which 
becomes uncleaved from sheddase ADAM17. Uncleaved AREG then signals back to stromal 
cells by binding to the epidermal growth factor receptor (EGFR) to induce ductal branching [23]. 
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Lateral duct branching may also be inhibited by stromal TGF-β1 that in turn inhibits the activity 
of HGF [24].  
Similar to puberty, pregnancy is governed by many of the same endocrine and paracrine 
factors. Early in pregnancy secondary and tertiary branching are increased to promote alveolar 
development.  During late pregnancy, prolactin, and progesterone work in concert to prepare the 
gland for lactation by promoting differentiation of alveoli, the structures responsible for 
synthesizing and secreting milk. Pathways downstream of progesterone signaling have 
implicated receptor activator of NFκB1 (RANK) and receptor activator of NFκB1 ligand 
(RANKL) in alveologenesis. Mammary involution is the final phase of lactation and occurs 
when milk-producing epithelial cells undergo apoptosis to return the gland to a simple ductal 
structure. Involution occurs in two distinct phases. In the first phase, apoptosis is triggered and 
plasmin helps by disrupting the cell-cell interactions with the ECM.  During the second phase, 
remodeling of the basement membrane, collapse of alveoli, and differentiation of adipocytes 
occurs [25], while plasmin works in concert with MMP3 to disrupt the basal lamina and cause 
premature involution [26].  
 
Humans 
Human breast development begins around the 5th week of gestation, when a 2-4 cell layer 
‘milk streak’ or ‘mammary band’ forms from the thickening of the ectoderm [27, 28]. Involution 
of the milk streak is involved in condensing the bud below the ectoderm into the mesenchyme 
where it will become the nipple primordium.  The formation of early epithelial ducts appears 
shortly after week 12 of gestation. Ultrastructural assessment of the gland in the second trimester 
fetus shows two distinct epithelial populations, central and basal cells, which share a similar 
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morphology to the basal cells in the epidermis, where glycogen accumulation is greatest. Unlike 
the mouse where there is one primary duct that extends from the nipple into 5-10 secondary 
ducts, the human has many lactiferous ducts that will radially extend to form their own separate 
ductal system with surrounding stroma and are separate from neighboring ducts. Between 18-21 
weeks of pregnancy, fetal epithelial outgrowths begin in the mesenchyme and quickly undergo 
formation of lumen that become lined with cuboidal cells. During this time the myoepithelium is 
fully developed. Ultrastructural images revealed epithelial cells in two stages, those that were 
larger and exhibited canonical apical protrusions and a smaller cell that was adjacent to the 
basement lamina, contained few organelles and had clear cytoplasm [29]. The breast epithelium 
is functional at birth, when hormones from the mother may cause secretory activity in the 
newborn.  
Between birth and puberty, the mammary gland grows in proportion to the body. Of the 
few studies that report data from peri-pubertal tissues, the breast was described as having small 
bundles of primary and secondary ducts whose distal end develops into bulbous structures 
analogous to the rodent TEBs. New branches arise from the main ducts and lateral buds from 
these structures eventually evolve into alveolar buds that will form clusters around the duct that 
forms the lobule type 1. This lobule type 1 structure is termed the terminal ductal lobular unit 
(TDLU) [30]. TDLUs were apparent in some but not all tissues, which may be accounted for by 
the specimens stage within pubertal development [31].  However, these bulbous structures are 
also thought to contain an undifferentiated cell population, similar to the TEBs in rodents. Adult 
mammary glands are composed of 80% fibrous tissue in the form of intra- and extra-lobular 
connective tissue, where the fat is pushed to the periphery. Once breast development is complete, 
the TDLUs are hormonally influenced by the menstrual cycle. In the virgin post-pubertal gland 
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Lobule 1-type (Lob1-type) TDLUs are the predominant structures and are analogous to the TEBs 
found in rodents. These structures (in both rodents and humans) are the site at which ductal 
carcinomas arise. Eventually these structures develop into Lob2-type which have more lobules 
per duct [32]. Transition from Lob2 to Lob3 structures occurs over years with the development 
of new alveoli, and if pregnancy is not achieved this may not occur. During pregnancy, ducts 
containing the Lob2 and Lob3 eventually develop secretory acinar cells of Lob4 [31]. Following 
lactation and weaning, glands regress back to predominantly Lob2 structures, while the glands of 
nulliparous women contain more Lob1. When menopause occurs, all women regardless of 
childbearing status will regress back to Lob1 structures. 
 
Mammary Stem and Progenitor Cells 
Identification 
The emergence of improved technologies and differentiating assays has advanced the 
field of mammary biology and the ability to isolate and characterize mammary stem cells 
(MaSC) in mice. The stem cell portion of the mammary gland is thought to play an essential role 
in development, differentiation, maintenance, pregnancy, and even carcinogenesis. Elucidating 
the mechanisms and dynamic changes that occur with these cell populations will be essential in 
understanding their role in normal and altered development. 
The defining characteristics of a stem cell are its ability to self-renew and produce multi-
lineage cell types. Studies performed over 50 years ago transplanted mammary tissue fragments 
into cleared endogenous fat pad, resulting in a gland that was capable of being fully re-
constituted regardless of which portion of epithelium was used [33]. Serial transplants of 
mammary fragments revealed that mammary reconstitution could be achieved up to 4 transplants 
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and in some cases 7-8 successions before reaching senescence [34]. During this same time frame, 
pioneering studies uncovered that the reproductive age or developmental stage that mammary 
tissue was obtained from had little influence on its growth potential when transplanted into 
younger donors [35]. Smith et al. [36] also showed that, regardless of age and developmental 
stage, samples taken from any portion of the mammary gland were able to reconstitute 
outgrowths. Even following primary transplants, reconstituted tissues were able to produce 
secondary outgrowths using as few as a single cell [37]. While transplants remain the gold 
standard for demonstrating multipotency of isolated cells, this was only indirect evidence that a 
stem cell population existed. Similar to stem cells from other tissues, studies have shown MaSCs 
exclude Hoechst dye, retain their DNA label due to asymmetrical divisions, and actively cycle 
and divide [38]; however, early studies failed to isolate pure populations. Together these data 
show that the mammary gland stem cell population likely exists throughout the lifespan of the 
animal.  
More recently, cytokeratin expression analysis revealed that the mouse mammary gland 
expressed lineage markers associated with basal and luminal phenotype during embryonic and 
early postnatal development and that throughout development they either retained these markers 
or switched [39]. Embryonic lineage tracing conducted in 129svXC57Bl/6 mice revealed that as 
early as E15.5 mammary buds co-expressed cytokeratin (CK) 5 and 14, but expression intensity 
often varied. Three days later and into infancy, CK8- positive cells localized in luminal-like cells 
and physically separated from CK14-staining outer layers. However, some CK14-positive cells 
were found in the inner layers co-expressing CK8. CK6 staining, which is thought of as a 
multipotent mammary epithelial progenitor marker due to its presence in the body cells of TEBs, 
was distinct from CK14+ cells and was abundant during late fetal development. By 2 weeks of 
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age, some double-positive CK6/14 cells were found in the inner core of the ductal termini and 
only one week later fewer double stained cells were evident. By weaning, CK6 was localized in 
TEB body cells and CK14 was dramatically decreased. Myoepithelial/basal cells co-expressed 
CK5/CK14 and in most cases CK5 expression was almost exclusively confined to the basal cells 
[39]. 
Other studies have confirmed some of these earlier findings of stage-specific cytokeratin 
expression and have provided information on cell and stage-specific protein expression. During 
placode formation (E11-12), basal markers, K14 and p63, and luminal marker, Gata3, were co-
expressed [40]. By E15, p63 began to localize to the outer developing ducts. Gata3 was also 
expressed in the basal layer in the distal ductal tree and luminal compartment of the nipple region 
following birth. Double positive C14K/CK18 cells were found in the primary ducts close to the 
nipple area, but areas closer to the primary ducts became more distinctly separated. Pulse chase 
studies where CD-1 mice were exposed to 5-ethynyl-2’-deoxyuridine (EdU) between E14-18 
followed by 5-bromo-2’-deoxyuridine (BrdU) treatment at PND 5 revealed that a small subset of 
these double stained cells were mitotically active indicating that a small population of embryonic 
stem cells may also be involved in postnatal mammary gland development. In contrast, CK6 
expression was absent in the mammary gland during all developmental stages in a study 
conducted by another group and CK5 expression was not shown until postnatal day 21 (PND 21) 
[41]. Also, CK14 expression was in the apical sections of the basal layer as early as E13.5; 
however, expression was limited to luminal cells that were very distant from the epidermis 
indicating that these cells are not involved in the epidermal-luminal transition. Ultimately, 
various factors including differences in strain, antibody, and even antibody efficiency may have 
played a role in the discrepancy between protein expressions.  
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Isolation of MaSC 
Prior to 2005, identification and isolation of mammary stem cells was a challenge due to 
insufficient cell markers and cell based assays that were incapable of preventing cell 
differentiation. Early studies using fluorescence activated cell sorting studies (FACS) identified 
stem cell antigen 1 (Sca1) as a potential marker because these epithelial cells showed label 
retaining capabilities, however, contaminating bipotent cells remained an issue [42]. Removal of 
endothelial and hematopoietic cells from freshly dissociated cells revealed that CD24 (heat stable 
antigen) and high expression of either CD29 (β1-integrin) or CD49f (α6-integrin) can form a 
heterodimer and serve as a potential marker of MaSCs. CD24 is also an antigen for cell surface 
glycoproteins. Similarly, CD29 is an integrin involved in cell adhesion and CD49f is a late 
activating antigen involved in cell adhesion and cell surface mediated signaling. CD24high/CD49f 
high or CD24 high/CD29f high labelled cells were able to reconstitute an entire gland during primary 
and successive transplants and were able to undergo complete development during pregnancy 
[43, 44]. However, only small populations of these cells were considered stem cells while all 
others were basal/myoepithelial. Also, epithelial cells enriched in CD24 high/CD49f high were 
positive for CK5 and CK14 while CD24high/CD49f low were found to be more mature and 
differentiated luminal cells. Prater el al. [45] found that enrichment of CD49f and EpCAM helps 
to separate the luminal cells much better from the myoepithelial/basal cells. Further sorting of 
the CD49f/EpCAM luminal population according to Sca1/CD49b status revealed three additional 
distinct luminal populations (Sca1+CD49b+, Sca1-CD49b+, and Sca1+CD49b-) that all have 
unique morphologies and cloning potentials [46]. Only the Sca1+/CD49b+ and Sca1-/CD49b+ 
populations were efficient in colony formation and were ER+. The Sca1+/CD49b+ were also 
observed to have a small proliferation capacity and increased expression of differentiation 
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luminal transcripts that included ER, FoxA1 and Gata3. Most stem cells are ERα- but there is 
evidence to suggest that a small population may be ERα+ and proliferate [47]. Expression of PR 
in mammary cells seems to be restricted to the luminal compartment [48]. Humans and rodents 
alike are constantly exposed to endogenous hormones when they undergo menstruation and an 
estrous cycle. Therefore, it is thought that both estrogen and progesterone elicit their effects on 
ER-/PR- cells through a paracrine mechanism. It is difficult to acquire normal human mammary 
tissue to test for self-renewal via transplants, therefore, in vivo and in vitro methods in mouse 
models have been used to identify potential human mammary markers. Similar to neuronal stem 
cells that form “neurospheres” under non-adherent and serum free conditions, the mammary 
gland has also been shown to produce “mammospheres” under similar conditions in the presence 
of bFGF and EGF. Mammospheres contained highly undifferentiated cells that were capable of 
forming multi-lineage colonies from single cells when grown under conditions containing serum 
[49]. With each successive passage the number of bi-potent progenitor cells increased. Sorting 
according to the surface markers Lin-CD49+EpCAM-/lo or CD10+ showed reconstitution in 
mouse mammary glands when transplanted with fibroblasts [50].  
 
Stem Cell Maintenance and Differentiation 
Similarities among the human and rodent mammary structure and mammary 
stem/progenitor populations have shown that there is great conservation of genes that are 
responsible for these populations [51]. Gene signatures from sorted FVB/N mice were identified 
and compared to the gene signatures from previously reported sorted mammary human 
populations and revealed that once normalization for species was accounted for, the samples 
within each species co-localized into three distinct cell types (luminal, stromal, and stem or basal 
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cells) [51]. When they compared transcriptional activity scores from each mouse subtype gene 
signature to that of the different human cell subtypes it revealed that genes within each subtype 
were highly conserved across species. Approximately 1200 signature mouse genes for all cell 
populations corresponded to their human orthologue, with the MaSC population having the 
highest number of signature genes and best conservation between species. Of these conserved 
genes, an array of upregulated genes included transcription factors (i.e. p63, Egr2 and Sox11), 
cytokeratin’s (CK5, 14, and 16), and genes associated with the Wnt/β-catenin and Notch 
pathways which have been shown to play a role in stem cell maintenance and differentiation [39, 
52, 53]. Luminal progenitor and mature luminal cells were observed to have a lower degree of 
conservation. Luminal progenitor cells expressed Kit, Elf5, and Cxcr4, a gene involved in 
metastasis of breast cancer, and more mature luminal cells expressed ERα, PR, and the RANKL. 
qRT-PCR confirmed these findings [51]. A more recent study detailed the major pathways 
involved in MaSC maintenance and demonstrated that the Wnt pathway, which is involved in 
patterning during development, is required [54]. Signaling of the Wnt pathway leads to 
stabilization and accumulation of β-catenin. β-catenin then translocates into the nucleus binding 
to LEFT/TFC resulting in the transcription of various proliferation genes. MaSC experienced a 
6.4-fold increase when Wnt1 was overexpressed using a MMTV promoter [55]. Conversely, 
decreased Notch signaling in the Cbf-1 knockout mouse and p53-/- mice have resulted in 
increased MaSC activity, where activity was defined as the transplant repopulating frequency 
[56, 57]. The ΔN63 isoform of the transcription factor p63, which is associated with p53, can 
induce Wnt signaling and self-renewal capacity, whereas the ΔT-63 isoform is more involved in 
luminal commitment and the hedgehog pathway[54, 58].  
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The MaSC and Puberty 
 Several of the genes and signaling pathways identified during the discovery of MaSC are 
essential during pubertal mammary gland development, a period of extensive epithelial growth 
[59]. In the mouse, TEBs are prevalent during this period and are highly mitotic. Within the cap 
cells of the TEBs resides a pluripotent stem cell population that is capable of self-renewal and 
differentiation. Since these structures are increased during puberty it is also thought that the 
MaSC and luminal populations are increased and genes involved in these processes are also 
changed to coordinate with the changes in cellular morphology. Exposure to environmental 
toxicants may alter the MaSC and luminal epithelial cells. Advances in this research may provide 
details into the initiation, promotion and progression of cancer thought to be caused by 
environmental exposure to endocrine disrupting chemicals (EDCs). 
 
The MaSC and Pregnancy 
Emerging evidence has suggested that another type of MaSC may contribute to the 
alveolar expansion that occurs during pregnancy. Parity induced mammary epithelial cells (PI-
MEC) are thought to originate from cells that have differentiated during pregnancy. Unlike more 
committed alveolar cells, this population is thought to either de-differentiate or not undergo 
apoptosis during involution or remodeling after lactation [60]. Use of the pregnant double 
transgenic Rosa-lacZ, which uses WAP-Cre and Rosa-lox-Stop-lox-lacZ and X-Gal staining, 
which identifies β-galactosidase activity in cells, revealed that Cre-activation was greatest in 
differentiated alveolar cells immediately following parturition. Whole mount preparations of 
glands undergoing involution had the greatest X-gal staining of positive cells located primarily in 
epithelial structures that were in close proximity to TDLUs. Interestingly, these cells resembled 
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terminal ducts seen in virgin mice; however, cell death did not occur in these cells. Subsequent 
pregnancies revealed that all developing alveoli were X-gal positive, but actively proliferating 
positive cells were restricted to the terminal ducts and developing alveoli. Transplantation of 
transgenic involuted whole tissue into the mammary fat pad of nulliparous recipients (9/22 
glands, n=11 animals) produced outgrowths that were X-gal positive throughout the entire ductal 
tree. Further studies by this group showed following isolation and sorting that within the 12% PI-
MEC population that 98% of GFP PI-MECs were CD24+, and a substantial number of them co-
expressed CD49f. Notably, these cells were also able to form mammospheres in culture, a 
phenomenon that has been shown to occur with multipotent human cells. Isolated GFP+ single 
cells were also able to reconstitute an entire mammary gland [61].  In other studies, luciferase 
expressing MaSCs were transplanted into cleared fat pads of 3-week old mice, followed by 
induction of pregnancy, and the authors reported that MaSC populations expanded 200-fold 
followed by an immediate decrease following parturition. Baseline levels were found to be 
dependent on whether nursing of pups occurred [62]. Progenitor cells have also been shown to 
increase later in pregnancy and during lactation. Mammary cells that were separated according to 
CD29 and CD24 expression have previously revealed that CD29loCD24+ is representative of the 
luminal subtype. When this population was further sorted by CD61 expression, a marker of 
progenitor luminal cells, it was found that at GD 18, CD61+ cells fell by 15-fold but this 
decrease coincided with an increase in alveolar luminal differentiation [55]. 
 
Humans 
Mammary stem cell identification in the human could not be obtained in the same fashion 
as rodents due to the ethical issues that surround human subjects. However, human mammary 
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epithelial cells (HMECs) isolated from mammary tissue from healthy individuals undergoing 
reduction mammoplasties were successfully found to survive, proliferate, and form spheroids in 
non-adhesive medium while most the cells experienced cell death [63]. These cells were termed 
‘mammospheres’ and found to contain 8-fold more bi-lineage progenitor cells than freshly 
cultured human mammary cells. Successive passages produced colonies that could produce all 
three epithelial cell types. Secondary and later spheroid generations were generated from single 
cells. Secondary cells were found to express α6 integrin, CD10, CK5 with moderate expression 
of epithelial specific antigen (ESA) and CK14. Genotyping and transcription confirmation 
studies identified genes within the Wnt/Frizzled pathways, CXCR4 and transcription factors that 
are responsible for cell cycle arrest.  
 
The Mammary Gland and Cancer Stem Cells (CSCs) 
The breast cancer field was profoundly changed when Perou and colleagues used cDNA 
microarrays and hierarchal clustering to classify tumors based on specific cellular gene 
expression [64, 65]. For the first time, tumors were identified into 5 subtypes; ER+ or ER- status 
was determined, then ER+ tumors were described as either luminal subtype A (ER+, CK8/18, 
low grade, slow growing) or luminal B (ER+, CK8/18, low grade, quick growing tumors), and 
ER- tumors were ERBB2+ (increased expression of genes in the ERRB2 amplicon and GRB7) 
or basal-like (increased expression of CK5 and 17, laminin, and fatty acid binding protein 7) or 
normal breast like. More recently, a claudin-low population (low expression of genes involved in 
tight junctions and cell adhesions that include claudin 3, 4, 7, occluding and E-cadherin) was 
identified [66]. Clinical implications were also associated with these subtypes where ER-/PR- or 
ERRB2- tumors had a much poorer prognosis, because hormone therapies were not developed 
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for this specific gene signature. Thus, it has been postulated that these cancer subtypes may 
originate from a less differentiated or stem-like population of cells. Therefore, the level of 
differentiation that a cell undergoes prior to transformation may dictate the tumor type, 
prognosis, and potential therapies. However, because mammary tumors are complex and 
heterogeneous there may be a multitude of cancer stem cell (CSCs) populations. 
MaSCs serve as good candidates for transformation due to their slow division rate, longer 
life spans, and increased potential for acquiring mutations due to long exposures to harmful 
agents. Similar to MaSC, mammary cancer stem cells or tumor initiating cells (TICs) are also 
capable of 1) self-renewal, 2) differentiation, 3) induction of apoptosis, 4) anchorage 
independence and migration and increased transporter activity [49]. Identification of their 
capabilities was illustrated by Al-Hajj et al. [47] when NOD/SCID mice were injected with 
primary or metastatic human tumor cells. Resulting tumors were identified by the cell surface 
markers CD44, CD24, and B38.1. CD44 is a cell surface marker for hyaluronic acid, but may 
also bind other extracellular matrix ligands that regulate cell to cell interactions, adhesion, and 
migration. Serial transplants of each sorted population showed that tumors were formed from 
CD44+CD24-/low populations requiring fewer cells compared to higher concentrations of 
unsorted cells [47]. When xenograft and unpassaged patient tumors were analyzed, they 
consisted of similar populations with diverse tumor cell types, and CD44+CD24-/low signatures. 
Serially passaging of this cell type produced phenotypically heterogeneous tumors that consisted 
of the CD44+CD24-/low and a diverse cell population containing non-tumorigenic cells. Recent 
evidence suggests that CD44+CD24- may also identify a mesenchymal phenotype that does not 
have regenerative capabilities [67]. Similar pathways associated with normal self-
renewal/maintenance and differentiation has been implicated in tumor formation. Other methods, 
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including ALDH activity, showed that ALDH+CD44+CD24- populations were enriched with 
CSCs [68].  
Molecular pathways similar to MaSCs have also been implicated in mammary 
tumorigenesis. Constitutive activation of the Wnt pathway has been shown to increase murine 
mammary tumors, potentially when β-catenin is signaled. MMTV-Wnt mice develop tumors that 
were capable of reconstituting glands similar to the original tumor with as few as 50 cells [69]. 
Other transgenic models including the MMTV-Her2-neu mice have been shown to develop focal 
mammary tumors that are capable of metastasizing after long latency [70]. These tumors were 
later found to overexpress CD49f, CD61, and ESA that were linked to a luminal progenitor cell 
type [71]. When cells were FACS sorted, CD49fhighCD61high cells included a TIC population 
capable of developing “tumorspheres” in culture. Since the MaSCs lacked ER, PR, and ERRB2 
expression, it is thought they are the initiating cells of basal-like cancers. That the MaSCs resides 
within the TEB, a structure often targeted and altered by environmental toxicants and endocrine 
disruptors, suggests that they can induce the formation of other mammary tumor subtypes. The 
next section will explore several endocrine disruptors and the current state of knowledge of their 
effects on the mammary gland. 
 
Bisphenol A (BPA) 
Chemical Properties 
BPA synthesis occurs with the condensation of two phenols and an acetone, in the 
presence of an acidic catalyst. The final product consists of the two phenol with hydroxyl groups 
oriented in the para position and bridged by a carbon with two methyl groups (Figure 1-2) [72]. 
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Uses and Routes of Exposure 
BPA is a high production volume chemical that is ubiquitous within the environment. 
BPA is used in the production of polycarbonate plastics, epoxy resins and as a developer in 
thermal paper. The main source of BPA exposure is through ingestion although transdermal and 
inhalation of contaminated dust are additional routes of exposure. The general population is 
thought to be exposed through contaminated food and beverages by leaching from the 
polycarbonates; BPA has successfully been identified in multiple food and beverage sources [73, 
74]. Biomonitoring studies have detected BPA in urine samples from approximately 90% of the 
general population in the U.S., Canada, and several Asian countries [75-77]. Several studies have 
quantified BPA levels in maternal and cord sera, amniotic fluid, and umbilical cord [78-81]. 
BPA has also been measured in the urine of infants and small children [82, 83]. Fetuses, infants, 
and adolescent children are considered to be the most susceptible populations to the effects of 
BPA because BPA 1) can cross the placenta and influence organogenesis and neurogenesis, 2) 
can elicit more harmful effects in children compared to adults due to lower hepatic uridine-
5’diphoso-gluruonosyltransferases (UGT) activity in children/infants, and 3) has a higher body 
burden and intake rate in children due to the products they drink from or put in their mouths [84]. 
Understanding the pharmacokinetics and disposition in younger populations will assist with 
building more robust physiological based pharmacokinetic models for an accurate risk 
assessment. 
 
Absorption, Distribution, Metabolism, and Excretion 
Following oral ingestion, BPA is readily absorbed and metabolized. In rodents, BPA is 
highly bound to plasma proteins and excreted in the bile, where it may be cleaved back to BPA 
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and reabsorbed from the intestine to the blood. Enterohepatic recirculation is common in rodents 
and can occur several times before being excreted into the feces. This repetitive process can 
prolong the presence of circulating free BPA in the body. Glucuronidation is the main 
metabolizing pathway for BPA in rodents, but urinary excretion is much lower compared to bile 
and fecal excretion. In contrast, humans undergo first pass metabolism; the parent compound is 
metabolized by the liver and gut UGTs, 2B15 and 1A9, and excreted into the urine, with 
approximately 80% chemical clearance in < 24 hr [85, 86]. The exact clearance rate varies based 
on route of administration, sex, dose, and age of exposure. The main metabolites of BPA are 
glucuronides, and a smaller percentage are sulfated conjugates that are metabolized by 
sulfotransferase 1A1 [87]. BPA is also capable of undergoing Phase I metabolism and this has 
been confirmed both in vitro and in vivo where the main metabolites were identified as ortho 
hydroxylated BPA and ortho-quinones [88-91]. There is new evidence to suggest that the BPA 
glucuronide (BPA-G) may not be as harmless as previously considered. Following the treatment 
of 3T3-L1 preadipocytes with BPA-G, lipid accumulation, adipogenesis, and significantly 
increased mRNA and protein levels of adipogenic and lipogenic markers were noted [92]. 
Although BPA-G was not estrogenically active, this finding suggests that adipose containing 
tissues such as the mammary gland may undergo changes that are driven by estrogen 
independent pathways in the stroma and estrogen-dependent mechanisms in the epithelium or 
vice versa.  
 
Toxicity and Mutagenicity 
BPA is not considered to be mutagenic, but there is clear evidence that it is genotoxic and 
aneuploidogenic [93-97]. Several epidemiological, animal, and in vitro studies have identified 
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health effects produced by BPA exposure. BPA affects sexual receptivity, maternal nurturing, 
and social behavior. Developmental exposures to BPA target endocrine regulated tissues such as 
the mammary glands, ovaries, testis, and thyroid, resulting in disorders linked to infertility, 
accelerated or delayed puberty, and altered mammary morphology or impaired lactation [98-
101]. The burgeoning field of obesogens has also highlighted the potential for endocrine 
disruptors like BPA to cause changes in adipogenesis and lipogenesis and has been linked to 
obesity occurrence in the United States [102, 103]. A detailed assessment of BPAs effects on the 
mammary gland stroma will be discussed later in the chapter. Accumulation of fat in the liver 
has also been reported in addition to inducing oxidative stress, hepatic mitochondrial 
dysfunction, and dose dependent increases of liver tumors in adult rats [104-106]. 
 
Estrogenicity and Endocrine Activity 
BPA is capable of binding to ERα (IC50= 1,030 ± 70 nM) and ERβ (IC50= 18.9 ± 0.84 
nM)  at higher concentrations compared to 17β-estradiol (ERα IC50= 0.88 ± 0.04 nM and ERβ 
IC50= 2.17 ± 0.12 nM) , but has a greater affinity for ERRγ compared to the traditional ERs 
[107]. Several studies have also shown BPA to be anti-androgenic [108, 109]. Many studies in 
the field have focused on the ERα classical pathway, but there is mounting evidence suggesting 
that BPA induces effects in a non-genomic and non-nuclear receptor-mediated mechanism [110-
112]. BPA exposures in vitro antagonize T3-induced transcription by displacing T3 from the 
binding pocket [113].  
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Regulatory 
For most of industry, and some government agencies and scientific communities, 
concerns about the safety of BPA in the marketplace has been minimized; it has been accepted 
that since BPA is readily metabolized in humans that the estrogenic effects do not pose a 
substantial risk to human health. As a result, the lowest observed adverse effect level (LOAEL) 
remains at 50 mg/kg/bw/day and the no observed adverse effect level (NOAEL) is set at 5 
mg/kg/bw/day although studies using much lower and human relevant concentrations have 
reported numerous adverse effects in several target tissues. The NOAEL and LOAEL were 
established based on the findings of two multigenerational rodent studies. The authors found that 
systemic toxicity (i.e. changes in body weight and organ weights) was observed at 5 mg/kg/bw/d 
in Sprague Dawley rats and toxicity in CD-1 mouse offspring was observed at 50 mg/kg/bw/d 
[114, 115]. When the margins of safety (MOS) were calculated for infants and adults they were 
deemed adequate. Therefore, based on the LOAEL, the US EPA has set the reference dose at 
0.05 mg/kg/body weight/day based on data from a small number of studies that were conducted 
at very high doses in adult animals and F1/F2/F3 generations. The US Food and Drug 
Administration (FDA) deems BPA safe at current levels occurring in food [116], but 
amendments passed in 2012 and 2013 now ban the use of BPA in baby bottles, sippy cups, and 
infant formula packaging, and many other countries including France, Turkey, and Sweden, have 
followed suit [116]. European countries have taken a more precautionary approach, and the 
European Union decreased the tolerable daily intake from 50 µg/kg down to 4 µg BPA/kg body 
weight; a level more than 10x lower than levels mandated by the U.S. EPA[117]. The EU has 
also passed a regulation stating that thermal paper containing BPA must be discontinued by 2020 
[118]. In other countries, such as Germany and Japan, manufacturers have voluntarily taken BPA 
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out of certain products. Increased consumer and public awareness surrounding the potential 
effects of BPA have spurred industries to replace BPA in several consumer products with 
chemicals that are similar or enhanced in their estrogenic potency. Potential replacement 
chemicals such as those with fluorine and sulfate group substitutions have not been extensively 
studied and their potential for exposure warrants further investigations to assess any potential 
human risks and hazards. 
 
Bisphenol AF (BPAF) 
Chemical Properties  
Similar to BPA, BPAF is composed of two phenolic groups that are joined by a central 
carbon, but the two methyl groups have been replaced by trifluoromethyl groups (Figure 1-2). In 
the presence of an organic sulfonic acid catalyst, hexafluoropropanone-2 and a phenol interact to 
synthesize BPAF [119]. The presence of the fluorinated groups increases its thermal and 
chemical stability to make it a durable component for many industrial and consumer 
applications, but as a result, may increase its persistence within the environment and potential 
human exposure.  
Uses and Routes of Exposure 
BPAF has been detected in indoor dust, domestic well water, soil, sediments, and 
foodstuffs in multiple countries [120-122]. Between 1986 and 2002, BPAF was moderately 
produced in the U.S. BPAF is commonly used as a crosslinking agent for fluoroelastomers, 
optical fibers, electronics, heat resistant adhesives, and as a monomer for polyimide, polyamides, 
polyester, and specialty polymers that include epoxy resins [123]. The manufacturing of rubber 
and plastic products and electrical/electronic equipment may have contributed to the potential 
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exposure of ~4400 employees [124]. Almost half of the exposed workers within the plastics 
industry during that period were women. Exposure to the U.S. general population is likely due to 
contact with resins and polycarbonates used in plastics. Neighborhoods downstream of a BPAF 
manufacturing plant in China measured BPAF in dust, soil, well water, and at low levels in tap 
water [120]. Due to increased soil and water contact and inhalation of dust, children are likely to 
have higher dermal and inhalation exposures. Higher incidences of inhalation exposures may 
occur in other countries as documented from collected indoor dust of Korean homes and 
businesses. BPAF was detected in 75.6% of Korean dust samples compared to 9% in Japan and 
no detection were observed in the U.S. samples [121]. However, exposure through foodstuffs 
may not be of high concern as it was detected at low levels in China and the U.S. [73, 122]. 
Urine from residents living near a BPAF manufacturing plant in China had total BPAF (adjusted 
for creatinine) that ranged from no detection to 0.217 ng/ml [125]. 
Serum bisphenol levels can provide details about exposure trends and establish human 
relevance in animal studies. Likely due to their rapid metabolism and excretion there are no U.S. 
studies that have reported serum BPAF levels from the general or occupational populations. One 
study measured urinary BPAF levels from convenience samples, and only detected it in < 3% of 
the samples and at concentrations ranging from < 0.1-0.12 µg/L [126]. An earlier study using 
HPLC extracted BPAF from human mammary and abdominal adipose tissue, validating the 
lipophilic properties and highlighting its potential target tissues [127]. 
 
Absorption, Metabolism, Disposition, and Excretion 
The main routes of BPAF exposure are through oral or dermal sources. Only one 
pharmacokinetic disposition study exists for BPAF in which all tissues and excretion routes were 
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evaluated. Following a single i.v. or oral exposure to both male and female Harlan Sprague-
Dawley rats and B6C3F1/N mice (3.4, 34, or 340 mg/kg) the majority of BPAF from all dose 
groups was recovered unchanged in the feces after 72 hr, and females tended to excrete more 
BPAF into the urine compared to males [128]. BPAF was highest in the male rat liver and GI 
tract following i.v. and oral administration of all doses, and highest in internal dose in the mouse 
gallbladder for both routes of administration. Glucuronide and sulfate metabolites were identified 
in the bile, and at lower levels in rat urine, but not in the feces. Earlier, more metabolic-specific 
studies in adult Sprague Dawley rats identified four urinary metabolites including BPAF-
glucuronide, BPAF diglucuronide, BPAF glucuronide dehydrated, and BPAF sulfate [129]. 
Several UDP-glucuronosyltransferases (UGT) were identified which may mediate BPAF 
glucuronidation, and UGT 2B7 produced the highest metabolic efficiency. Bioactivation using 
human liver microsomes and recombinant CYP isozymes in the presence of NADPH and GSH 
either produced hydroxylated BPAF or 4-hexafluorohydroxyisopropylidene-phenol [130]. While 
the UGTs facilitate conjugation to decrease BPAF’s activity in adult-derived tissues/cells, they 
may be less efficient at metabolizing BPAF in the fetus due to low expression and metabolic 
activity. One study showed that basal liver UGT 1A6 and 2B1 gene expression and 
glucuronidation activity following BPAF exposure was significantly lower in male and female 
offspring between GD 18.5 and PND 21when compared to their mother’s liver UGT activity 
[131]. However, several other UGTs that were shown to have high glucuronidation efficiency in 
human liver microsomes [129] were not tested. Therefore, the activity of these important 
metabolic pathways remains unknown. Overall, BPAF metabolism is similar to BPA in that it is 
metabolized by conjugation and excreted in the urine and feces. This process is also thought to 
decrease the estrogenicity of the chemical. When BPAF and BPAF-G (10-1000 nM) were 
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assessed in the ER+ breast cancer cell lines MCF-7 and T47D, cell proliferation was increased in 
both cell lines by 100 nM and 1000 nM BPAF [129]. ER responsive genes (GREB1, TFF1, and 
CTSD) were also significantly increased at these concentrations. BPAF-G at any of the 
concentrations was unable to induce proliferation of gene expression changes in either cell line 
indicating that it had less estrogenic activity. 
 
Toxicity and Mutagenicity 
BPAF tested negative for mutagenicity in S. typhimurium TA98 and TA100 with and 
without the addition of S9 metabolic activation, and was not cytotoxic at concentrations ranging 
from 12.5-100 µmol/L [93]. In the same study, they showed that after 4 and 24 hr, BPAF 
concentrations ≤ 10 µmol/L were unable to induce DNA damage in HepG2 cells, however 
reduced cell viability in those cells was reported at concentrations ≥ 50 µmol/L [93]. BPAF 
arrested metaphase in a dose dependent manner in V79 lung fibroblasts cells and increased the 
number of micronucleated cells [95]. In Syrian Hamster Embryo cells (SHE), BPAF decreased 
cell growth at 50 µM and transformed Ouar and TGr mutations above control levels [96]. Genetic 
mutations were not observed at the Na+/K+ ATPase locus or the hrprt locus following 48 hr 
treatment, nor were chromosomal aberrations observed. Treatment of SHE cells with BPAF 
(12.5-50 µM) for 48 hr increased the percentage of aneuploid metaphases with chromosome 
losses and gains within the diploid range. Kanai et al. [132] showed that after 48 hr of BPAF 
treatment (12.5-50µM) SHE cells exhibited decreased colony transforming efficiencies in a dose 
dependent manner. Zebrafish studies conducted at concentrations ranging from 0.05-1 mg/L 
delayed hatch rates, decreased hatchling survival rates, and depressed egg fertilization in 
offspring [133-135]. Offspring experienced hepatotoxicity (male only), acellular testicular 
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development, delayed oocyte development, and pericardial edema. The LD50 in adult male rats 
following acute exposures is 3400 mg/kg [136]. Following a 28-day exposure in male and female 
rats, BPAF concentrations ≥ 30 mg/kg reduced body weights due to a decline in food 
consumption, reduced hematopoiesis, and dilated the lumen of the large intestines in both sexes 
[137]. Atrophy of the mammary gland, anterior pituitary, Leydig cells and adrenal zona 
fasciculata were evident, and irregularity of estrous cycles was also observed. In a 14-day study, 
male rats given ≥ 50 mg experienced a decrease in body weights without altering absolute testis 
weight and only increased the relative testis weight at the highest concentration [138].  
 
Estrogenicity and Endocrine Activity 
MCF-7 cell-based estrogenicity tests (E-SCREEN) revealed that BPAF was able to 
induce proliferation and PR and pS2 expression at concentrations comparable to BPA [108, 139-
141]. Co-treatment with ICI 182,780 (an estrogen receptor antagonist) and BPAF in MCF-7 cells 
diminished the previously observed proliferative effects [132]. SHE cells (ER- cell line) treated 
with increasing doses of BPAF decreased colony forming efficiency and induced morphological 
transformations at concentrations lower than those reported for BPA [132]. Changes that occur in 
this cell line following estrogenic exposure indicate a genotoxic effect (i.e. aneuploidy, gene 
mutation or chromosomal aberration). Other estrogenic assays using a yeast two hybrid system 
(+/- S9) found that BPAF was capable of increasing β-galactosidase in the presence and absence 
of S9 [141]. Luciferase and radio-ligand binding assays concluded that BPAF is a full agonist for 
ERα and an antagonist for ERβ. Also, BPAF had a greater affinity to the ERα compared to BPA, 
but had the greatest affinity for ERRγ [107].  Free triiodothyronine (1000 µg/L), testosterone 
(50-250 µg/L), and estradiol levels (50, 125 and 1000 µg/L) were increased in female zebrafish 
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offspring and decreased testosterone (25 and 125 µg/L)  and increased estradiol (25 and 125 
µg/L) in male offspring following exposure to BPAF for 28 days or 120 days [133, 135]. 
Vitellogenin, an egg yolk precursor protein expressed by female fish and other species may also 
be expressed in males following chemical exposures. Hepatic vitellogenin expression was 
increased in both sexes and significantly greater in males (25 and 125 µg/L) compared to females 
and serum vitellogenin levels were increased in adult males (50-1500 µg/L) [134, 135].  
In uterotrophic assays conducted in the immature rat model, BPAF has been shown to 
increase absolute and relative uterine blotted weights (8, 40, and 100 mg/kg/bw/d), confirming 
estrogenicity reports in a hER/HeLa cell reporter gene assay [142]. BPAF (600 mg/kg) increased 
the glans penis weight in the Hershberger assay in male rats [143]. When BPAF was 
administered in conjunction with testosterone propionate (TP), the seminal vesicle (50 and 600 
mg/kg), glans penis (50 and 600 mg/kg), and Cowper’s gland (600 mg/kg) weights all increased 
compared to vehicle + TP. These high dose studies in adult male rats provided some animal 
evidence to support earlier findings from luciferase assays that BPAF had a greater androgen 
activity compared to BPA, however, the assay was too variable to make this conclusion [108]. 
Following 14 days of exposure to BPAF (0, 2, 10, 50, and 200 mg/kg/d) Sprague Dawley adult 
male rats experienced decreased cholesterol levels and serum testosterone, while it increased 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) at BPAF concentrations ≥ 50 
mg/kg/d [138]. In this same study testicular mRNA and protein expression of genes involved in 
cholesterol biosynthesis (SREBP-1c), transport (SR-B1, StAR, P450cc), and steroidogenesis 
(17β-HSD, Inhibin B, LHR and ERα) were found to be reduced at the 200 mg BPAF/kg body 
weight dose.  
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Regulatory   
The CDC’s National Health Report has no human exposure data on BPAF, likely because 
it is not regarded as a high production volume chemical.  Currently there are no regulations in 
place for BPAF at the US EPA or FDA. However, because of increasing studies and evidence 
that this chemical acts as an endocrine disruptor, the National Institutes of Environmental Health 
Sciences took the initiative in 2008 to nominate BPAF for future study within the National 
Toxicology Program (NTP). Only one study has come from this effort [128],  but as more studies 
are performed they will help to determine BPAF’s toxicological effects and provide information 
for health assessment in future regulatory and risk assessment decisions.  
 
Bisphenol S (BPS) 
Chemical Properties and Uses 
BPS is composed of two phenolic groups bridged together by a sulfonyl group (Figure 1-
2) and is synthesized with sulfonic acid or oleum and two phenols. During this process a phenol 
reacts with a sulphonating agent in an ortho-, meta or para chlorotoluene at temperatures 
between 100-200 ͦ C [144]. Its structure makes it more resistant to thermal challenges and light 
compared to BPA. 
 
Routes of Exposure 
Inhalation, dermal, and oral ingestion are the main routes of exposures for BPS due to its 
many applications. It is used as a curing agent and anticorrosive in epoxy glues and adhesives, 
polycarbonate in plastics, resins in canned foodstuffs, and a developer in thermal paper and dyes. 
BPS has been detected in various paper products (i.e. flyers, mailing envelopes, tickets, etc.) and 
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currency bills from 81 samples in the U.S. (Albany, NY), 10 samples in other U.S. cities, and in 
three Asian countries [145]. Foodstuffs were tested in nine cities in China and the highest levels 
were in meat and meat products, fish and other seafood, and cereals and cereal products. 
However, a sum of all measurable bisphenols revealed that the highest concentrations were 
measured in vegetables, beverages, fish and seafood, and condiments, all of which contact plastic 
packaging or resin lined cans [122]. Findings from the same group showed that BPS is found in 
indoor dust. BPS was measured in 100% of the tested samples, and was highest in Japan and the 
U.S.; it was most abundant in work offices and domestic households [121]. When daily intake 
levels by inhalation of indoor dust were estimated for the U.S. by age group, infants and toddlers 
were estimated to have higher levels than any other group. During development, children spend a 
great amount of time playing and sitting on the floor and have higher respiratory rates. Thus their 
rate of potential dust-borne exposure is greatly increased compared to adults.  
 The widespread use of BPS as a replacement for BPA has instigated several 
biomonitoring studies. BPS was measured in the majority of urine samples from cashiers prior to 
and post-shift but was only detectable in the serum of a small portion of those cashiers. Similar 
to indoor dust findings, urinary BPS concentrations from the U.S. and seven Asian countries 
were greatest in samples from Japan and the U.S. [77]. Urinary detection rates varied from 42-
100% of samples; they were highest in males and in those participants ≤ 19 years old. The 
highest urinary concentrations were also measured in males, and in participants aged 40-49 years 
old. Urinary BPS levels in convenience samples collected between 2000-2014 revealed 
significant changes in detection rate and concentration over time; as time progressed, the 
detection rates increased as well as the geometric mean, from 0.18 to 0.25 µg/L [126]. BPA 
levels were the most often detected bisphenol in convenience samples during all collections, 
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compared to BPS, but the increases in BPS concentrations over time suggest a trend of increased 
exposure to humans. Ingestion by transfer from plastics or contaminated foods is the primary 
route of exposure in the general population. However, occupational settings may increase 
thermal paper exposures due to handling. This was evident in cashiers who had significantly 
increased post-shift urinary BPS levels compared to pre-shift [146].  
 
Absorption, Distribution, Metabolism, and Excretion 
Although studies involving BPS continue to increase in PubMed, there has yet to be 
published data that details the absorption, distribution, or preferential excretion route in any 
species. It is likely that BPS acts in a similar manner to BPA, but disposition studies in multiple 
species and route of excretion data are needed. A handful of studies have shown that BPS 
metabolism may be similar to that of BPAF and BPA. Testing of human urine revealed that BPS 
was detected in 78% of samples and the mean amount in the conjugated form was 97%. These 
data imply that BPS is highly conjugated by glucuronidation and readily excreted into the urine 
[147]. In later studies using human liver microsomes (HLM), it was determined that UGT 1A9 
enzyme had the highest efficiency for metabolizing BPS [148]. Incubations with human 
intestinal microsomes (HIM) showed that BPS was minimally glucuronidated, suggesting that 
most BPS conjugation occurs in the liver. Further studies revealed that BPS can be bioactivated 
to an ortho hydroxylated metabolite when HLMs and HIMs were incubated in the presence of 
NADPH and cytochrome P450s (CYP450); the CYP most active towards BPS was CYP3A4 
[149]. BPS was assessed for reactive metabolite formation with HLM, NADPH, and glutathione 
and no reactive metabolites were formed, a stark contrast from BPA. Lastly, incubations with 
NADPH and UDPGA were completed to assess metabolic competitiveness and glucuronide 
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production was heavily favored and greatest in HLMs compared to HIMs. Similarly, when BPS 
was incubated with HLMs in the presence or absence of UDPGA, BPSM1, the hydroxylated 
metabolite, formation was reduced when UDPGA was present.   
 
Toxicity, Mutagenicity, and Genotoxicity 
In the Ames test using TA98 and TA100 and the umu test  (T1A135), which induces β-
galactosidase activity in the absence and presence of S9, BPS was unable to increase reversion or 
β-galactosidase activity at concentrations ranging from 4-500 µg/plate [93, 94]. Cytotoxicity was 
not evident after 24 hr in HepG2 cells (12.5-100 µmol/L), nor was acute toxicity achieved in 
Daphnia magna. BPS (0.1µmol/L and 10 µmol/L) induced DNA damage after 24 hr in HepG2 
cells but the effects were not dose dependent. In wild type and mutant DT40 chicken embryo 
cultures, RAD54-/-, a mutant deficient in the homologous recombination pathway, was sensitive 
to bisphenol A and several other bisphenol alternatives [150]. Specifically, BPS caused a 
decrease in cell proliferation and increased chromosomal anomalies. Recently, Zhang et al. [151] 
reported that BPS exposure in hepatic and renal cells did not induce toxicity, apoptosis, or 
catalase (CAT) activity at concentrations ranging from 1 µM-0.1 mM. Only at high doses (0.1-1 
mM), during the same time frame, did both cell types exhibit BPS dose dependent increases in 
toxicity, apoptosis, and CAT activity [151]. Using multiple fluorescence spectral analyses, they 
also determined that at high doses, BPS changed the structure and activity of CAT by binding to 
Gly 117 residue where the substrate binds to the enzyme. 
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Estrogenicity and Endocrine Activity 
In vitro and in vivo studies have clearly shown BPS to be estrogenic, although to a lesser 
extent compared to same doses of BPA. Although BPS has been shown to induce proliferative 
effects in MCF-7 cells, (10-9-10-5M), the effects were only found to be greater than BPA at very 
high concentrations (≥10-5M) [141]. At the highest concentration tested, β-galactosidase was 
increased when incubated with S9 and 50% inhibition was achieved in a fluorescence 
polarization test. Kitamura et al. [108] confirmed similar findings in MCF-7 cells (EC50 BPA 
>BPS, estrogenicity test) and that NIH-3T3 transfected cells (adrogenicity test) treated with BPS 
had an IC50 that was 10-fold lower than BPA [108]. BPS was positive for anti-adrogenicity, 
negative for androgenic activity, and produced no activity in the GH3 cells. The lack of GH3 
activity implies that BPS does not induce thyroid-hormone like activity. BPS can also produce 
non-genomic estrogenic effects [152]. In the GH3/B6/F10 rat pituitary cell line BPS decreased 
ERK response in the presence of E2 and caused photoactivation in a non-monotonic dose 
response. By itself, BPS increased cell proliferation but decreased cell numbers when E2 was 
present by activating apoptosis via caspase 8 and 9.  
 
Regulatory 
 Currently, there are no regulatory guidelines that have been put forth for BPS, however, 
the continued use in products, monitoring in humans and increasing number of scientific studies 
will likely prompt changes in the near future. 
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BPA and the Mammary Gland 
Mammary Morphology and Carcinogenesis 
 Only a handful of chemicals besides BPA have been extensively studied for effects on the 
mammary gland (i.e.diethylstilbesterol, perfluorooctanoic acid, genistein, DDT, and atrazine). In 
utero exposure by daily subcutaneous injections to 0.5 or 10 mg/kg BPA accelerated mammary 
gland development in 4-week old female CD-1 mice when corpora lutea were present [153]. The 
same route of exposure given during a pre-pubertal exposure (PND 15) did not produce any 
effects in the mammary gland at 4, 8, or 24 weeks of age [154]. Prenatal exposures to human 
relevant BPA doses (25-250 µg/kg; peristaltic pump) in CD-1 mice caused altered ductal 
migration in the mammary stroma (1 mo). By 6 mo., TEBs, ducts, and alveolar buds were 
increased [155]. BrdU incorporation in the epithelium was decreased at 10 d, but increased 
within the stroma by 6 mo. Prepubertal BPA administration to ovariectomized CD-1 and 
C57Bl/6 weanling mice increased the glandular sensitivity to estradiol during puberty, and as a 
result increased TEBs, ductal extension, and decreased apoptotic activity [99]. Progesterone 
receptor (PR) expression was increased in the epithelium, but Wnt4, which is downstream of PR 
and plays a role in lateral branching, was unchanged. Wadia et al. [156] showed that when 
perinatally BPA (250 ng/kg/bw/d) exposed CD-1 and C57Bl/6 mice were ovariectomized (PND 
25) and administered estradiol (0, 0.5 and 1 µgE2/kg/bw/d) for 10 days, they experienced similar 
sensitivity to E2 in the mammary gland. In both strains, the number of TEBs increased with 
increased E2 doses and was significantly greater with 0.5 µg E2 + 250 ng BPA compared to 0 ng 
E2 +250 ng BPA. Together these studies revealed that the timing of exposure and amount of 
BPA exposure are critical to determining 1) the effects observed in the mammary gland, 2) when 
these effects can be detected, and 3) how they will influence later life development. 
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 Early life exposure to BPA in rodents has also been linked to a shift in susceptibility to 
carcinogenesis. Following prenatal exposure of Wistar-Furth rats to 25 µg BPA/kg/body weight, 
an increased BrdU:apoptosis index in the epithelial and stroma during puberty were reported 
[157]. The percentage of hyperplastic lesions was also significantly increased above control 
levels at PND 110 and 180 (at 25 mg/kg/bw).  Administration of the carcinogen, N-nitroso-N-
methyl urea (NMU, 25 mg/kg/bw, i.p.), at PND 50 increased the incidence of hyperplastic ducts 
at PND 110 and 180 and produced malignant tumors. As early as 3 mos, a beaded duct was 
observed but only at the lowest concentration. By 9 mos., beaded ducts were apparent in all 
BPA-exposed groups. When Sprague Dawley rats perinatally exposed (25 or 250 µg BPA/kg 
body weight; oral gavage) were administered the mammary carcinogen dimethylbenzanthracene 
(DMBA; single dose 30 mg/kg/bw) at PND 50, they experienced increased tumor formation in a 
dose dependent manner and decreased tumor latency with significance achieved at the highest 
dose. At PND 50, the time of carcinogen exposure, mammary glands from the highest dose 
exhibited increased cell proliferation and decreased apoptosis. Protein expression of Akt, pAkt, 
PR-A, and SRC1-3 were all increased in this group [158]. FVB/N mice exposed to BPA in utero 
and given DMBA also had increased mammary tumor frequency, in a dose dependent manner 
[159]. Prenatal exposure to 0.25-25 µg/kg BPA in CD-1 mice caused an increased fraction of 
alveolar buds at 3 (0.25 µg/kg) and 9 mo. (2.5 µg/kg) and a decreased volume in ducts at 9 mo. 
(0.25 µg/kg) [160]. In yet another study, Sprague Dawley female rats perinatally exposed to 25 - 
250 µg BPA/kg body weight (s.c. via Alzet osmotic pump) had preneoplastic lesions in the 
gestational and gestational/lactational exposed groups as early as PND 50 and progressed into 
neoplastic lesions as early as PND 90 [161]. Delclos et al. [162] observed minimal grade ductal 
hyperplasia in female rats at PND 21 from three dose groups following oral exposure to BPA 
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(2.5-2700 µg/kg/bw/d) between GD 6 and PND 90. Hyperplasia was significantly increased at 
PND 90 in the 2700 µg/kg group. When lesion severity was considered, 2/3 groups presenting 
with hyperplasia at PND 21 were also significantly increased at PND 90. By PND 90 mammary 
glands from females in the 2.5 µg/kg group had developed adenocarcinoma. Males all 
experienced ductal hyperplasia at PND 90 when severity was evaluated. 
  The male mammary gland has rarely been assessed for effects of EDCs due to limited 
amount of epithelial structure in male mice and limited information available on male mammary 
development over the life stages. Male offspring perinatally exposed to BPA developed 
mammary glands that had increased branching points and ductal area at 3-4 mo., but in a non-
monotonic dose response [163]. Between 7-9 mos., significantly increased branching points was 
only observed in 2.5 and 25 µg/kg, and in male mice 12-15 mos. of age, the response shifted and 
was only present at the two highest concentrations. In 7-9 mo. old males, cell proliferation was 
increased (25 µg/kg), but apoptosis was unchanged. Interestingly, following prenatal 
subcutaneous injections, male rat offspring experienced increased ductal growth at PND 5 (250 
µg/kg) followed by significantly decreased epithelial growth when measured as the distance 
between the lymph node and the mammary gland final edge at PND 30 (250 µg/kg) [164]. This 
group also exposed rats to BPA (64 µg/kg/bw/d) between GD 9 and PND 21 via drinking water. 
Mammary gland changes in BPA-exposed male offspring were not observed at PND 5, but at 
PND 15 and 30 the number of TEBs was reduced in BPA-exposed glands. Only at PND 30 was 
the distance between the lymph node and the mammary gland final edge significantly decreased. 
At PND 30 AR expression in the ducts, TEBs and TDs were all reduced whereas ER expression 
and the proliferation index were unchanged and PR was not expressed in any of the mammary 
structures. Taken together this data reinforces the concept that the mammary gland is sensitive to 
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endocrine disrupting chemicals and that the same chemical can exert opposing effects in the male 
and female mammary glands. 
 
Mechanisms of Action 
  Due to the mammary gland’s structural and signaling complexity, the introduction of an 
endocrine disruptor like BPA during critical windows of development may initiate several 
different mechanisms of action.  
BPA did not promote the differentiation of human embryonic stem cells into ‘induced’ 
differentiated mammary epithelial cells, but increased mammosphere area in a dose-dependent 
manner (p<0.05, 10-9M) [165]. Pluripotent embryonic stem cell markers (Oct4, Sox2 and Nanog) 
were increased in a dose dependent manner for BPA and at low E2 (10-9M) levels, but decreased 
E-Cadherin was decreased following low-dose BPA exposure alone. This suggests that BPA may 
be able to drive pluripotency in an estrogen-dependent manner, while promoting an estrogen- 
independent pathway for E-cadherin expression. Perinatal BPA exposure has also been shown to 
increase mammary cell numbers, PR expression in luminal cells (6 and 12 mo.), and expression 
of the downstream regulator Wnt4 without altering the individual number of FACS sorted basal, 
epithelial or stromal cells [48]. Wang et al. also discovered that Balb/C mice administered BPA 
during puberty demonstrated increased progenitor cell and transiently increased basal cell counts 
[166]. Following a single dose of DMBA (30 mg/kg) at 2 mo., mice treated with BPA and 
DMBA experienced increased hyperplastic lesions compared to control, BPA alone and DMBA 
alone. When solid 3D MaSC were transplanted to determine stem cell efficiency there was a 
significant increase in hyperplastic lesions in BPA MaSC and BPA+DMBA MaSC regenerated 
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glands at all time points. Deep sequencing profiles from the BPA exposed mammospheres 
revealed altered genes that were commonly seen in breast cancer patients. 
Transcriptional and epigenetic profiles of the mammary gland have also been assessed to 
understand pathways associated with morphological changes. Fetal glands from ERα+/+ and  
ERα-/- mice treated with EE2 or BPA (250 ng/kg) only had distinguishable transcriptional 
profiles when separated by stroma/epithelial compartments, and no significant differences were 
noted by treatment or ERα genotype [8]. Hierarchal clustering by tissue type revealed distinct 
changes with treatment in the stroma that were less evident in the epithelium, regardless of ER 
expression, suggesting that ER may not play a significant role in BPA-mediated fetal gland 
changes. BPA downregulated genes associated with the focal adhesion pathway in peri-ductal 
tissue from ERα+/+ mice compared to ERα+/+ vehicle mice. Genes involved in adipogenesis were 
also increased in peri-ductal tissue of both ERα+/+ and ERα-/-. When the effects of BPA were 
assessed in the mammary epithelium from ERα+/+ tissues, it increased transcripts associated with 
apoptosis compared to vehicle. Transcripts analyzed for potential ER regulation in ERα+/+ 
showed a change in epithelial genes involved in branching, focal adhesion, and extracellular 
matrix, while the genes in the peri-ductal stroma were involved in breast cancer. These data 
demonstrate that not only can BPA affect transcriptional regulation in the mammary epithelium 
but also in the stroma, indicating that they are both important for BPA induced alterations. It also 
shows that BPA effects can be ER and non-ER mediated. Mammary glands from prenatally BPA 
exposed rats (25 and 250 µg/kg) were evaluated for gene expression changes during time points 
where morphological changes were observed (PND 21, 35, 50, and 100 days) [167]. Genes 
altered at PND 21 and PND 35 primarily involved cell differentiation and Gad1. The number of 
genes changed between PND 21 and 35 decreased in both dose groups (25 and 250 µg/kg), but 
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increased by PND 50 where most altered genes were associated with immune function, cell death 
and stress response (25 µg), differentiation, growth arrest, fatty acid binding protein 3, and whey 
acidic protein (250 µg). By PND 100, mammary glands from the highest dose had upregulation 
of genes involved in immune response and downregulation of differentiation genes. This may be 
an important mechanistic clue, as in addition to epithelial tissue, the mammary gland is 
comprised of immune cells which aid in normal development, as well as inhibition of tumor 
development and progression [168, 169].  
Through microarray and RT-PCR validation, Fischer et al. [170] identified that CD-1 
mice gestationally exposed to BPA (5 mg/kg) showed significant decreases in several genes from 
the chemokine family, interleukins, and interferons [170]. In this study the authors reported that 
important leukocyte cell markers (CD45, CD19, Ly6G, and FSP1) and ERα expression were 
decreased while ERβ was increased. The effect of BPA on the mammary epigenome has also 
been investigated [171]. Wistar-Furth rats prenatally exposed to BPA levels previously shown to 
induce ductal carcinomas in situ were evaluated for DNA methylation changes at several 
developmental time-points (PND 4, 21, and 50). These studies demonstrated that most 
methylation changes were evident at PND 21, but more transcriptional changes due to treatment 
were observed at PND 50. Hypo- and hypermethylation were noted across several chromosomal 
loci, but differences observed between BPA and vehicle varied over time and no consistent dose 
effect was noted. By PND 50, BPA increased jun expression and decreased p57, a gene involved 
in cell cycle regulation. 
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Research Goals 
The NTP fact sheet on BPA suggests there is minimal concern for developmental 
toxicities in fetuses, infants and children pertaining to the mammary gland and early puberty in 
females [172]. However, there is an increasing body of evidence in animal studies using human 
relevant doses, as well as some epidemiological studies, that point to BPA’s ability to change the 
breast architecture and increase risk of breast tumor development. In my studies, I will use a 
mouse model that has been prenatally exposed to BPA, BPAF, or BPS address several research 
gaps, such as 1) quantifying BP analogue internal dose following maternal exposure and confirm 
fetal transfer, 2) identifying altered mammary gland morphologies and the potential of these 
chemicals to induce abnormalities that may include neoplasia, and 3) examining early life 
signaling pathways that may play a role in the observed early and later life effects.    
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Figure 1-1: Endocrine disrupting compounds may interfere at multiple sites and times. As illustrated there are many tissues and 
endogenous chemicals including steroid hormones, metabolic hormones and cytokines that regulate breast development, structure, and 
function.  
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Figure 1-2: Chemical structures of BPA, BPAF, and BPS.  
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CHAPTER 2 
Disposition and early developmental effects of bisphenol analogues in CD-1 mice 
OVERVIEW 
 Growing concern over the use of Bisphenol A in plastic consumables has resulted in the 
implementation of replacement analogues including the fluorinated and sulfonated derivatives, 
BPAF and BPS. Both chemicals have estrogenic activity that is comparable/enhanced vs BPA, 
which may cause detrimental changes to the developing offspring, often manifesting later in life. 
Current disposition data for these chemicals are either nonexistent or fail to address the 
uniqueness of maternal-fetal exposures. This study assesses the pharmacokinetic and disposition 
properties of BPA, BPAF, and BPS in the maternal-fetal unit. Timed pregnant CD-1 mice were 
given a single gavage dose of BPA (50 mg/kg), BPAF or BPS (5 mg/kg), or sesame oil at 
gestational day 16. At 2, 4, 8, 12, 18, 24, and 48 hr post-exposure, urine, feces, amniotic fluid, 
and serum were collected from dams. Similarly, on postnatal days (PND) 3, 4, and 5, serum and 
feces from dams and pooled serum from offspring were collected. Total concentrations (free plus 
conjugated species) of BPA, BPS, and BPAF in serum, urine, and amniotic fluid were quantified 
by online-solid phase extraction coupled to HPLC–isotope dilution–tandem MS. Concentrations 
of the reagent blanks suggested that external contamination did not occur during sample 
collection/analysis. Maximal maternal (Cmax) serum and urinary concentrations were achieved 
within 2 hr for BPA and 4 hr for BPAF and BPS. Serum and urinary half-lives were similar 
between compartments and were shortest following BPAF exposure. BPAF fecal recovery was 
~30-50% greater than BPS, but fecal half-life was like serum and urine. Each analogue was 
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recovered from the amniotic fluid as early as 2 hr post exposure but Cmax was not reached for any 
chemical until 18 hr. Between PND 3 and 5, maternal serum concentrations decreased by 90-
1000 fold or were below the limit of detection, suggesting that pup urine does not significantly 
contribute to chemical recirculation. Pup serum concentrations were similar between males and 
females. The slight differences in disposition across analogues were likely due to their chemical 
properties, but confirm placental transfer of BPAF and BPS. Recovery of each analogue in the 
amniotic fluid regardless of dose amount suggests the potential for fetal exposure and warrants 
additional studies to determine how early life exposure to these chemicals may impact early and 
long term offspring development.  
 
INTRODUCTION 
 Bisphenols are a class of chemicals characterized by two hydroxphenyl groups often 
joined by a bridging carbon and one or more substitution groups. The most widely studied 
bisphenol is Bisphenol A (BPA), a synthetic component used in the production of plastics and 
epoxy resins. BPA has been shown to act as a weak estrogen and endocrine disruptor in rodent 
models. Within the last decade, several chemical analogues have gained notoriety due to their 
similar structure and estrogenic activity compared to BPA. Specifically, concerns involving the 
use of Bisphenol AF (BPAF), a fully fluorinated derivative, and Bisphenol S (BPS), which 
includes a sulfonyl group in place of the bridging carbon, continue to increase because of their 
potential to induce effects similar to BPA.  
 Bisphenol S was initially nominated in 1994 [1] to the National Toxicology Program 
(NTP) for toxicological assessment, but was later withdrawn. In 2014, it was once again 
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nominated due to its potential for human exposure and health effects [2]. Bisphenol S is also 
used as a component in plasticizers and resins and as a developer in thermal receipt paper. It is 
considered a high production volume chemical [3], with several routes of exposure including 
dermal, oral, and inhalation [4-7]. BPS was found to be estrogenic by studies conducted in vitro 
[8, 9] and in vivo [10]. Although increasing evidence of human exposure to BPS exists [7, 11, 
12] there remains a lack of toxicity and pharmacokinetic data from any mammalian or laboratory 
species. Available data reported negative findings for BPS in the Ames test and only induced 
DNA strand breaks in HepG2 cells 24 hr post exposure [13]. Zhou et al. [14] identified 
conjugation as the main metabolic pathway (97-100%) for BPS in human urine samples. The 
main human hepatic enzyme responsible for glucuronidation was identified as UGT1A9 [15]. 
The same group later identified an orthohydroxylated BPS metabolite (BPSM1) that was formed 
following human liver, intestinal microsomal or cytochrome P450 incubation with (nicotinamide 
adenine dinucleotide phosphate) NADPH [16]. CYP3A4 and 2C9 produced the greatest 
enzymatic activity when human liver microsomes (HLM) were coupled with NADPH, and UDP-
glucuronyltransferase (UDPGA) glucuronidation was favored [16].  
 In the United States, between 1986 and 2002, BPAF was moderately produced within the 
range of 10,000-500,000 pounds/annually [17]. Similar to BPS, BPAF was nominated to the 
NTP testing program in 2007 due to concerns of potential occupational and general population 
exposures [17]. Its primary uses are as a crosslinking agent in fluorelastomers and polycarbonate 
copolymers in several consumer products. Apart from a few laboratories, very little progress has 
been made in understanding the toxicity of this chemical. To date, studies have confirmed that 
BPAF is not mutagenic, nor able to induce DNA strand breaks 4 and 24 hr post exposure [13]. 
When assessed for aneuploidogenic potential, non-cytotoxic concentrations of BPAF induced 
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micronuclei and disrupted the cytoplasmic microtubule complex and mitotic spindle in V79 cells 
[18]. BPAF also inhibited cell growth (50 µM) in Syrian hamster embryo cells, but failed to alter 
gene mutations at the Na+/K+ ATPase locus. Similar studies confirmed the aneuploidy findings 
and revealed that they were induced within the near-diploid range [19]. BPAF has increased 
proliferation, pS2 secretion, and progesterone receptor expression in MCF-7 cells [20-22], and 
acted as an agonist for ERα and antagonist towards ERβ in transfected HeLA cells [23, 24]. 
Metabolism studies performed by Li and coworkers [25] identified glucuronidation as the major 
metabolizing pathway for BPAF and identified four metabolites in Sprague Dawley rats. They 
also determined that multiple recombinant human UGT enzymes were effective at 
glucuronidating BPAF, and identified UGT2B7 as the most efficient. A single disposition study 
involving both sexes of adult Harlan Sprague Dawley rats and B6C3F1/N mice showed that the 
main route of BPAF excretion was through feces compared to urine, following both oral and 
intravenous (i.v.) administration [26]. Incubations with [14C] BPAF and human, rat, or mouse 
hepatocytes produced glucuronide and sulfate metabolites that were easily identified by liquid 
chromatography tandem mass spectrometry (LC/MS/MS) from parent BPAF. Rodent metabolite 
profiles also confirmed previous findings and showed that glucuronidation reduced BPAF’s 
estrogenic effects [27]. Although to a lesser extent, BPAF bioactivation is also possible. 
Incubation of BPAF with HLM, NADPH with cytochrome P450’s, or glutathione (GSH) 
produced three metabolites (OH-BPAF, 4-hexafluorohydroxy-isoprpylidene phenol, and GSH 
conjugate of 4-hexafluoroisopropylidene phenol) [28].  
 As concerns continue to mount over the potential human exposure to BPAF and BPS 
there remains limited disposition data and no pharmacokinetic data. The fact that BPA have been 
extensively assessed for toxicity and estrogenicity and that both BPAF and BPS share similar 
    
63 
 
structures, metabolism, and estrogenic properties with BPA, have prompted the need for more 
studies with these lesser characterized chemicals. It is especially important to understand how 
these chemicals may affect fetal and infant populations. With very little human disposition data 
to rely on and only limited BPA pregnant disposition studies in rodents [29-31], these studies 
were designed to determine the disposition and pharmacokinetics of BPAF, BPS, or BPA 
following a single oral exposure to pregnant CD-1 mice. Chemicals were measured in multiple 
matrices to determine the extent of offspring exposure. Once the excretory half-lives were 
established, time pregnant mice were orally exposed to these chemicals during pregnancy to 
determine early life effects on offspring.  These studies will aid in understanding the implications 
that these chemicals may have on human health. 
 
MATERIALS AND METHODS 
Chemicals and Dosing Solutions 
 
 Bisphenol A (BPA) and Bisphenol S (BPS) ( ≥99.0 % and ≥97.5 % purity, respectively) 
were obtained from Sigma Aldrich (St. Louis, MO) and Bisphenol AF (BPAF) (98 % purity) was 
obtained from 3B Pharmachem International Co. Ltd. (Wuhan, P.R. China). Prior to use, each 
chemical’s purity was confirmed by the NTP chemical contract lab. All dosing solutions were 
prepared daily by dissolving the test chemical in pure sesame oil (Jedwards, International, Inc., 
Braintree, MA) and stored in clear glass vials to avoid exogenous bisphenol (BP) contamination 
from plastics. 13C12-BPA was obtained from Cambridge Isotope Laboratories, Inc. (Andover, 
MA) and 13C12-BPS was purchased from CanSyn Chem Corp. (Toronto, Canada).  13C12-BPA 
was used as an internal standard for BPA and BPAF [14].   
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Animals  
 Timed pregnant CD-1 mice were obtained from Charles River Laboratories (Raleigh, 
NC). Upon arrival at the NIEHS, dams were weighed and randomly assigned to the vehicle or 
treatment groups. Body weights were approximately equal in all groups prior to randomly 
assigning dose. All dams were acclimated for a minimum of 2-3 days prior to dosing. Pregnant 
dams were individually housed in polypropylene cages and received AIN-93G (Harlan 
Laboratories, Indianapolis, IN) feed. Tap water was provided ad libitum and supplied in 
polypropylene bottles that were tested for estrogenicity by E-SCREEN. Cages were lined with 
SaniChip Hardwood bedding (PJ Murphy Forest Products, Inc., Montville, NJ). Animal facilities 
were maintained on a 12:12h light-dark cycle, at a controlled temperature (20-24oC) with 40-
60% relative humidity.  All animals were treated humanely and in accordance with the protocols 
of the National Institute of Environmental Health Sciences Animal Care and Use Committee. 
Dams were weighed daily prior to dosing and were administered each chemical by concealed 
allocation. Unless noted all dams carried to term and pups delivered to small litters (n<4 pups) 
were excluded from these studies. 
    
Experimental Design 
 Disposition Studies. Pregnant dams arrived on gestational day 14 (GD 14), and on GD 16 
dams were given a single oral gavage dose of either vehicle (n=10), 50 mg BPA/kg body weight 
(n=30), 5 mg BPAF/kg body weight (n=30), or 5 mg BPS/kg body weight (n=30).  50 mg 
BPA/kg is 1000x the Environmental Protection Agency recommended daily intake (EPA RDI) 
[32]. However, no human data for BPS/BPAF exist and therefore these concentrations were 
chosen to ensure that we could obtain an appreciable measurement in the collected tissue 
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samples. At 2, 4, 8, 12, 18, 24, and 48 hr post exposure, dams were sacrificed to obtain serum, 
urine, feces, amniotic fluid, and a randomly chosen fetus (1 pup/dam). A subset of animals from 
each dose group was randomly chosen to continue through pregnancy until full term. Parturition 
in CD-1 dams normally occurs on the eve of GD 18, where the next day is considered postnatal 
day 1 (PND 1). All pups remained with their respective dams, and litters were not equalized to 
maximize data collection from the offspring. On PND 3, 4, and 5, dams were sacrificed to obtain 
serum, urine, and fecal samples. Pups were sexed and sacrificed on those same days to obtain 
pooled male and female serum and urine, by litter.   
 
 Early Developmental Outcomes. In separate studies, the effects of BPA, BPS, and BPAF 
on early development and pubertal timing in mouse offspring were evaluated in two blocks (~3 
weeks apart).  Block 1 was received on GD 9 and Block 2 was received on GD 8. Dams were 
oral gavage dosed b.i.d (determined by disposition results) between GD 10-17 with either vehicle 
(n=7-8 dams/treatment/block), BPA 50, 5, or 0.5 mg/kg body weight (n=7 
dams/treatment/block), BPAF 5, 0.5, or 0.05 mg/kg body weight (n=7 dams/treatment/block) or 
BPS 5, 0.5, or 0.05 mg/kg body weight (n=7 dams/treatment/block).  10-fold increments of dose 
were chosen to cover a wide range and to determine if any observed effects would occur in a 
dose responsive manner. Dams were closely monitored on GD18 (expected day of parturition) 
and all litters were sexed and weighed within one hour of birth (PND 1). On PND 3 (Block 1) or 
4 (Block 2) each litter was equalized to 10 pups per dam, with a 6:4 (female: male) ratio when 
possible.   
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Disposition Studies 
 Matrix Collection, Preparation, and Analysis. Samples for each time-point were collected 
from a different dam within the same chemical dose group, as opposed to serial collections from 
the same dam, because the fetal tissue collections required euthanasia. Dam and pup/fetal trunk 
blood were obtained following swift decapitation.  Dam blood was collected in polypropylene 
tubes and pup/fetal blood was collected in glass vials with deactivated glass inserts. Pup/fetal 
serum samples from the same sex within a litter were pooled to maximize volume/concentration 
yields.  Blood samples settled at room temperature (26oC) at least 30 min followed by 
centrifugation at 3000 rpm at 4o C for 20 min.  Dam serum was then transferred to glass vials and 
pup serum was transferred into new glass inserts and kept frozen at -80oC until analyzed. 
 Dam urine was collected in microfuge tubes during elimination when animals were 
retrieved from their cage and it was transferred to glass vials with inserts. Ingestion of offspring 
urine by the dam during early lactation is a common maternal behavior and precluded the 
adequate collection of pup urine [33]. Fresh fecal excrement was obtained during natural 
elimination or by removing feces from the lower gastrointestinal tract at necropsy. Amniotic 
fluid was drawn from each fetal sac using a needle and syringe following removal of the entire 
litter from the uterus onto ice.  Fetuses/pups were swiftly decapitated for blood collection; 
however, the fetus that was preserved for disposition was decapitated and then wholly contained 
in a tube (with blood) and frozen. 
 Metabolic cages were not used to collect excreta in order to minimize maternal stress, 
avoid fluctuations in food intake and weight, and to prevent the incidence of fetal skeletal 
malformations [34]. All samples were collected, weighed, and stored in glass vials followed by 
immediate transfer to ice, then storage at -80oC.  
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 A detailed method for urine, serum, and amniotic sample preparation for the detection of 
bisphenols can be found in Zhou et al. [14]. Briefly, samples were prepared with and without 
enzymatic treatment. Approximately 50 µl of 3C12-BPA (Cambridge Isotope Laboratories, Inc, 
Andover, MA) or 13C12-BPS (CanSyn Chem Corp, Toronto, Canada) were added to 100 µl of 
urine or amniotic fluid and diluted to 1 ml with 0.1 M formic acid to measure free bisphenol 
species. Total bisphenol concentrations were measured by mixing 100 µl of sample with 50 µl of 
deconjugation standard and 50 µl of glucuronidase/sulfatase. Samples were incubated with 750 
µl of formic acid at 37o C for 4 hr. All samples were vortexed, centrifuged and prepared for 
analysis on an automated online SPE-HPLC-MS-MS Agilent 1200 module (Santa Clara, CA) 
and an ABSciex 5500 QTRAP mass spectrometer (MS) (Sciex, Redwood City, CA). The limit of 
detection (LOD) for urine were BPA (0.4 ng/ml), BPAF (0.1 ng/ml), and BPS (0.1 ng/ml). 
Amniotic fluid and serum LOD were 0.1 ng/ml for all bisphenols.  
 Frozen fecal samples were lyophilized overnight. Approximately 25 mg of dry fecal 
material was hydrated in 800 ul of 1:1 acetonitrile-methanol containing 2 µg of heavy isotope 
labeled internal standard. Samples were sonicated for 30 min followed by centrifugation to 
remove particulates. Each sample was aliquoted (0.3 ml) into two tubes and either diluted with 
1.2 ml of water for enzymatic deconjugation or prepared for solid phase extraction. Supel-Select 
SAX (Sigma Aldrich, St. Louis, MO) 30 mg (bed weight), 1 ml SPE tubes were conditioned with 
3 ml 1:1 acetonitrile: methanol followed by 3 ml of water using a positive pressure manifold with 
a 1 ml/min flow rate. Samples were loaded into tubes and washed with 1 ml of 5% ammonia 
followed by a methanol wash and then washed with 1 ml of a 40% methanol-2% formic acid 
solution. The bed was completely dried with nitrogen and the bisphenols were eluted with 1:1 
acetonitrile-methanol, containing 1% formic acid, solution followed by elution with nitrogen. 
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Half of the sample was prepared for liquid chromatography-electron spray ionization tandem 
mass spectrometry (LC-ESI-MS/MS) analysis. Samples prepared for enzymatic deconjugation 
were dissolved in 500 µl of 200 mM acetate buffer (pH 5.2).  200 µl of glucuronidase/sulfatase 
were added to each sample and incubated overnight at 37o C. Samples were cooled to room 
temperature to perform solid phase extraction. LC-ESI-MS/MS analysis was performed on an 
Agilent 1200 capillary HPLC (Agilent Technologies, Santa Clara, CA) and an ABSciex API 
3000 tandem MS (Sciex, Redwood City, CA). Separation was performed using a water: 
acetonitrile gradient with 0.1% acetic acid modifier on a 1.0 X 150 mm C18 column at a flow 
rate of 65 µL/min. The injection volume was 3 µL. Bisphenols were detected in negative ion 
mode and two MS/MS transitions were monitored for each analyte. Peak areas were used for 
quantitation with stable isotope labeled internal standard correction. Calibration curves (R2 > 
0.998, 1/X weighting) were constructed with matrix matched samples. LOD and LOQ were 
determined for BPS (0.3 ng and 2 ng), BPAF (0.6 ng and 2 ng), and BPA (1 ng and 15 ng).  
 
Half-Life Calculations 
Excretion half-life values are based on first order elimination and were calculated as follows, 
based on previous reports [35] 
t1/2= 0.693 
          m 
m=slope of the line from ln [BP Analog] vs. T’ 
T’ = Time – Time at Peak Concentration 
Area Under the Curve (AUC) Calculations 
 The AUC is a measurement of the body’s exposure to a chemical after administration 
against time. AUC is usually calculated with plasma concentration following i.v. dosing and 
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assumed to distribute into the blood immediately. Since these animals were oral gavaged it takes 
a slightly longer time to reach systemic circulation and thus blood at time zero is not collected. In 
order to calculate AUC for an oral dose it was necessary to use back extrapolation to determine 
time zero [36]. Time zero was calculated using Cp0 = ln (Cpt +kt) where: 
Cp0 = extrapolated plasma concentration at time zero 
Cpt = plasma concentration at any time 
kt = elimination rate constant  
The linear trapezoidal method was used to calculate the area under the curve (AUC) from time 
zero to the last collection [37]. 
First segment: ΔAUCx-(x-1)= (Cpx+Cpx-1) x (tx-tx-1) 
                                                       2 
Last segment: ΔAUClast-∞ = Cplast/kel  
kel= elimination constant 
tx = time at any segment 
tx-1= time at any segment minus one 
 
Early Developmental Outcomes 
 On PND 1, male and female offspring from each litter were first sexed and then weighed 
as a sex-specific group. Mean pup weight was determined using the formula BW= sex-specific 
group weight/# of pups. The number of pups per litter was recorded and pup sex was used to 
calculate sex ratio for each dose group and vehicle control. 
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Statistical Analysis 
 In all studies, the dam is considered the unit of measurement and unless noted all data are 
represented as the mean ± standard error of the mean (SEM).  Bisphenol content in excreta and 
bodily fluids is expressed as total bisphenol = (free bisphenol + conjugated bisphenol). A two-
way ANOVA using Tukey’s post hoc test was conducted to evaluate for block effects.  No 
differences were observed between blocks and therefore they were combined and evaluated for 
outliers using GraphPad QuickCalcs Outlier test (http://graphpad.com/quickcalcs/Grubbs1.cfm).  
Statistical significance was determined using ANOVA, with a Dunnett’s post-hoc test on SAS 
9.3 Enterprise (Cary, NC).  Bisphenol concentrations below the LOD/LOQ were represented as 
LOD/SQRT (2) and used in analyses. All graphs and tables were generated using Microsoft 
Excel 2010 and GraphPad Prism 7.     
 
RESULTS 
 Half-life determination of bisphenols in the pregnant and lactating dam.  The 
concentrations of BPA, BPAF, and BPS in maternal serum over two days during late gestation is 
illustrated in Figure 2-1. Within 12 hr of exposure, there was a rapid decline of maternal 
bisphenol serum concentration for each chemical and by 24 hr baseline levels were achieved for 
BPAF and BPS, while BPA achieved baseline levels at ~48 hr. BPAF and BPS serum levels 
peaked within 4 hr of exposure, compared to the earlier peak in BPA dams at 2 hr. Similarly, 
maximal urinary (Figure 2-2) and fecal (Figure 2-3) concentrations (Cmax) for BPAF and BPS 
were achieved by 4 hr. Similar to the serum results, urinary BPA concentrations peaked at 2 hr. 
BPA, BPAF, and BPS all distributed into the amniotic fluid (Figure 2-4), but unlike the short 
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time to maximal concentration (Tmax) in the excreta and serum, all chemicals demonstrated a 
Tmax of approximately 18 hr in amniotic fluid. 
 The concentrations of each chemical were used to calculate the pharmacokinetic 
parameters found in Table 2-1. The mean serum t1/2 of BPA, BPAF and BPS were 5.5, 4.5, and 
7.0 hr., respectively and the extrapolated AUC0-1 and AUC0-∞ did not vary significantly by 
chemical. BPA administered levels were 10x greater than the other two phenols, and as expected, 
measured serum levels for both BPAF and BPS were approximately 6-10x lower in comparison 
to BPA serum levels. Urinary samples had similar t1/2 as the serum for all three chemicals. 
Interestingly, BPS recovery was ~30x greater than BPAF, although both groups were 
administered the same dose (5 mg/kg). In contrast, BPAF recovery was ~3x greater in the feces 
compared to BPS although the administered dose, Tmax and t1/2 were very similar.  Although the 
Cmax for all three chemicals in the amniotic fluid was achieved ~18 hr post exposure, recovery 
levels of BPAF remained close to baseline within the final 30 hr of collection (2.1-24.7 ng/ml), 
compared to BPA (30.2-858 ng/ml) and BPS levels (2.9-357 ng/ml), and thus the t1/2 was unable 
to be calculated. BPS was detected in the amniotic fluid at levels 10x greater than BPAF 
although the administered doses were equal.  
 Serum from dams was also collected between 3 and 5 days post-partum to assess whether 
internal dose was still measurable 5-7 d post-exposure. Figure 2-5 illustrates that dams had 
measurable BPA levels that decreased in a linear fashion from PND 3 to 5. A slight increase in 
serum BPA recovery was observed from GD 18 to PND 3, but the difference could have been 
due to maternal behaviors or variability between animals. Apart from PND 4, postnatal serum 
BPAF levels were ≤ LOD and although detectable, serum BPS levels were also significantly 
lower than GD 18 levels. 
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 Serum concentrations of bisphenols from both male and female offspring were also 
measured on PND 3-5 to determine if chemical metabolizing differences existed due to sex 
(Table 2-2), which may result in higher measurable levels of one sex vs. the other. As previously 
noted, we attempted to collect pup urine, but it was difficult to obtain due to maternal grooming. 
Similar to dam serum BPA levels, offspring serum BPA levels were greater (≥ 10x) compared to 
BPAF and BPS likely due to the administered dose being 10x higher. The serum levels between 
BPAF and BPS offspring were very similar to one another. When dam serum levels from PND 
3-5 were compared to pup serum levels (data not shown), regardless of sex, BPA and BPS dam 
serum levels ranged from 1.5-4.4-fold and 2.2-7.7-fold higher than pups, respectively. The range 
of BPAF serum fractions could not be calculated due to serum levels that were < LOD for either 
dam or offspring. Overall, dam serum levels exceeded pup levels by 2-8 fold and pup sex was 
not a significant modifier of neonatal serum concentrations for any of the three chemicals.    
 Early developmental outcomes. Because the determined serum and urinary half-life was 
short for the three bisphenols tested (Table 2-1), it was decided that twice daily dosing 
approximately 7 hours apart during daylight hours would prolong exposures. In addition to the 
single bisphenol concentrations administered in the disposition studies, concentrations that were 
10 and100x lower were also assessed to determine potential health-related changes across a 
greater and more human relevant dose range. Following a late gestational exposure (GD 10-17) 
to vehicle, BPA, BPAF or BPS, maternal and offspring outcomes were measured. All treated 
dams gained a similar amount of weight during gestation, regardless of dose, when compared to 
vehicle (Figure 2-6). Approximately 50% of the vehicle dams gave birth on the expected day of 
parturition (GD18) compared to BPA (43-60%), BPAF (67-71%) and BPS (67-85%) (data not 
shown). On average, litter sizes for controls and all treatment groups ranged from 11-13 pups, a 
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size that is very common for CD-1 litters (Table 2-3). In the vehicle control group, the number of 
male offspring per litter was slightly greater (7.7 ± 0.8) compared to the treated groups, but 
statistical differences were not observed. Female body weights and counts per litter, and sex ratio 
were all unchanged with the exception of the BPS 0.5 mg/kg group that had significantly greater 
number of females compared to vehicle. 
 
DISCUSSION 
 In this study, pregnant CD-1 dams were exposed to BPA, BPAF, or BPS to determine the 
disposition and pharmacokinetic half lives in a pregnant rodent model. As a result, we were able 
to establish the internal dosimetry within the dam and her offspring. All chemicals were rapidly 
absorbed and measurable in serum, excreta, and amniotic fluid within 2 hr post administration. 
The half-lives of BPA, BPAF, and BPS in serum, urine and feces were all < 24 hr and similar 
observations have been made in non-pregnant rodents and humans [38, 39]. This study is the first 
to confirm placental transfer of BPAF and BPS as both chemicals were recovered in the amniotic 
fluid, demonstrating the likelihood of fetal exposure. Measurement of the bisphenols in the 
offspring serum confirmed maternal to fetal transfer that was similar between male and females, 
suggesting that sex-specific differences in metabolism are negligible during this early time of 
development. Extended dosing studies using the same concentrations revealed that BPA, BPAF, 
and BPS were neither materno- nor fetotoxic as there were no changes observed in gestational 
weight gain for the dam, length of gestation, pup birth weights, postnatal mortality, or total litter 
size. 
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 Following a late gestation single oral exposure to BPA, BPAF, or BPS, each chemical 
was quickly absorbed and detected at its peak concentration in the maternal serum within 2-4 hr. 
Previous studies that examined the disposition of BPA in pregnant mice (10 mg/kg) and rats 
(1g/kg) found that following a single administration of BPA maternal blood levels peaked at 15 
and 20 min., respectively, continuously decreasing as time progressed [30, 40]. Therefore, it is 
quite possible that the Cmax and Tmax may have occurred within the first hour following BPA 
exposure in our study. BPA concentrations steadily declined after the 2 hr collection; however, 
both BPAF and BPS serum concentrations peaked at 4 hr and then began to decline. Therefore, 
we are confident that our BPAF and BPS Tmax, Cmax and t1/2 findings are representative of the 
absorption/excretion of these chemicals. As expected, BPA concentration in the serum was 
greater than that of the other bisphenols tested due to the higher administered dose, and BPAF 
and BPS recovery differed by 6-10 fold in serum from BPA, suggesting that their structural 
differences had little influence on circulating blood levels.  
 A comparison of t1/2 in the pregnant mouse model revealed that regardless of the chemical 
to which dams were exposed, or the matrix from which the t1/2  was estimated,  their t1/2 was less 
than 24 hr; confirming a previous finding for BPA in non-pregnant rodents [38]. Bisphenols 
continued to decrease in the dam in a linear fashion into the postnatal period and were below the 
LOD in most BPAF samples at PND 3. Maternal BPS serum levels between PND 3 and 5 were 
all < 1 ng/ml, which is roughly 20-100 fold higher than pre-and post-shift serum levels (0.010-
0.100 ng/ml) in cashiers exposed to receipts containing BPS [7]. 
 The effects of BPA in humans remain a controversy because most BPA is thought to be 
rapidly metabolized and excreted, resulting in low levels of free circulating BPA that are not 
expected to cause any damage. Following absorption, BPA is rapidly glucuronidated, which 
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decreases its estrogenic activity and, depending on the species, is eliminated through feces via 
biliary excretion or the urine. It may also be sulfated and hydroxylated by cytochrome P450s, but 
to a lesser extent. Therefore, it is thought that the rapid metabolism and efficient removal of BPA 
negates its harmful effects in tissues. More recently, Li et al. [27] identified four BPAF urinary 
metabolites (BPAF-diglucuronide, -glucuronide, -glucuronide dehydrate, and -sulfate) following 
a single dose administration in non-pregnant Sprague Dawley rats. Similarly, BPS-glucuronide 
was found to be the predominant metabolite following co-incubation of the parent compound 
with NADPH and UDGPA [16]. These data indicate that all three analogues are likely eliminated 
following glucuronidation, although it is not known if that form is active or not. In fact, recent 
studies in mouse 3T3-L1 cells have shown that BPA-glucuronide is indeed active, stimulating 
adipogenesis of these cells in a dose responsive manner [41].  
 In our study, BPAF recovery in the urine was ~30 fold lower compared to BPS recovery, 
even though both groups were administered the same dose. Although overall fecal bisphenol 
recovery was lower compared to other maternal matrices, BPAF concentrations were 30-fold 
higher than BPS in this matrix. We hypothesize that low recovery in the feces may be a result of 
distribution to other tissues and will require additional testing. This data does not support the 
findings by Waidyanatha et al. [26], who demonstrated that cumulative excretion of BPAF 
regardless of sex, dose and administration was predominant in the feces of non-pregnant Sprague 
Dawley rats and B6C3F1/N mice. However, it should be emphasized that because these animals 
were not placed in metabolic cages we were unable to perform cumulative collections of urine 
and feces and therefore were unable to calculate the cumulative excreta to determine the 
predominant route of excretion. If feces is the main route of excretion for BPAF this may be an 
indicator of why urine samples from a human population [12] collected between 2000 and 2014, 
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had BPAF levels that were below the limit of detection. We cannot simply assume that because 
samples from all collection points had non-detectable levels of BPAF, that those individuals 
were not exposed to BPAF, as the animals in our study certainly were exposed and we could not 
measure BPAF a few days later. It may simply suggest that BPAF has undergone rapid urinary 
elimination or that BPAF is predominantly excreted via feces and is being measured in an 
imperfect matrix. Since we measured lower total BPAF in the matrices collected compared to 
BPS, this may also suggest the alternative possibility that BPAF is being distributed to more 
lipophilic tissues such as the mammary gland or adipose tissues since it has been recovered from 
human adipose tissues [42]. 
 This study is the first to our knowledge to confirm that BPAF and BPS undergo maternal-
fetal transfer. In this study, each bisphenol chemical was detected in the amniotic fluid as early 
as 2 hr post exposure although it required an additional 16 hrs. to reach Tmax. BPAF recovery was 
the lowest (20.2 ± 2.5 ng/ml) at its peak concentration, compared to BPS (277.3 ± 41.4 ng/ml) 
and BPA (735.3 ± 70.4 ng/ml). A potential explanation for this may be retention in the fetal 
tissues (and less excreted to amniotic fluid) or  higher levels of  BP analogues (free form) in the 
umbilical cord sera compared to amniotic fluid, since we did not observe a difference in dam: 
fetal serum between sexes [43]. BPA was also found to be more readily recovered in second 
trimester patients compared to third trimester, the latter of which is comparable to the gestational 
time point for this study [43]. Although fetal tissues were not assessed (no reliable analytical 
method), several studies involving pregnant rodents (mice and rats) and oral BPA exposure have 
shown that whole fetuses achieved maximal concentrations within the first 20 min (slower than 
maternal serum/urine) following maternal exposure and that their internal dose rapidly decreased 
in a manner similar to the maternal samples [29, 30]. This may not be the case for BPAF, as 
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suggested by our recovery data. Regardless of absolute levels of recovered bisphenols, these data 
demonstrate that the placenta does not act as a barrier to BPAF or BPS, similar to data for BPA.   
 Metabolic differences between males and females may play a role in the severity or lack 
of observed effects in some studies. In addition to an in utero exposure in our study, offspring 
were also exposed to any residual bisphenols through lactation. Serum from neonates of both 
sexes was measured between PND 3 and 5 to determine if sex differences existed. A single in 
utero exposure to the three chemicals did not result in any differences between male or female 
serum measurements. The lack of serum differences between sexes suggest that the CD-1 mouse 
model can serve as an appropriate model for determining the effects of BPAF and BPS for future 
studies involving additional time-points and for various collection types. Recent findings in 
C57Bl/6 neonates revealed low basal UGT expression between early gestation and PND 21 [44]. 
Based on these findings we anticipated that the metabolizing enzymes needed for bisphenol 
glucuronidation are not active in the CD-1 neonate, however, to confirm this it will be necessary 
to measure those enzymes in our model system. During gestation, compounds with varying 
chemical properties can traverse the placenta. In most cases an enzymatic conjugation reaction to 
make the compound more hydrophilic for rapid elimination occurs, however, the chemical may 
be deconjugated back to its parent compound or may accumulate within the fetus and neonate 
due to low metabolizing activity.  
 Yabusaki et al. [45] showed that UGT activity in perinatal liver microsomes following 
BPA and BPAF exposure were similar between adult males and females for each chemical, but 
overall activity was greater in BPA-exposed offspring compared to BPAF-exposed offspring. 
They also showed that the two predominant UGT isoforms (2B1 and 1A6) in C57Bl/6 offspring 
had relatively low expression and that was similar between males and females between GD 18.5 
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to PND 3. In our study, we attempted milk sample collections, but they were difficult to obtain in 
the volume needed for MS/MS. But, the fact remains that by PND 3 both BPAF and BPS in 
serum were below the LOD or close to baseline, so either any residual chemical that is being re-
introduced by lactation is being rapidly eliminated or lactational transfer of bisphenols is 
negligible at this point. Total bisphenol A has been reported in the milk of lactating North 
Carolina women, and was typically within 3-fold of the LOD (0.3 ng/ml) for milk, and milk 
levels were 10-fold lower than urine concentrations [46].  
 Fetal or maternal toxicity were not observed with the doses chosen from the disposition 
study and were therefore used as the highest dose in our developmental study, along with the 
addition of several lower concentrations within a dose range of 100-fold. When these animals 
were orally dosed twice daily for 8 days, all dams exhibited a normal gestation period of 18 days 
and had similar weight gain during pregnancy. Altered weight gain in offspring has been 
reported in rats and mice following much higher levels of BPA exposure [47, 48]. No significant 
effects of bisphenol treatment were detected on litter size at birth or on PND 1 female and male 
body weights. However, sex ratio was statistically higher for females in the 0.5 mg/kg BPS 
group. Pre-weaning pup survival was also unchanged, like studies involving lower doses [48]. 
Taken together, these data imply that fetal and maternal toxicity are not occurring at the doses of 
bisphenols used in this study, however, it does not rule out the potential for other endocrine 
related effects to occur during later development. 
 Although BPA has been removed from certain consumer products, the use of BPAF or 
BPS as replacements, or in novel applications, may still pose an environmental and human health 
risk. BPA disposition studies have previously been performed for multiple species and strains as 
well as administration routes [38, 49-52]. The increased presence of other bisphenol analogues, 
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including BPAF and BPS also require an understanding of their dispositions to determine if they 
may pose many of the same risks that have been associated with exposure to BPA. This is 
especially concerning for populations that may be at greater risks for the potential effects, 
including infants and children during their formative years. Few studies have assessed the 
pharmacokinetics of these chemicals, so it makes understanding the pharmacodynamics much 
more difficult. For some endpoints, such as fetal and tissue measurements, we lacked protocols 
for the mass spectrophotometer.   
 While additional human data is needed to understand if we are testing within a human 
relevant dose range, we were able to determine that the maternal disposition for BPAF and BPS 
are very similar to BPA with the exception of the predominant route of elimination. This in turn 
helped to establish the proper dosing regimen for future reproductive and developmental studies. 
The primary route of BPAF and BPS fetal exposure is likely through placental transfer and 
metabolizing capabilities during early development are similar between males and females for 
this strain. The changes in expression of metabolizing genes may become disproportionate later 
in development, affecting the appropriateness of this model for all applications; however, these 
studies were not designed to address that hypothesis and should be investigated in future studies. 
Overall, these studies will help to pave the direction for future studies and human risk 
assessment. 
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 BPA (50 mg/kg) BPAF (5 mg/kg) BPS (5 mg/kg) 
Serum    
AUC0-1 (mg*hour/L) 136.0 111.3 184.4 
AUC0-∞ (mg*hour/L) 136.2 111.4 186.4 
Tmax (hours) 2 4 4 
Cmax (ng/ml) 1090.0 ± 270.0 108.3 ± 103.6 179.7 ± 78.3 
t1/2 (hours) 5.5 4.5 7.0 
    
Urine    
Tmax (hours) 2 4 4 
Cmax (ng/ml) 136300.0 ± 91304.2 9320.0 29800 ± 14268.9 
t1/2 (hours) 5.3 4.7 8.2 
    
Amniotic Fluid    
Tmax (hours) 18 18 18 
Cmax (ng/ml) 735.3 ± 70.4 20.2 ± 2.5 277.3 ± 41.4 
t1/2 (hours) 7.6 n.d. 6.9 
    
Feces    
Tmax (hours) n.p. 4 4 
Cmax (ng/ml) n.p. 334.2 ± 78.7 10.1 ± 2.0 
t1/2 (hours) n.p. 6.0 6.3 
 
Table 2-1: Toxicokinetic parameters of BPA, BPAF, and BPS in maternal serum, urine, feces 
and amniotic fluid. AUC (area under the curve), Tmax (time and maximal concentration), Cmax 
(maximal concentration), t1/2 (half-life), n.d. (not determined), n.p. (no protocol was available at 
the time of analysis). Mean ± SD. 
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 BPA (ng/ml) BPAF(ng/ml) BPS (ng/ml) 
Age Females  Males Females Males Females Males 
PND 3 3.70 ± 1.18 (3) 3.33 ± 0.93 (3) <LOQ (3) 0.08 ± 0.02 (3) 0.11 ± 0.07 (4) 0.15 ± 0.13 (3) 
PND 4 1.12 ± 0.15 (4) 2.17 ± 1.67 (3) <LOQ (3) 0.15 ± 0.16 (4) 0.10 ± 0.06 (4) 0.08 ± 0.01 (4) 
PND 5 1.10 ± 0.56 (3) 1.10 ± 0.61 (3) 0.13 ± 0.11 (4) 0.26 ± 0.22 (4) 0.12 ± 0.05 (4) 0.12 ± 0.06 (4) 
 
Table 2-2: Total bisphenol serum concentrations in female and male offspring following a single in utero exposure on  
GD16. Mean ± SD. 
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 Male Female  Total Litter Size Sex Ratio (% female) 
 Body Weight (g) # per litter Body Weight (g) # per litter   
       
Vehicle 1.46 ± 0.04  7.7 ± 0.8 1.35 ± 0.03 5.0 ± 0.7 12.75 ± 0.69 39.5 ± 4.9 
       
BPA       
0.5 mg/kg 1.50 ± 0.04 6.8 ± 0.6 1.47 ± 0.09 5.4 ± 0.5 12.23 ± 0.51 44.4 ± 4.0 
5 mg/kg 1.59 ± 0.06 5.7 ± 0.7 1.51 ± 0.05 5.7 ± 0.7 11.33 ± 0.86 49.8 ± 4.6 
50 mg/kg 1.61 ± 0.03 6.4 ± 0.5 1.50 ± 0.03 5.4 ± 0.4 11.91 ± 0.69 37.3 ± 0.3 
       
BPAF       
0.05 mg/kg 1.48 ± 0.05 6.4 ± 0.4 1.45 ± 0.06 6.4 ± 0.7 12.80 ± 0.76 49.1 ± 3.7 
0.5 mg/kg 1.55 ± 0.06 6.7 ± 0.6 1.45 ± 0.05 6.2 ± 0.7 12.91 ± 0.55 47.4 ± 4.7 
5 mg/kg 1.55± 0.07 4.8 ± 0.7 1.45 ± 0.07 6.2 ± 1.0 11.91 ± 1.09 55.1 ± 5.7 
       
BPS       
0.05 mg/kg 1.53 ± 0.06 6.4 ± 0.5 1.48 ± 0.06 5.1 ± 0.4 11.50 ± 0.73 44.1 ± 2.5 
0.5 mg/kg 1.47 ± 0.06 5.0 ± 0.8 1.42 ± 0.04 6.7 ± 0.8 11.70 ± 0.68   59.0 ± 5.1* 
5 mg/kg 1.44 ± 0.03 6.2 ± 0.5 1.41 ± 0.04  5.8 ± 0.6 12.00 ± 0.85 48.1 ± 2.8 
 
Table 2-3: PND 1 pup weights and litter outcomes following BP analogue in utero exposure. Vehicle (n= 4), BPA 0.5 (n = 3), BPA 5 
(n = 4), BPA 50 (n = 3), BPAF 0.05 (n = 6), BPAF 0.5 (n = 5), BPAF 5 (n = 6), BPS 0.05 (n = 4), BPS 0.5 (n = 4) and BPS 5 (n = 5). 
Data are represented as mean ± SEM. 
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Figure 2-1: Time course of BPA, BPAF and BPS in maternal serum following a single oral 
administration to pregnant CD-1 dams. Mean ± SD for BPA (n = 3), BPAF (n = 3) and BPS  
(n = 3). 
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Figure 2-2: Gestational maternal urinary concentration following a one-time exposure to 
bisphenol analogues (2-48 hr) Mean ± SD for BPA (n = 2-3), BPAF (n = 1-3) and BPS (n = 3). 
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Figure 2-3: Maternal fecal concentration following a one-time exposure to bisphenol analogues 
(2-48 hr). Mean ± SD for BPAF (n = 3) and BPS (n = 3). 
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Figure 2-4: Amniotic fluid concentration following a one-time exposure to bisphenol analogues 
(2-48 hr). Mean ± SD for BPA (n = 3), BPAF (n = 2-3) and BPS (n = 3). 
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Figure 2-5: Postnatal maternal serum concentration following a onetime exposure to BP 
analogues. Gestational day 18 (GD 18) was added as a reference for comparison. Postnatal day 
(PND). Mean ± SD for BPA (n = 3), BPAF (n = 3) and BPS (n = 3). 
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Figure 2-6: Maternal body weight gain during gestational BPA, BPAF, or BPS exposure. A) 
BPA, B) BPAF, and C) BPS. Vehicle (n = 13), BPA 0.5 (n = 13), BPA 5 (n = 12), BPA 50 (n = 
13), BPAF 0.05 (n = 10), BPAF 0.5 (n = 12), BPAF 5 (n = 12), BPS 0.05 (n = 12), BPS 0.5 (n = 
11), and BPS 5 (n = 13). Data are represented as mean ± SEM. 
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CHAPTER 3 
Precocious development, ductal hyperplasia, and mammary tumors in CD-1 mice following 
prenatal exposure to bisphenol analogues  
OVERVIEW 
The continued efforts to phase out Bisphenol A (BPA) from consumer products have 
been met with the challenges of finding safer alternatives. Several replacement analogs have 
been implemented including Bisphenol AF (BPAF) and Bisphenol S (BPS); however, both 
possess estrogenic characteristics higher than or similar to BPA and may equally pose a risk to 
the developing mammary gland, including an increased susceptibility to developing later life 
disease. This study aimed to determine whether early life exposure to BPA and alternatives could 
affect female pubertal mammary gland development and produce effects that would persist into 
adulthood. Timed pregnant CD-1 mice were exposed to vehicle, BPA (0.5, 5, 50 mg/kg), or 
BPAF (0.05, 0.5, 5 mg/kg) or BPS (0.05, 0.5, 5 mg/kg) via oral gavage between gestational days 
10-17. Mammary glands were collected from female pups at PND 20, 28, 35 and 56, and at 3, 8, 
and 14 months for whole mount, histo-pathological evaluation, and qPCR; serum steroid levels 
were also measured at these same time points. Pubertal assessment included time at vaginal 
opening, time at first estrus, and mammary gland development. In the bisphenol exposed groups, 
accelerated mammary gland development was evident during early puberty and prolonged the 
presence of TEBs during early adulthood (3 months). By late adulthood (8 months and on), 
bisphenol-exposed female offspring exhibited varied morphology that included hyperplastic and 
inflammatory mammary lesions within and surrounding the ducts and stroma that were
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especially prominent in the BPAF 5 mg/kg and BPS 0.5 mg/kg group. By 14 months, the 
incidence of epithelial proliferative lesions and inflammation of the mammary gland within these 
groups was significantly higher than in vehicle controls, with significant dose-related trends in 
the BPAF-exposed animals. These lesions included perivascular inflammation, lobuloalveolar, 
tubuloalveolar, and papillary hyperplasia, and squamous metaplasia. There were also a few 
diagnosed adenocarcinomas, squamous cell carcinoma, histiocytic sarcoma, and carcinomas in 
the bisphenol-exposed animals. Steroid levels were altered at limited time-points, were non-dose 
responsiveness and varied by hormone. Adult mammary mRNA levels of Esr1, Pgr, Ar, and 
Gper1 genes from the classical estrogen pathway revealed minimal to no changes compared to 
vehicle control. Altogether, this data suggests that early exposure to BPAF or BPS may shift the 
window of development to make the mammary gland more susceptible to pre-neoplastic lesions 
at an incidence greater than that observed in BPA-exposed animals. It also suggests that early life 
events and/or non-classical estrogen pathways may play a critical role in mediating these 
phenotypes. 
 
INTRODUCTION 
 Bisphenol A (BPA) is a chemical commonly used in the manufacturing of plasticizers, 
epoxy resins, thermal paper, dental sealants, lining of canned foods and, prior to 2012 was a 
component used in sippy cups and baby bottles. Several rodent studies have linked BPA 
exposure at human relevant doses to neurobehavioral deficits, reproductive alterations and 
hepatic tumors [1-6].  In addition, early and pre-pubertal exposures markedly increased epithelial 
tissue growth, decreased apoptosis and decreased the latency of preneoplastic and neoplastic 
lesions in the mammary gland [7-10]. There remains a controversial debate surrounding its 
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relevance to human health, as human exposures are low when measured in urine, and biological 
activity of BPA metabolites is poorly understood.  
 Between 2003 and 2004, BPA was detectable in urine samples of >90% of the general 
population [11, 12]. The 4th National Exposure Report published by NHANES and the CDC 
reported that the highest urinary geometric mean for total BPA in every age group occurred 
between 2003 and 2004 compared to samples collected between 2005 and 2010 [13]. During this 
time, higher urinary concentrations were observed in males compared to females, and in 
populations of Non-Hispanic blacks compared to Mexican Americans and Non-Hispanic whites. 
BPA has also been recovered in maternal serum, amniotic fluid, umbilical cords, and fetal cord 
blood indicating that BPA readily crosses the placenta [14-18]. Distribution into milk in humans 
and rodents has also been reported [18-21]. Exposure to BPA during the fetal, perinatal or the 
early formative years are of great concern because of BPA’s weak estrogenic activity and known 
endocrine disrupting properties. 
 In 2010 the World Health Organization estimated that between the ages of 0-6 months 
breastfed infants were exposed to 0.3 µg/kg body weight BPA daily, while infants formula fed 
with polycarbonate bottles were estimated at 8x breast fed levels, and those given canned 
formula in polycarbonate free bottles were exposed to 0.5 µg/kg body weight [22]. This 
suggested that most of the exposure that infants acquired was through plastic bottles.  Therefore, 
several initiatives have been put into place to minimize the use of BPA in certain products. In 
July 2012, the FDA banned the use of BPA in baby bottles and sippy cups, with an expected 
phase out date of July 2013 in infant formula packaging [23]. While these first steps were 
necessary, there was still evidence suggesting that infants and smaller children were exposed 
through additional routes including through gestation and lactation, inhalation of contaminated 
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dust or oral exposures through canned foods and beverages often consumed by older children 
[19, 24, 25]. The combination of FDA use restrictions and voluntary recalls by some 
manufacturers has led to the increased use of other bisphenol analogues that are similar in 
structure and activity to BPA.  
Bisphenol AF (BPAF) was nominated for health effects assessment by the NTP in 2008 
due its estrogenic potential in vitro. Activity assays have shown that BPAF (53.4 nM) binds to 
estrogen receptor alpha (ERα) ~20x greater than BPA (1030 nM) and is an agonist for ERα and 
full antagonist for ERβ [26, 27]. Its production is considered to be moderate (10,000-500,000 
pounds) [28]; however, the six fluorine atoms located at the bridging carbon are likely to make it 
a persistent chemical and therefore make widespread human exposure inevitable. BPAF has been 
detected in contaminated air, soil, water and sediment downstream of factories involved in 
fluoro-elastomer production [29, 30]. Reports estimate that ~4300 occupational workers were 
exposed to BPAF between 1981and 1983, with one third of the exposed being women [31]. In 
addition, close to 1430 women in the molding and casting machine operations industry were 
thought to be exposed. More recently, BPAF was detected in the urine of a Chinese population 
downstream from a manufacturing plant [32]. The general population may be exposed through 
products used for dental sealant and composites and foodstuffs [25, 33].  
 Bisphenol S (BPS), another common BPA analogue, has been measured in thermal 
receipt papers, currency bills, and canned foodstuff, and is also used as a modifier for leather 
fiber, polymers, and as an epoxy curing agent [25, 34]. Similar to BPA, BPS was detected in 
100% of indoor samples from U.S., China, Japan, and Korea indicating that oral, dermal, and 
inhalation are all potential routes of exposure [24]. Human exposure to BPS has been confirmed 
by urinary measurements in the U.S. and seven Asian countries with the highest concentrations 
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found in Japan, followed by the U.S. [35]. Urine levels from cashiers, an occupation that 
extensively handles receipt paper, were significantly increased in cashiers post-shift compared to 
pre-shift [36]. Intermittent low dose exposure to this chemical may pose an increased risk to this 
population, especially women of childbearing age.  
The mammary gland is an essential tissue that is required for lactation and infant 
nourishment. Similar to other female reproductive tissues, it is influenced by many hormones 
and growth factors, with the primary drivers depending on the stage of development. Estrogens 
and progesterone are critical for ductal growth, elongation, branching, and differentiation and 
exposure to chemicals that can mimic these endogenous chemicals can alter normal mammary 
development. Similarly, when epithelial tissue from progesterone knockout mice (PRKO) was 
transplanted into stroma lacking PR, ductal development was stunted, indicating that expression 
of nuclear receptors in the stroma play a significant role in mammary development [37]. 
Mammary glands from ERα knockout mice (ERKO) develop rudimentary ductal structures but 
can grow normally in the presence of wild-type stroma that contains ERα [38, 39]. Studies of 
prenatal and perinatal exposure to human relevant low doses of BPA in rodents have caused 
changes in early postnatal mammary gland development that have persisted into adulthood and 
in some instances shifted the windows of susceptibility to developing preneoplastic and 
neoplastic mammary lesions [8-10]. While there is insufficient evidence in humans to delineate 
BPA’s role for adversely changing the breast environment, there are a limited number of studies 
that have linked BPA exposure to breast cancer in humans. Canadian women working in 
occupational and industrial manufacturers of automotive plastics, food canning, agriculture, and 
bar-gambling all had elevated breast cancer risk, with the highest risk for premenopausal women 
working in food canning (OR = 5.70; 95% CI, 1.03-31.5) and automotive plastics (OR = 4.76; 
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95% CI, 1.58-14.4) [40]. These women were likely exposed to a mixture of bisphenol analogues, 
among other industrial chemicals. There are several established and emerging breast cancer risk 
factors in pre-menopausal woman that include increased breast density, lifestyle, menstrual 
history and exposure to chemicals (i.e. DES, PAHs, and BPA) [41-43].  
 The most recent NHANES report (2011-2012) has shown an overall decline in the 
urinary BPA geometric mean concentration in both sexes and all ethnicities and age groups 
between 2003 and 2010 [44]. Similarly, urinary measurements from the U.S. general population 
between 2000 and 2014 showed a decline in BPA, but the percentage of samples detecting BPS 
and the average concentrations detected steadily increased, suggesting a change in exposure 
trends for BPS and BPA [12]. Although BPAF was below the limit of detection (<LOD) in the 
majority of the urine samples tested (98.4-100%, 2000-2014), BPAF has been extracted from 
mammary and abdominal tissue indicating that it may partition to adipose rich tissues, including 
the mammary gland [45]. To date, no study has evaluated BPAF and BPS effects on the 
developing mammary gland, nor any latent health repercussions that may be associated with 
early life exposures. The aim of this study was to determine if fetal exposures to BPAF or BPS at 
relatively low levels are capable of altering postnatal and adult mammary gland development of 
mice in a similar fashion to BPA. We report not only altered development of mammary tissue, 
but endocrine disruption and latent mammary tumor formation, suggesting these analogues are 
not suitable BPA replacements and may present a risk to the developing child. 
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MATERIALS AND METHODS 
Chemicals and Dosing Solutions 
 
All chemicals, except for Bisphenol AF (3B Pharmachem International Co. Ltd, Wuhan, 
P.R. China), were obtained from Sigma Aldrich (St. Louis, MO). The purity of all tested 
chemicals were confirmed by the NTP Chemistry/Chemical Contract and were found to be ≥ 
97.5 % (BPS), 98% (BPAF), and ≥99.0 % (BPA) pure. All chemicals arrived in powder form 
and were placed in a DryKeeper (Sanplatec Corp, Osaka City, Japan) at 25% humidity. Dosing 
solutions were prepared daily by dissolving in pure sesame oil (Jedwards, International, Inc., 
Braintree, MA) and stored in clear glass vials with screw on caps to prevent exogenous bisphenol 
contamination.  
 
 
Animals  
 
Outbred timed pregnant CD-1 mice were purchased from Charles River Laboratories 
(Raleigh, NC) and received on gestational day 8 (GD 8). All dams were acclimated a minimum 
of 2 days prior to dosing. Throughout the entire study, animals were maintained at a controlled 
temperature of 20-24oC with ~40-60% relative humidity and a 12:12 light/dark cycle. Upon 
arrival, animals were weighed and placed into polypropylene cages containing laboratory 
bedding (Sani-Chip Hardwood Bedding, PJ Murphy Forest Products, Inc., Montville, NJ) that 
had been tested and know to be free of estrogen activity [46]. Animals were randomly allocated 
to treatment groups; maintain equal initial body weight means in each group.  Exogenous dietary 
estrogens were minimized by providing AIN-93G (Harlan Laboratories, Indianapolis, IN) feed 
and tap water ad libitum. All animals were treated humanely and in accordance with the 
protocols of the National Institute of Environmental Health Sciences Animal Care and Use 
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Committee. Dams were weighed daily prior to dosing and dosing was based on daily body 
weight (BW). All chemicals were administered to the animals by a trained technician. The 
technician was blinded to chemical/dose (color coded) and animals received chemical exposure 
by concealed allocation. Any dam that produced a litter of < 4 pups total, litters with only males 
or who appeared unable to care for her litter was excluded from all final analyses. Female pups 
produced by these dams were followed up for up to 14 months.  
 
    
Experimental Design 
 
 These studies were initially powered to detect changes in pubertal indices, such as 
vaginal opening and mammary development in female pups. Earlier disposition studies in the 
pregnant CD-1 dam revealed that the bisphenol serum half-lives ranged from 4.5 – 7.0 hours and 
therefore to ensure that chemical steady state was reached; animals were gavaged twice a day 
(Chapter 2). Therefore, beginning on GD 10, approximately when the rudimental epithelial 
ductal tree begins to form, timed pregnant dams were oral gavaged twice daily with BPA 50 (n = 
11), 5 (n = 12), or 0.5 mg/kg bw (n = 13); BPAF 5 (n = 11), 0.5 (n = 11), or 0.05 mg/kg bw (n = 
10); BPS 5 (n = 12), 0.5(n = 11) or 0.05 mg/kg bw (n=12); or vehicle control (pure sesame oil, 
n=12), in dose volumes of 10 µl/g bw until GD 17. Dosing was concluded on GD17 because this 
strain normally gives birth on GD 18, unlike other mouse strains whose gestation length is < 19 
days [47]. The vehicle control group served as the common control group for all three 
compounds. Non-treatment related experimental conditions were identical across all study 
groups. The BPA dose range was based on a low observed adverse effect level (LOAEL) of 50 
mg BPA/kg, a no observed adverse effect level of 5 mg/kg for BPA, and the reference dose 
currently set by the EPA, which is 0.05 mg BPA/kg/d [48, 49].  
103 
 
Physiologically relevant BPA levels, lower than the reference dose set by the EPA have 
resulted in abnormal mammary gland development during critical periods of development in 
several rodent models; however, there is no data to suggest an effective dose range for either 
BPAF or BPS. Therefore, a dose range that includes the BPA reference dose concentration (50  
µg/kg/bw) was chosen to estimate the response in the mammary gland, considering that several 
studies suggested estrogenic potential of these two analogues [27]. These levels were also chosen 
because we anticipate that exposure to these chemicals will be lower compared to BPA exposure. 
Parturition occurred on the eve of GD 18 and the next day was considered postnatal day 1 
(PND 1). Litters were culled to 10 pups at PND 3; all attempts were made to maintain a 
minimum 5:5 male to female ratio, however, the maximum number of females was retained to 
ensure that there were a sufficient number of females for analyses. Female offspring were 
assessed for pubertal maturation beginning on PND 16 and weaned at PND 21. At PND 20, 28, 
35, and 56 (1 per litter) and 3, 8, and 14 months, female offspring (mostly 1, but sometimes 2 per 
litter) were euthanized by swift decapitation to obtain trunk blood for serum analysis and 
mammary glands for RNA, whole mount, and/or /histopathological analysis. Although there was 
not a designated collection between 11 and 13 months or after 14 months of age, several animals 
became moribund or exhibited estrous cycling irregularities that prohibited collection during the 
scheduled collections. With the exception of the 14 months collection (at diestrus), all animals at 
each time point were collected in the estrus stage of their estrous cycle. 
 
 
Mammary Gland Preparation and Analysis 
The 4th and 5th inguinal mammary glands were removed and processed for whole mounts 
and contralateral glands were fixed in 10% neutral buffered formalin (Fisher Scientific, Fair 
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Lawn, New Jersey) for histopathology. Fixed glands were embedded in paraffin and cut into 
5µm sections for hematoxylin and eosin (H&E) staining or immunohistochemistry. Whole 
mounts were prepared by flattening glands on a charged slide followed by fixation in Carnoy’s 
solution, staining with carmine alum and defatting in xylene [50]. Qualitative and quantitative 
assessments were performed at PND 20 and 35, hallmark time-points often assessed in academic 
and contracted studies (of weaning and puberty). Qualitative developmental scores were assigned 
separately by two individuals using a scale from 1-4 (1=poor development and 4=best 
development) [51].  Depending on age and level of development, scores were based on lateral 
and longitudinal epithelial growth, presence/absence of terminal end buds (TEBs), branching 
density, budding, and appearance of ductal ends.  Glands from each collection time point were 
separated and analyzed by chemical without knowledge of the chemicals identity or dose. Since 
the samples were compared to vehicle controls, the assessor was un-blinded to the vehicle 
control group. All glands were randomly evaluated by trained lab staff. Longitudinal growth, 
mammary epithelial area (MEA), duct length, and TEB count were quantitatively measured 
using ImageJ (https://imagej.nih.gov/ij/). Glands were also quantitatively assessed for branching 
density using ImageJ and the modified Sholl analysis method [52]. A detailed description of this 
method is illustrated by Stanko et al. [52]. Briefly, images of glandular epithelium are 
skeletonized, binarized, dilated and used to measure the MEA and longitudinal distance, defined 
as the most anterior position of the collecting duct to the most distal branch on the gland, using 
ImageJ. The total number of radial intersections (N) in the MEA was determined by Sholl 
analysis method. The branching density of the gland was then calculated using the formula 
N/MEA. TEBs were defined as buds that were ≥ 2x the diameter of its duct and are represented 
as TEBs/mm2. All quantitative measurements were performed on the 4th inguinal gland. 
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 Upon examining whole mounts at 3 months, numerous TEBs were noted in some slides, 
which is unusual for this age of CD-1 mice (S. Fenton, personal communication). Therefore, all 
whole mounted glands were visualized by light microscopy (Leica Z16 APO, Leica 
Microsystems, Buffalo Grove, IL), and terminal epithelial duct ends greater than 2X the diameter 
of the duct were considered a terminal end bud and recorded as an occurrence. Whole mounts 
from 8 and 14 month old mice were also examined for abnormalities (potential lesions) using 
light microscopy as described above. Unusual development was recorded. It should be noted that 
the Sholl method and certain quantitative measurements are unable to be performed on these 
glands due to extensive growth and tissue density. 
Contralateral fixed glands from mice of 3, 8, and 14 months old were embedded in 
paraffin, cut into 5 µm sections, stained with H&E, visualized on an Olympus BX41 (Olympus 
Scientific Solutions Americas Corp., Waltham, MA) and digitally captured on an Olympus DP70 
camera. A board-certified veterinary pathologist (S.B.H) evaluated all histopathology samples 
and was blind to treatment.  
Neoplastic and non-neoplastic mammary lesions were diagnosed using standardized 
nomenclature proposed by the International Harmonization of Nomenclature and Diagnostic 
Criteria for Lesions in Rats and Mice (INHAND) [53]. On occasions where a definitive 
diagnosis could not be made, a pathology peer review group was convened to resolve the 
diagnosis. Microscopic lesions were graded using a standard four-point scale of minimal, mild, 
moderate, and marked severity grade criteria.  
During the latter endpoints (3,8 and 14 months) some mammary gland whole mounts 
contained gross abnormalities that were often not noted in the single contralateral section 
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histopathology findings, all mammary gland whole mounts were sectioned for histopathology 
and assessed by a pathologist to diagnose the abnormality. A detailed description of this method 
has recently been published [54] (Appendix I). Briefly, mammary whole mounts were immersed 
in xylene overnight to remove excess Permount (Fisher Scientific), and allow for ease of 
scraping tissue off of the slide. Glands were halved at the midline, placed in cassettes, and 
processed in a succession of xylene and xylene: molten paraffin steps before final embedding. 
Glands were sectioned at 4 µm, stained with H&E and evaluated using the same criteria as the 
contralateral glands. 
 
Detection and Monitoring of Puberty and Cyclity 
 
Beginning on PND 16, all female offspring were checked daily for vaginal opening (VO), 
by trained observers, using the methods described in Goldman et al. [55]. Upon opening, cervical 
lavage using 1X PBS, pH 7.4 (Gibco, Waltham, MA) was conducted to determine the timing of 
first estrus and their estrous stage at VO. Morning lavage was continued until each animal 
exhibited estrus. Beginning on PND 24 and thereafter until 5-6 estrous cycles were achieved, 
soiled bedding from aged matched male control mice was collected into a homogenous mix and 
dispersed into all female cages to circulate male urinary proteins known to normalize the estrous 
cycle. From PND 63 until PND 84 the same group of animals was re-assessed for estrous cyclity 
by examining cervical cytology using the same methods.  
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Hormone Analysis 
Necropsy occurred between 9 and 11 AM and in the same estrous cycle stage (estrus, 
except for 14 months at diestrus) to minimize effects of hormonal fluctuation. Briefly, following 
trunk blood collection in a BD Vacutainer SST Plus tube (BD Bioscience, Franklin Lakes, New 
Jersey), the blood was inverted and stored at room temperature for 30 minutes. Samples were 
centrifuged at 1100g for 15 minutes, serum collected in a fresh tube, and stored at -80oC until 
processing. 
Serum preparation and analysis were performed per the manufacturer’s protocols. 
Samples were run on a Steroid Hormone Panel Kit from Meso Scale Discovery (MSD) 
(Rockville, MD) to determine estradiol, progesterone, testosterone, and DHEA concentrations. 
Samples and standards were added to 96-well plates pre-coated with antibody and incubated for 
2 hours at room temperature. A SULFOTAG label tracer was added to each well which  
generates a signal to determine the analyte concentration. The plates were washed 3x with 1X 
PBS-T and after final wash, 150 ul of a 1X Read-Buffer added to each well and plates were 
immediately imaged on a Sector Imager 2400 System (Meso Scale Discovery, Rockville, MD). 
All samples were run in duplicate, on the same day. Standards for all hormones were supplied in 
in the Meso Scale Discovery reagent kit, with the exception of testosterone (sample range 
0.1ng/ml - 16 ng/ml) that was purchased from Steraloids (Newport, RI).    
 
RNA Preparation 
RNA was extracted from frozen mammary tissue by homogenizing the gland with Trizol 
using Lysing D Matrix tubes (MP Biomedicals, Germany). Samples were homogenized in a MP 
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Biomedical Fast Prep-24 SG at 6.0 m/sec for 40 s intervals. Samples were homogenized a total 
of 2-3 times and placed on ice in between each interval. Samples were transferred to a clean tube 
and centrifuged to remove debris and the lipid layer. Following the manufacturer’s protocol, 
chloroform was added to obtain the organic layer and RNA was precipitated with isopropanol 
and washed with 75% ethanol. All samples underwent on-column DNAse I digestion using the 
RNA Mini Kit (Qiaqen, Germany). RNA quantity and integrity were measured on a Nano Drop 
2000c and Bioanalyzer. Samples with RNA integrity numbers ≥ 7.9 were used for PCR. One 
microgram of RNA was reverse transcribed with the High Capacity cDNA Synthesis Kit 
(Applied Biosystems, Warrington, UK) and amplified with the BioRad Thermocycler. cDNA 
was mixed with Taqman Universal PCR Master mix, No AmpErase UNG, and Taqman probes 
shown in Table 3-1 (Roche, Branchburg, NJ). Amplification was performed on a QuantStudio 7 
Flex PCR (Applied Biosystems, Foster City, CA) and analyzed using QuantStudio Real-Time 
PCR Software and Microsoft Excel 2010. Mean Ct values ≥ 35 or with a standard deviation of ≥ 
0.5 between duplicates were not included in the final analyses. Cdkna1 was used as the 
housekeeping gene for all samples. All analyses were performed using the 2-ΔΔCt method and are 
illustrated as the fold change relative to vehicle control. 
 
Statistical Analysis 
 Unless noted, all data are represented as mean ± SEM. The dam was considered the unit 
of measurement.  In nearly all cases only one pup per dam was sampled at any given time point. 
When multiple pups per dam were evaluated in the same analysis of quantitative endpoints, such 
as timing of vaginal opening and first estrus, mixed effects analysis of variance (ANOVA) with 
Dunnett’s test was used to account for potential litter effects. TEB occurrence was statistically 
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evaluated using one-sided Cochran-Armitage trend tests across vehicle control and each 
compound’s dose groups and one-sided Fisher’s exact tests comparing the vehicle control group 
to each dose group. ANOVA with Dunnett’s multiple comparisons test was applied to 
quantitative endpoints for which one pup per litter was assessed.  Hormone measurements were 
log transformed prior to statistical analyses to improve normality. Mean severity scores were 
calculated for 3, 8 and 14 month lesions whenever applicable and one-sided Fisher’s exact tests 
were performed to compare lesion incidences in each dose group to the vehicle control group. 
All analyses were performed using SAS 9.3 (Cary, NC). All Graphs and tables were generated 
using Microsoft Excel and GraphPad Prism and statistical significances were denoted at p ≤ 0.05.  
 
RESULTS 
Female Offspring Body Weight Changes. Body weight was assessed on PND 20, 28, 35, 
and 56 and at 3, 8, and 14 months for all female offspring prenatally exposed to vehicle, BPA, 
BPAF, or BPS (Figure 3-1). No differences among groups were observed at PND 20 or 28 but at 
PND 35 the BPAF 0.5 mg/kg group was significantly smaller compared to controls. By PND 56 
average body weights for this group were similar to vehicle control, however, BPS 5 mg/kg 
females were approximately 6 grams smaller than controls (17%). By 3, 8, and 14 months no 
significant differences were observed between any exposure group and the vehicle control group.   
Pubertal Assessment. All females were assessed for timing of pubertal development 
(including vaginal opening (VO), first estrus and mammary development). VO occurred between 
PND 25 and 26 in all groups with no significant differences observed among the groups (Figure 
3-2). Similarly, time to first estrus in BPA, BPAF or BPS exposed groups did not differ 
significantly from the vehicle control group. Estrous cyclity was monitored for 3 consecutive 
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weeks between PND 63-83. The number of cycles for each exposed group and the vehicle 
control group were not significantly different (data not shown), so the mean number of days in 
each estrous stage was compared between the vehicle control and exposed groups (Table 3-2). 
There were no significant differences between groups for the number of days spent in estrus and 
in diestrus over that three-week span, these females spent nearly 40% more time in diestrus 
compared to estrus. On average, animals were observed in proestrus only 5-10% of those days, 
and The BPA 5 mg/kg group experienced a significant decrease in the number of days spent in 
proestrus compared to vehicle control group but since the mouse spends such a limited time in 
proestrus this may not be biologically relevant.   
Bisphenol analogues hasten pubertal mammary gland development. Prenatal exposure to 
BPA, BPAF, or BPS influenced development of the mammary gland in female offspring 
evaluated on PND 20 (Figure 3-3). Specifically, mammary glands from females in BPAF (0.5 
and 5 mg/kg) groups exhibited increased longitudinal growth, branching density, TEB counts, as 
well as TEB/mm2.  Control glands averaged ~2.3 TEBs per gland on PND 20, while animals in 
the BPA 5 mg/kg and BPAF 5 mg/kg groups averaged ~10 TEBs.  Differences in mammary 
epithelial branching density differences were also observed between control vs. exposed (BPA 
0.5 mg/kg, and BPS 0.05 and 0.5 mg/kg groups). Mammary epithelial area (an indication of 
lateral and longitudinal growth) in the exposed groups did not differ significantly from the 
vehicle control group. Qualitative developmental scoring assessments mirrored the quantitative 
findings. BPA 5.0 mg/kg and BPS 5.0 mg/kg exposed groups had significantly increased 
developmental scores compared to controls indicating an accelerated phenotype (Table 3-3). On 
PND 20, all BPAF glands exhibited significantly accelerated development, and number of TEBs 
and branching points increased in a dose dependent manner (Figure 3-4).  
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At PND 28, only the BPAF exposed groups demonstrated significantly accelerated 
development. By PND 35, the BPA 50 mg/kg, BPAF 0.05 and 5 mg/kg, and every BPS exposed 
group exhibited developmental scores that were significantly increased compared to the vehicle 
control group. In comparing vehicle control whole mounts to BPS-exposed glands on PND 35, 
TEBs were apparent in all control glands, however, as BPS exposure dose increased, distance 
between the 4th and 5th glands decreased until the 4th and 5th glands had grown together (5.0 
mg/kg BPS). It was also noted that epithelial growth had either approached or surpassed the 
lymph node, something that was observed in few control glands (Figure 3-4). When glands were 
evaluated three weeks later (PND 56), the control and low doses of all treatment groups had 
caught up to the accelerated pace of development seen in earlier ages, and only BPS 0.5 mg/kg 
group still exhibited an advanced mammary phenotype. 
Prenatal exposure to BPA, BPAF, and BPS leads to latent effects in the mammary gland. 
Mammary gland whole mounts and histological sections from female offspring were also 
evaluated between early and late adulthood to determine the occurrence and incidence of 
mammary lesions following prenatal exposure to BPA, BPAF, or BPS. At 3 months gross lesions 
were not observed in whole mounts for any chemical. Similarly, the contralateral glands 
exhibited no microscopic pre-neoplastic lesions. However, TEBs were observed in 
approximatively 41-75% mammary glands in each of the exposed groups (exception is BPAF 5 
mg/kg group, 14%) compared to only 25% of vehicle control glands (Figure 3-5). Differences in 
TEB occurrence were not statistically significant using yes/no criterion. Those whole mounts 
containing TEBs were removed from slides and sectioned to determine if the TEBs were typical 
or exhibited disrupted growth patterns. Most TEB were confirmed to be within normal range, 
however mixed cell inflammation, was apparent in several of the exposed groups (BPA 50 
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mg/kg, BPA 5 mg/kg and BPAF 0.05 mg/kg). At the completion of the study ~15% of the 
mammary glands collected had a single or a combined diagnosis of inflammation with 45% 
(68/150) of the findings occurring at ≥ 14 months (Table 3-4 and Figure 3-6). By 14 months of 
age, most cases of inflammation were diagnosed by the presence of perivascular lymphocytes 
and were observed in all groups including the vehicle control (3 of 65 diagnoses), however, the 
occurrence was more prevalent in the chemically exposed groups and determined to be 
statistically significant in the animals from the BPS 0.5 mg/kg and BPAF 5 mg/kg groups.  
 By 8 months, epithelial proliferative lesions were evident in the exposed groups that were 
absent from vehicle control animals. One animal in the BPAF 5 mg/kg group presented with 
ductal squamous metaplasia at 8 months, and by 14 months numerous types of proliferative 
lesions in the ductal tissue were observed in exposed groups (Table 3-4-3-7 and Figure 3-6), with 
a significant trend in overall lesion development in the BPAF exposed groups, and significantly 
higher incidence in the BPAF 5 mg/kg group than in the vehicle control group. Although the 
BPS-exposed groups a significant trend, the BPS 0.5 mg/kg group developed significantly more 
proliferative lesions than the vehicle controls. The BPS exposed group had a significantly higher 
incidence of lobuloalveolar hyperplasia than vehicle controls, whereas the BPAF 5 mg/kg group 
saw an increased incidence of ductal squamous metaplasia, and a significant trend for that 
diagnosis. A total of twenty-four exposed animals were found to have lobuloalveolar hyperplasia 
of the mammary gland between 8 and 16 months (17 from timed necropsies and 7 from 
moribund animals).  
 No tumors were detected in any vehicle control group mammary glands at any time up to 
14 months (Table 3-5) and spontaneous mammary tumor development in CD-1 mice is rare, 
especially in the ages necropsied in this study. Histopathology identified tumors as early as 11 
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months (Table 3-4) in mammary glands of prenatally exposed groups. Although statistical 
significance was not achieved for any chemical or dose group, potentially because this study was 
not powered for tumor formation, eight different tumor types were identified in exposed groups. 
Adenocarcinomas were identified as the reason for early necropsy of two moribund animals in 
the BPS 5 mg/kg group.  The multiple tumor types included squamous cell carcinoma (n=2), 
papillary carcinoma (n=1), adenocarcinoma (n=2), carcinoma (n=1), and histiocytic sarcoma 
(n=1), and a benign fibroadenoma (n=1) (Figure 3-7). These lesions were identified between 11 
and 16 months. 
Serum hormone levels during puberty and late adulthood following prenatal exposure to 
BPA, BPAF, or BPS. Serum estradiol, progesterone, testosterone and dehydroepiandrosterone 
(DHEA) were measured on PND 20, 35, 56, and at 3, 8, and 14 months in prenatally exposed 
female offspring (Figure 3-8a and 3-8b). Prior to VO at PND 20, serum estradiol levels in all 
BPAF-exposed groups and the high and mid dose BPS-exposed groups were 90-160% higher 
than vehicle control levels. Progesterone levels were also raised in BPAF 5 mg/kg and BPS 0.05 
mg/kg groups prior to VO. Similarly, BPS 0.05 mg/kg and BPA 50 mg/kg groups demonstrated 
elevated DHEA levels. By PND 28, estradiol, progesterone, and DHEA serum levels in all 
treated groups were similar to vehicle control levels, with the exception of testosterone which 
was significantly decreased in BPAF 5 mg/kg and BPS 0.05 mg/kg groups. Interestingly, at PND 
35, testosterone levels were still decreased however, not in the same groups as at PND 28. 
Testosterone levels at PND 35 in the BPA 5.0 mg/kg, BPAF 0.05 mg/kg and BPS 0.5 mg/kg and 
5 mg/kg groups were significantly decreased compared to vehicle controls. By PND 56, the only 
significant differences were in testosterone and DHEA for the BPA 50 mg/kg group. In contrast 
to increases in early serum levels between treated and control groups, all notable differences 
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between treated and vehicle control groups in early adulthood were reductions (Figure 3-9). At 3 
months, progesterone levels were reduced in BPS 5 mg/kg groups. DHEA was also reduced by 
27-42% in at least one dose group for each compound. Estradiol (BPS 0.05 mg/kg), testosterone 
and DHEA (BPS 0.5 mg/kg) were also reduced at 8 months, but no dose-related trends were 
evident. Serum hormone measurements from 14-month old animals revealed no significant 
differnces between vehicle control and treated groups. Overall, there was no trend over time or 
within a chemical/dose group that were detected for any of the serum measurements even though 
the females were carefully estrous cycle staged prior to necropsy.  
Nuclear receptor expression in BP analogue treated female offspring. Since BPA, BPAF, 
and BPS are all considered to act as endocrine disruptors, we wanted to test whether an early life 
exposure could alter nuclear receptor expression in the mammary gland, and potentially pose as a 
mechanistic underpinning for phenotypic effects. Esr1, Pgr, Ar, and Gper1 expression was 
measured in mammary gland tissue by RT-PCR at 8 and 14 months (Figure 3-10). At the 8 
month evaluation, Esr1 expression was significantly decreased in BPA 0.5 mg/kg and 50 mg/kg 
and BPAF 0.05 mg/kg groups. Exposure to BPA 50 mg/kg group resulted in downregulation of 
Ar whereas exposure to BPAF 0.05 mg/kg and BPS 5 mg/kg reduced Pgr expression. No 
significant differences in steroid receptor expression were observed at 14 months between 
exposed and vehicle control groups. 
 
DISCUSSION 
 Altered pubertal mammary gland development and increased susceptibility to tumors 
following early life exposures to BPA have been illustrated in several rodent studies [7, 8, 56]. 
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Our findings herein suggest that other estrogenically similar bisphenol analogues may target 
endocrine dependent tissues; specifically, the mammary gland. In these studies, we provide 
evidence that limited prenatal exposure of female mice to BPA, BPAF, or BPS caused 
accelerated pubertal mammary development without altering other pubertal indicators (VO, 
timing to first estrus and cyclity). This is not the first report of the mammary gland being a 
sensitive pubertal end-point [57, 58] (Appendix II). We observed proliferative effects in the 
mammary gland that persisted into adulthood and later life, such as significantly increased 
incidences of inflammation and proliferative epithelial lesions (lobuloalveolar hyperplasia, ductal 
squamous metaplasia). We also report the development of adenocarcinomas in the BPS 5 mg/kg 
group that appeared at < 12 months of age. 
 Compromised mammary gland development before birth may account for the many 
alterations and manifestations that arise in the gland later in life, especially following endocrine 
disrupting exposure. This study showed that by PND 20 mammary glands from treated groups 
had an increased number of TEBs, branching density and TEBs per area of gland; these 
characteristics occurred in a dose dependent manner and persisted into young adulthood (PND 
56; 8 weeks.), and were concomitant with a pre-pubertal rise in serum estradiol levels. There is 
particular interest in the TEB because they are highly proliferative structures that are prominent 
early during puberty and contain cells sensitive to the effects of carcinogens and endogenous 
hormones critical for cell proliferation [59]. Their presence and differentiation are carefully 
orchestrated through a series of paracrine, endocrine, and autocrine events; however, the shift of 
these events can alter the timing and longevity of their presence. An increase in TEB counts and 
TEB/ductal area within one month of birth following low level BPA exposure has been 
previously observed [5, 8, 56], but we report here the extended presence of TEBs into adulthood 
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for all three bisphenols tested. In this study, TEBs were still present in 41-75% of mammary 
glands from nearly every chemically exposed group at 3 months. Although TEBs were still 
observed in 25% of the vehicle controls and were not considered significantly different from 
chemically exposed glands, their mere presence over multiple estrous cycles introduces 
intermittent exposures to endogenous hormones that increases the risk for later life tumor 
development.  
 Increasing evidence suggests that the role of the immune system is critical in the 
manifestation of breast cancer. We noted an increased incidence of inflammatory infiltrates 
comprised primarily of lymphocytes, plasma cells, and macrophages in the mammary gland of 
every chemically treated exposed group, with a the suggestion of a dose response trend (p=0.06) 
in the BPAF group, and significant increases compared to vehicle controls in the BPAF 5 mg/kg 
and BPS 0.5 mg/kg exposed groups. Macrophages play an essential role in the mammary 
microenvironment during normal development and breast cancer progression. Recently, Fischer 
et al. [60] reported that following a prenatal exposure to BPA (5 mg/kg), ovariectomized CD-1 
female mouse offspring that were given estradiol (300 ng) were shown to have down regulation 
of chemokines (i.e. Cxcl2, Cxcl4, Cxcl14 and Ccl20), interleukins and interferons (IL1β, IL1rn, 
IL7R, lrg1 and lfr9), and leukocyte markers (CD45, CD19, Ly6G and FSP1) at 2 months of age. 
Downregulation of many of these genes reduces the immune systems timely recognition and 
response for destroying abnormal cells. Similarly, reduction of apoptotic genes allows for 
uncontrolled cell proliferation and could promote an environment that is tumor friendly. With 
respect to our data, the increased incidence of inflammation throughout adulthood mammary 
development that we observed may have been influenced by early changes in the 
immunomodulatory response. Further studies will be necessary to evaluate this mechanism. 
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Contrary to these findings, Moral et al. [61] showed up-regulation of immune response genes in 
the mammary gland after 50 days (5 mg BPA/kg) and 100 days (250 mg BPA/kg) in rats given 
BPA concentrations 5-50x higher than those used in our study. These changes may be associated 
with the administered doses. Species differences may also play a role, but we could not rule out 
compensatory gene changes in response to the infiltrates. The fact that over 90% of the 
inflammation diagnoses occurred in doses ≤ 5 mg bisphenol/kg in our study may suggest that 
inflammatory responses are sensitive end points for BPA and the other analogs. It should also be 
noted that macrophages and other leukocytic infiltrates are necessary during pubertal and adult 
human breast development for the formation of the first TEBs; macrophages regulate and 
maintain an immunostimulatory presence throughout the estrous cycle [62, 63]. A potential shift 
in important immune responses may suggest the reason for the extended presence of the TEBs at 
3 months and requires further investigation. 
 Lobuloalveolar hyperplasia was also observed in every treated group with the exception 
of BPAF 0.05 mg/kg and BPS 0.05 mg/kg by 14 months. In rodents, lobuloalveolar hyperplasia 
often resembles the mammary gland from pregnant female rodents or pseudopregnancy and in 
some but not all cases may lead to an advanced hyperplastic state of the mammary gland. 
Vandenberg et al. [64] observed increased alveolar buds and lobuloalveolar units as early as 3 
months in CD-1 females following a perinatal exposure to BPA (0.25, 2.5 or 25 µg/kg). By 9 
months, intraductal hyperplastic lesions or “beaded ducts” were prevalent in multiple animals. 
BPA also produced lobuloalveolar hyperplasia in PND 90 and 140 mice exposed through a 
gestational (250 µg/kg) or gestational/lactational (0.25 and 25 µg/kg) exposure [10]. Mammary 
glands from rat offspring exposed to estradiol from gestation to PND 90 developed these 
structures, also [65]. Lobuloalveolar hyperplasia is considered a non-neoplastic lesion and there 
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is no association between these structures and tumor formation to date, but they frequently 
develop following exposure to hormones and endocrines disruptors. Therefore, we believe there 
is a link between bisphenol exposure and the development of lobuloalveolar hyperplasia 
formation in the mammary gland and that prolactin is possibly playing a role. We hypothesize 
that since exposure to estrogenic xenobiotics caused hyperprolactinemia and lobuloalveolar 
hyperplasia in female rats [66]. This potential mechanism warrants further investigation. 
 Several rat studies have examined the effects of early BPA exposure on the formation of 
preneoplastic and neoplastic lesions [67, 68]. Fetal exposure to low doses of BPA via a different 
route of administration (Alzet osmotic pumps) than was used in our study produced ductal 
hyperplasia and carcinoma in situ in Wistar-Furth at PND 50 and 95 that were confirmed to be 
actively proliferating [69]. Similarly, Sprague-Dawley rats developed mammary 
adenocarcinomas following gestational only and a combination of gestational and lactational 
exposure to BPA [10]. The few studies shown to induce mammary tumors following BPA 
exposure in a mouse model have involved a mammary tumor initiator (i.e. DMBA). Keri and 
Lozado et al. [70] showed that following prenatal exposure to 25 or 250 µg/kg BPA exposed 
female offspring given DMBA had a significantly higher predisposition for DMBA induced 
mammary tumors. In our study no animals from BPA dosed dams developed a tumor of any 
type, and we presume that we used doses that were too high to obtain the same results from those 
previous studies. However, we demonstrated that BPA tends to increase the rate of development 
of the mammary gland, with our lowest dose maintaining one of the highest developmental 
scores within the BPA-exposed group. 
 When this research began, the only human bisphenol data that existed was on BPA. One 
report recently published measured serum BPS in cashiers pre- and post-shift [36] but besides 
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this there are no reports of BPAF and BPS serum measurements from the general human 
population. Therefore, estimating a dose for human relevance relied on using BPA data, and 
thereofe our lowest BPAF and BPS dose are at the calculated EPA reference dose for BPA at 50 
ug/kg/bw (0.05 mg/kg/bw) daily [71]. An adenocarcinoma was identified as early as 11 months 
in the BPS high dose, with a second finding a month later in the same group. However, it was the 
BPS 0.5 mg/kg group which presented with a multitude of tumors likely arising from one or a 
combination of the many cell types that comprise the mammary gland. The CD-1 strain is an 
outbred strain that has been shown to develop spontaneous mammary tumors in both control 
male and females at 18 months or 2 years, however, many of these lesions were not identified 
until the animals were two years old, with the exception of one analysis where one female 
developed a mammary adenocarcinoma at 41-45 weeks [72-75]. While it is possible that the two 
year animals developed tumors that went undetected, the fact that none of our vehicle controls at 
3, 8, or 14 months developed a neoplasm may suggest that these tumors may truly be due to early 
life exposure to the bisphenols. 
 BPA is considered a weak estrogenic compound and therefore we were interested in 
determining if there would be changes in serum hormone levels well after prenatal exposure to 
BPA, BPAF, or BPS. Both BPAF and BPS have been shown to be agonists for ERα and produce 
proliferative effects in MCF-7 cells [27, 33, 76, 77]. In our study, serum estradiol, progesterone 
and DHEA levels were increased very early during puberty (PND 20) to complement the 
simultaneous mammary gland morphological observations. At PND 28 and 35, only testosterone 
levels were altered and were mostly reductions; by PND 56 increases in estradiol and DHEA 
were observed in the BPA 50 mg/kg group. By 3 months no dose-related trends were noted, 
however, all significant hormone changes were noted as reductions. DHEA was reduced in every 
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group except BPA 50 mg/kg, BPAF 0.05 mg/kg and BPS 0.05 mg/kg and 5 mg/kg groups at 3 
months and BPS 0.5 mg/kg at 8 months. In humans and other primates, the adrenals serve as a 
main contributor to DHEA secretion which can then be converted to both estrogens and 
androgens in target tissues, including the ovaries [78]. DHEA and other androgens have been 
implicated as having inhibitory effects against mammary proliferation and since the levels of 
circulating DHEA tend to decrease between the ages of 20 and 50, there is reason to believe that 
the incidence of breast cancer and its progression may, in part be due, to this decline [79-81]. In 
vitro studies in the H295R steroidogenesis assay showed that BPA, Bisphenol B (BPB) and 4-
cumylphenol increased 17β-estradiol and estrone levels. BPS did not cause any changes to any of 
these hormones but increased progesterone (744%) and 17α-OH progesterone levels (BPS, 
1676% vs. BPS, 22%) compared to BPA and other analogues including Bisphenol F, Bisphenol 
E and BPB [82].  
 The mammary gland is composed of various tissue and cell types that are governed by 
endocrine, autocrine and paracrine signals. Therefore, there is probably not one definitive 
mechanism of action for BPA and mammary tumor formation and the same may go for BPAF 
and BPS. ERα is expressed in fetal stromal cells but not epithelium [83]. This suggests that since 
estrogenic pathways are less influential in the epithelium during fetal mammary gland 
development that the stroma plays a major in role in the signaling changes seen in the 
epithelium. It is quite possible that these early life mechanistic changes are driving the altered 
phenotypes observed at puberty and in later life. Mammary gland gene expression analysis of 
Esr1, Pgr, Ar, and Gper1 as well as serum hormone levels showed very few changes at 8 months 
and no changes at 14 months that would point to a direct classical estrogen mediated mode of 
action. In a previous study at PND 50, BPA treated animals (250 ug/kg) had no change in protein 
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expression of ERα, however, PR-A, which is vital for ductal elongation, and the downstream co-
regulators SRC-1, SRC-2, and SRC-3 were all significantly increased [67]. Rosenmai et al. [82] 
also showed that while BPS increased estrogenic activity in vitro that it was the least potent and 
only showed a decreasing trend in activity for the AR assay. These changes are not very 
surprising since BPA has been shown to have a stronger binding affinity to ERRα and BPAF to 
ERβ as an antagonist at lower doses [27].  
 Our data did not indicate that pubertal timing or body weight during pre-puberty and 
adulthood were altered following early exposure to the three analogues as administered. Similar 
results were obtained following pre-pubertal exposures to BPA (10 mg/kg) in CD-1 mice [84]. 
Body weight, vaginal opening and the length of estrous cyclity were all similar to controls. In a 
similar study, Nah et al. [85] showed that when females were administered BPA (0.1, 1, 10, and 
100 mg/kg) during pre-puberty no changes in body weight gain in the two low dose groups 
occurred, while  reductions were seen in the two highest dose groups. Perinatal exposure to 
drinking water containing 1 mg/L of BPA resulted in increased PND 1 body, perigonadal white 
adipose tissue and brown fat weights in female but not male Sprague Dawley rats [86]. Several 
lipogenic and adipogenic genes were also altered in the adipose tissue. Interestingly, all dose 
groups experienced accelerated VO compared to controls. BPA did not affect weight gain or VO 
in our animals; however, paracrine signaling is essential for normal mammary gland 
development. Alterations of these same genes in our chemically exposed mammary glands could 
suggest a potential mechanism of action. In a study in rats, perinatal exposure to low doses of 
BPA (0.1 and 1.2 mg/kg) showed increased neonatal body weights in both males and females 
(PND 4 and 7) but this trend only persisted into adulthood for the lowest dose (females 
only)[87]. Furthermore, the high dose animals exhibited significant reductions in the number of 
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estrous cycles and percent of animals with regular cycles at 4 and 6 months. Considering that we 
observed no changes in the BPA 50 mg/kg group nor the lowest BPAF and BPS dose groups (1/2 
concentration of the lowest BPA concentration used in the previous study), we can only suggest 
that the timing of exposure was played a critical role in the differences observed. The only study 
that examined the estrous cycle for BPAF showed that concentrations ≥ 30 mg/kg caused cycling 
irregularities and also reduced body weights in both sexes [88]. Conflicting findings involving 
BPA urinary levels and precocious pubertal and mammary gland development have also been 
reported in epidemiological studies [89, 90]. Differences in rodent and human effects suggest 
that in addition to amount and timing of exposure that there are populations that may be more 
susceptible to changes induced by these three chemicals. 
  Our findings suggest that BPAF and BPS use in materials used by women of child-
bearing age or infants/children should be reconsidered. The fetal mammary gland is a sensitive 
target organ for these chemicals. Our data have shown that BPAF and BPS prenatally exposed 
female animals developed proliferative epithelial lesions by mid-life and a significant 
inflammatory response that may predispose them to tumor formation later in life. In fact, two 
animals in the high dose BPS group developed adenocarcinomas prior to one year of life, and 
triggered a necropsy at 14 months of age in the remaining animals. The majority of neoplasia 
incidents in this study (7/8) occurred in the BPS exposed animals. Although TEB occurrence did 
not reach significance compared to vehicle controls, the extended presence of these structures, 
the significant pre-pubertal spikes in serum estradiol, and the altered immune responses (i.e. 
increased perivascular inflammation) may play a role in the alterations that were observed later 
in life. This is the first report of BPAF and BPS effects in the mammary gland and these findings 
warrant further studies to determine relevance of these findings for human breast cancer 
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susceptibility. It is important to note that animals from this study were only exposed during the 
late fetal period when mammary bud formation was taking place. Therefore, our future studies 
will focus on epigenetic and/or stem cell changes that may have occurred during this critical 
period, in hopes of informing us of the modes of action involved in these observed later life 
effects.
  
 
Table 3-1: Taqman Gene Primer List used for Mammary Gland Samples 
Gene Identifier Vendor 
Esr1   Mm00433149_m1 Applied Biosystems 
Pgr Mm00435628_m1 Applied Biosystems 
Ar  Mm00442688_m1 Applied Biosystems 
Gper1  Mm02620446_s1 Applied Biosystems 
Cdkna1 Mm04205640_g1 Applied Biosystems 
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Table 3-2: Days spent in estrus, diestrus and proestrus during PND 63-83 following in utero exposure to BPA, BPAF, or BPS  
 Estrus (d) Diestrus (d) Proestrus (d) 
Vehicle 7.2 ± 4.0 11.7 ± 3.3 2.0 ± 1.0 
    
BPA 0.5 mg/kg 7.6 ± 2.9 11.4 ± 2.7 1.2 ± 1.3 
BPA 5 mg/kg 7.7 ± 2.7 11.0 ± 2.4 1.0 ± 0.6* 
BPA 50 mg/kg 6.1 ± 2.4 12.1 ± 3.1 1.4 ± 1.2 
    
BPAF 0.05 mg/kg 7.3 ± 2.2 11.2 ± 2.9 1.5 ± 1.2 
BPAF 0.5 mg/kg 7.0 ± 2.3 11.7 ± 2.6 1.6 ± 1.0 
BPAF 5 mg/kg 5.6 ± 2.4 12.8 ± 1.4 1.4 ± 0.7 
    
BPS 0.05 mg/kg 7.5 ± 3.3 11.2 ± 3.8 1.7 ± 1.0 
BPS 0.5 mg/kg 6.0 ± 3.7 12.4 ± 4.0 1.3 ± 1.3 
BPS 5 mg/kg 6.7 ± 2.0 11.4 ± 2.2 1.7 ± 1.3 
 
Data are presented as the mean number of days in that stage ± SEM. Dam is the unit of measurement. Litter numbers (n): Vehicle (n = 
9), BPA 0.5 (n = 12), BPA 5 (n = 12), BPA 50 (n = 9), BPAF 0.05 (n = 9), BPAF 0.5 (n = 11), BPAF 5 (n = 11), BPS 0.05 (n = 12), 
BPS 0.5 (n = 11) and BPS (n = 10). Statistically significantly different from the control group by Dunnett’s test at *p < 0.05;  
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Table 3-3: Qualitative pubertal mammary gland development scores of female offspring exposed in utero to BPA, BPAF, and BPS 
 Vehicle BPA 
  0.5 mg/kg 5 mg/kg 50 mg/kg 
PND 20 2.03 ± 0.07 2.41 ± 0.12 2.79 ± 0.22 *** 2.45 ± 0.23 
PND 28 2.33 ± 0.18 3.00 ± 0.25 1.92 ± 0.22 2.50 ± 0.26 
PND 35 1.92 ± 0.21 2.50 ± 0.33 2.46 ± 0.22 2.89 ± 0.21* 
PND 56 2.39 ± 0.15 3.00 ± 0.12 2.79 ± 0.26 3.11 ± 0.22 
     
  BPAF 
  0.05 mg/kg 0.5 mg/kg 5 mg/kg 
PND 20 - 2.77 ± 0.27** 2.79 ± 0.19*** 2.80 ± 0.17*** 
PND 28 - 2.79 ± 0.33 2.57 ± 0.18 3.25 ± 0.23* 
PND 35 - 3.12 ± 0.35* 1.96 ± 0.18 3.05 ± 0.46* 
PND 56 - 2.95 ± 0.17 2.78 ± 0.28 2.93 ± 0.37 
  BPS 
  0.05 mg/kg 0.5 mg/kg 5 mg/kg 
PND 20 - 2.44 ± 0.14 2.38 ± 0.19 2.69 ±0.24** 
PND 28 - 2.75 ± 0.22 2.38 ±0.19 3.04 ± 0.20 
PND 35 - 3.21 ± 0.23** 3.00 ± 0.23** 2.88 ± 0.23* 
PND 56 - 2.96 ± 0.34 3.22 ± 0.22* 2.61 ± 0.21 
 
Evaluations on postnatal days (PND) 20-56 demonstrate advanced development in bisphenol treated animals.  Glands are scored on a 
scale of 1 (poor development) - 4 (best development).  (-) Denotes that there was a common vehicle control group for all chemicals. 
Data are presented as the mean ± SEM. Dam is the unit of measurement. Litter number= n (1 animal/litter/time point). Vehicle (n = 5-
9), BPA (n = 5-10), BPAF (n = 4-10) and BPS (n = 5-10).  Statistically significantly different from the control group by Dunnett’s test 
at *p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 3-4: Mammary gland diagnosis at time of death following prenatal exposure to BPA, BPAF, or BPS 
Time of Death (Weeks) 1-10 11-20** 21-30 31-40* 41-52 Total between 53 and  
68 weeks*† 
Total between 1-68 
weeks 
Total number of animals  92 4 55 27 150 328 
Inflammation  3  1 6 68 78 
Ductal Squamous metaplasia    1  15 16 
Lobuloalveolar hyperplasia    1 4 19 24 
Miscellaneous (cyst, keratin, hemorrhage)      9 9 
Histiocytic Sarcoma      1 1 
Fibroadenoma      1 1 
Papillary Carcinoma      1 1 
Squamous Cell Carcinoma      2 2 
Adenocarcinoma/Carcinoma     2 1 3 
Total Neoplasia     2 6 8 
 
*Includes animals from scheduled necropsies at 3 months (12 wk), 8 months (32 wk) and 14 months (56 wk). 
**Refer to Deaths.xlsx to describe animals that were included but no official diagnosis was made due to the animal dying and 
autolyzing issues (Appendix III). 
†Some animals may had have had multiple diagnoses  
 
  
127 
  
 
Table 3-5: Proliferative epithelial lesions and tumors following prenatal exposure to BPA, BPAF, or BPS 
Exposure (mg/kg bw/day) Incidence  
 Total Lesions Cancer Diagnosis (age) 
Vehicle 0/27 0/27 None 
    
BPA 0.5 4/34 0/34 Lobuloalveolar hyperplasia (12 and 14 months (3x) 
BPA 5 5/31 0/31 Lobuloalveolar hyperplasia (8, 12 (2x) and 14 months (2x)) 
BPA 50 1/21 0/21 Lobuloalveolar hyperplasia (14 months) 
    
BPAF 0.05 1/33 0/33 Squamous metaplasia (14 months) 
BPAF 0.5 3/34 0/34 Lobuloalveolar hyperplasia (14 months)  
Squamous metaplasia (14 months (2x) 
BPAF 5 12/37 1/37 Lobuloalveolar hyperplasia (14 (3x) and 15 months) 
Squamous metaplasia (8 and 14 months (6x)) 
Squamous cell carcinoma (14 months) 
    
BPS 0.05 1/24 0/24 Squamous metaplasia  
BPS 0.5 15/34 4/34 Carcinoma (14 months)  
Histiocytic sarcoma (14 months)* 
Lobuloalveolar hyperplasia (14 months (5x))* 
Papillary carcinoma/hyperplasia, papillary (14 months) 
Squamous cell carcinoma (14 months) 
Squamous metaplasia (14 months (4x))* 
BPS 5 6/33 2/33 Adenocarcinoma (11 and 12 months) 
Fibroadenoma (14 months) 
Lobuloalveolar hyperplasia (11, 14 and 16 months) 
    
 (x) number of animals with diagnosis 
*Some animals in the BPS 0.5 mg/kg group had more than one lesion 
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Table 3-6: Lesion Incidences 
 Vehicle  BPA  BPAF  BPS 
3 months 0  0.5 5 50  0.05 0.5 5  0.05 0.5 5 
Number examined 8  11 11 9  9 8 7  9 9 9 
Inflammation, mixed cell 0  0 1 
[1.0] 
1 
[1.0] 
 1 
[1.0] 
0 0  0 0 0 
              
8 months              
Number examined 5  8 5 5  7 5 6  3 5 5 
Lobuloalveolar hyperplasia 0  0 1 
[1.0] 
0  0 0 0  0 0 0 
Inflammation, mixed cell 0  0 0 0  0 0 1 
[1.0] 
 0 0 0 
Squamous metaplasia, ductal 0  0 0 0  0 0 1 
[1.0] 
 0 0 0 
              
14 months              
Number examined 13  14 11 6  14 18 22  11 18 13 
Carcinoma 0  0 0 0  0 0 0  0 2 0 
Fibroadenoma 0  0 0 0  0 0 0  0 0 1 
Histiocytic sarcoma 0  0 0 0  0 0 0  0 1 0 
Lipoma 0  0 1 0  0 0 1  0 0 0 
              
Cyst 0  0 0 0  0 1 0  1 0 0 
Cyst lined by squamous 
epithelium 
0  0 0 0  0 0 2  0 1 0 
Duct dilation 0  0 0 1  0 0 0  0 0 0 
Hemorrhage, focally 
extensive 
0  0 0 1  0 0 0  0 0 0 
Inflammation, 
lymphoplasmacytic 
perivascular 
2 
[1.0] 
 5 
[1.0] 
3 
[1.0] 
3 
[1.7] 
 7 
[1.0] 
7 
[1.0] 
5 
[1.0] 
 2 
[1.0] 
11* 
[1.3] 
3 
[1.0] 
Inflammation, mixed cell 1$$ 
[1.0] 
 0 0 0  1 
[1.0] 
2 
[1.0] 
8 
[1.2] 
 2 
[1.0] 
6 
[1.3] 
2 
[1.0] 
Inflammation, neutrophilic 0  0 0 0  0 0 1 
[1.0] 
 0 0 0 
Inflammation, not specified 0  0 0 0  0 0 1  0 0 0 
Keratin 0  0 0 0  1 0 0  0 0 1 
Loose keratin 0  0 0 0  0 0 1  0 0 0 
Lobuloalveolar hyperplasia 0$  3 
[1.0] 
2 
[2.0] 
1 
[1.0] 
 0 1 
[1.0] 
3 
[1.7] 
 0 5* 
[1.2] 
1 
[1.0] 
Lymph node: inflammation, 
neutrophilic 
0  0 0 0  0 0 0  0 1 
[3.0] 
0 
*Differs from the control group by Fisher’s exact test at p < 0.05; ** p < 0.01. 
# Significant trend for BPA by the Cochran-Armitage trend test; ## p < 0.01. 
$ Significant trend for BPAF by the Cochran-Armitage trend test; $$ p < 0.01. 
% Significant trend for BPS by the Cochran-Armitage trend test; %% p < 0.01. 
Numbers in brackets, [ ], are the mean severity scores where 1 = minimal, 2 = mild, 3 = moderate. 
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Table 3-6: Lesion Incidences (cont.) 
14 months Vehicle  BPA  BPAF  BPS 
Lymph node: Inflammation, mixed with 
eosinophilic crystals 
0  0 0 0  0 0 0  0 0 1 
Lymph node: squamous cell carcinoma 
or met from zymbal’s gland 
0  0 0 0  0 0 1  0 1 0 
Lymph node: vascular angiectasis 0  0 0 0  0 0 0  0 1 0 
Lymph node: increased cellularity, 
plasma cells 
0  0 0 0  0 0 1  0 0 0 
Papillary hyperplasia, multifocal 0  0 0 0  0 0 0  0 1 0 
Squamous metaplasia, ductal 0$$  0 0 0  1 
[1.0] 
2 
[1.0] 
7* 
[1.4] 
 1 
[2.0] 
4 
[1.2] 
1 
[1.0] 
Tubuloalveolar hyperplasia 0  0 0 0  0 0 1 
[1.0] 
 0 0 0 
*Differs from the control group by Fisher’s exact test at p < 0.05; ** p < 0.01. 
# Significant trend for BPA by the Cochran-Armitage trend test; ## p < 0.01. 
$ Significant trend for BPAF by the Cochran-Armitage trend test; $$ p < 0.01. 
% Significant trend for BPS by the Cochran-Armitage trend test; %% p < 0.01. 
Numbers in brackets, [ ], are the mean severity scores where 1 = minimal, 2 = mild, 3 = moderate. 
 
 
  
 
 Table 3-7: Combined Incidences (p-values) 
  Vehicle BPA Vehicle BPAF Vehicle BPS 
14 months 0 0.5 5 50 0 0.05 0.5 5 0 0.05 0.5 5 
Number 
examined 
13 14 11 6 13 14 18 22 13 11 18 13 
Inflammation, 
all types 
3 
(0.156) 
5 
(0.385) 
3 
(0.590) 
3 
(0.257) 
3 
(0.062) 
8 
(0.079) 
9 
(0.126) 
14 
(0.023) 
3 
(0.159) 
4 
(0.395) 
15 
(0.001) 
4 
(0.500) 
Neoplasias 0 0 0 0 0 0 0 0 0 
(0.287) 
0 
(--) 
2 
(0.329) 
1 
(0.500) 
Epithelial 
proliferative 
effects 
0 
(0.375) 
3 
(0.124) 
2 
(0.199) 
1 
(0.316) 
0 
(<0.001) 
1 
(0.518) 
3 
(0.182) 
10 
(0.004) 
0 
(0.500) 
1 
(0.458) 
7 
(0.012) 
2 
(0.240) 
Lymph node, 
all effects 
0 0 0 0 0 
(0.076) 
0 
(--) 
0 
(--) 
1 
(0.629) 
0 
(0.287) 
0 
(--) 
2 
(0.329) 
1 
(0.500) 
 
Trend p-values are in parentheses in the Vehicle column; pairwise p-values are in parentheses in the Dose columns. All p-values are 
one-sided. 
(--) indicates that the pairwise p-value cannot be calculated
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Figure 3-1: BPA, BPAF, and BPS exposures on pubertal and adult weight gain in CD-1 female 
offspring. p < 0.05 is statistically significant compared to vehicle control using ANOVA and a 
Dunnett’s t-test. N=4-10 litters/dose group. 
 
  
V e h ic le 0 .5  5 5 0
2 2
2 4
2 6
2 8
3 0
B P A
D o s e  (m g /k g )
V
O
 (
d
a
y
s
)
        
V e h ic le 0 .0 5  0 .0 5  5
2 2
2 4
2 6
2 8
3 0
B P A F
D o s e  (m g /k g )
V
O
 (
d
a
y
s
)
               
V e h ic le 0 .0 5  0 .0 5  5
2 2
2 4
2 6
2 8
3 0
B P S
D o s e  (m g /k g )
V
O
 (
d
a
y
s
)
   
 B)                                   
        
V e h ic le 0 .5  5 5 0
2 4
2 6
2 8
3 0
3 2
B P A
D o s e  (m g /k g )
1
s
t 
E
s
tr
u
s
 (
d
a
y
s
)
          
V e h ic le 0 .0 5  0 .0 5  5
2 4
2 6
2 8
3 0
3 2
B P A F
D o s e  (m g /k g )
1
s
t 
E
s
tr
u
s
 (
d
a
y
s
)
                   
V e h ic le 0 .0 5  0 .0 5  5
2 4
2 6
2 8
3 0
3 2
B P S
1
s
t 
E
s
tr
u
s
 (
d
a
y
s
)
D o s e  (m g /k g )
 
Figure 3-2: Pubertal assessment in CD-1 female offspring prenatally exposed to BPA, BPAF, or BPS. Data are reported as mean age 
with standard error bards (days old) at A) Vaginal opening (VO) and B) Occurrence of first estrus for the various doses of bisphenol. 
Time to VO and first estrus were compared using mixed effects ANOVA, accounting for litter effects. N= 4-10 litters/dose group. No 
statistical differences were observed when bisphenol exposed animals were compared to vehicle controls using mixed effects ANOVA 
with a Dunnett’s test. N=4-10 litters/dose group.  
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Figure 3-3: Mammary gland whole mounts from BPAF females on PND 20 (top panel) and BPS females on PND 35 (bottom panel). 
Representative image of A and E) Vehicle Control, B) BPAF 0.05 mg/kg, C) BPAF 0.5 mg/kg, D) BPAF 5 mg/kg, F) BPS 0.05 
mg/kg, G) BPS 0.5 mg/kg and H) BPS 5 mg/kg. 
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Figure 3-4: Sholl analysis and quantitative mammary gland parameters in BPA, BPAF, or BPS 
treated female offspring at PND 20. Mean ± SEM. p < 0.05 is statistically significant compared 
to vehicle control using ANOVA and a Dunnett’s t-test. Vehicle (n = 8-10), BPA (n = 9), BPAF 
(n = 5-8) and, BPS (n = 8-10).  
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 Figure 3-5: Increased occurrence of terminal end buds in mammary glands of 3-month old 
females prenatally exposed to BPA, BPAF, or BPS. Representative image of A) Control and B) 
Treated mammary whole mount. Occurrence is represented as a percentage of total animals. 
Vehicle (n=8), BPA 0.5 (n=11), BPA 5 (n=11), BPA 50 (n=9), BPAF 0.05 (n=9), BPAF 0.5 (n=8), 
BPAF 5 (n=7), BPS 0.05 (n=10), BPS 0.5 (n=8), and BPS 5 (n=8).  
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A)            B) 
 
C)             D) 
 
 
 
 
 
Figure 3-6: Histological evaluation of non-neoplastic mammary lesions following early life 
bisphenol analogue exposure. Representative images illustrate A) Lobuloalveolar hyperplasia, B) 
Cyst, C) Lymphoplasmacytic Perivascular Inflammation and D) Squamous Metaplasia, ductal 
  
 
  
 
 A)                     B) 
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Figure 3-7: Histological evaluation of neoplastic mammary lesions following early life BP analogue exposure. Representative images 
illustrate A) Adenocarcinoma, B) Squamous cell carcinoma, and C) Histiocytic sarcoma. 
Histiocytic 
 
138 
  
      A)          PND 20            B)  PND 28   C)          PND 35              D)    PND 56 
V 0 .5  5 5 0 0 .0 5  0 .5  5 0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
E
s
tr
a
d
io
l 
(p
g
/m
l)
** * *
* *
B P A B P A F B P S
D o s e  (m g /k g )
 
V 0 .5  5 5 0  0 .0 5 0 .5  5 0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
E
s
tr
a
d
io
l 
(p
g
/m
l)
B P A B P A F B P S
D o s e  (m g /k g )
 
V  0 .5   5   5 0   0 .0 5 0 .5   5   0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
D o s e  (m g /k g )
E
s
tr
a
d
io
l 
(p
g
/m
l)
B P A B P A F B P S
 
V 0 .5  5 5 0 0 .0 5  0 .5  5 0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
E
s
tr
a
d
io
l 
(p
g
/m
l)
B P A B P A F B P S
D o s e  (m g /k g )  
       E)              F)              G)    H)  
V 0 .5  5 5 0 0 .0 5  0 .5  5 0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
P
ro
g
e
s
te
ro
n
e
 (
n
g
/m
l)
*
*
B P A B P A F B P S
D o s e  (m g /k g )  
V 0 .5  5 5 0  0 .0 5 0 .5  5 0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
P
ro
g
e
s
te
ro
n
e
 (
n
g
/m
l)
B P A B P A F B P S
D o s e  (m g /k g )
 
V 0 .5  5 5 0 0 .0 5  0 .5  5 0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
D o s e  (m g /k g )
P
ro
g
e
s
te
ro
n
e
 (
n
g
/m
l)
B P A B P A F B P S
 
V 0 .5  5 5 0 0 .0 5  0 .5  5 0 .0 5  0 .5  5
0
5
1 0
1 5
2 0
P
ro
g
e
s
e
ro
n
e
(n
g
/m
l)
B P A B P A F B P S
D o s e  (m g /k g )  
Figure 3-8a: Steroid serum levels from bisphenol analogue-exposed females during pubertal development (Estradiol and 
Progesterone). A, E) PND 20; B, F) PND 28; C, G) PND 35; and D, H) PND 56. Mean ± SEM. n=3-4 per group. *p<0.05 is 
statistically significant compared to vehicle control by Dunnett’s test. 
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Figure 3-8b: Steroid serum levels from bisphenol analogue-exposed females during pubertal development (Testosterone and DHEA). 
A, E) PND 20; B, F) PND 28; C, G) PND 35; and D, H) PND 56. Mean ± SEM; n=3-4 per group. *p<0.05 is statistically significant 
compared to vehicle control by Dunnett’s test. 
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Figure 3-9: Effects of prenatal BPA, BPAF, or BPS exposure on female serum hormone levels 
at 3, 8, and 14 months. A, D, G, and E) 3 months; B, E, H, and K) 8 months; and C, F, I, and L). 
14 months. Mean ± SEM. n=2-6. *p<0.05 and **p < 0.01 is statistically significant compared to 
vehicle control by Dunnett’s test. 
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Figure 3-10: Expression of steroid receptor mRNA in the mammary gland at A) 8 and B) 14 months. Mean ± SEM. n= 1-4 * p < 0.05 
and ** p < 0.01 is statistically significant compared to vehicle control. 
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CHAPTER 4 
Isolation and characterization of mammary stem cells following prenatal bisphenol analogue 
exposures in CD-1 mice 
 
OVERVIEW 
 Early life exposures to human relevant doses of bisphenol A (BPA) in various rodent 
models have resulted in altered mammary development with an increased susceptibility to 
tumorigenesis.  The proliferative wave of mammary stem cells (MaSC) during puberty and their 
increased susceptibility to damage during specific windows of development may serve as a 
plausible explanation for these changes.  The mammary-specific mode of action of BPA or its 
sulfonated and fluorinated analogs, BPS and BPAF, respectively, remains elusive. We 
hypothesize that early life exposure to bisphenol analogs may play a role in “reprogramming” the 
stem cells, an effect that cannot be visualized until puberty when branching morphogenesis 
predominates.  Previous findings identified increased epithelium during puberty following 
exposure to BPAF and BPS and therefore the main objective of this study was to identify and 
quantify MaSC changes in the peri-pubertal CD-1 mouse to determine if these effects correlated 
with observed morphological changes. Timed pregnant CD-1 dams were gavaged 2x daily with 
vehicle (sesame oil), BPAF (5 mg/kg) or BPS (0.5mg/kg) between gestational days 10-17.  A 
subset of control female offspring was evaluated on postnatal days (PND) 19, 22, 28, and 35 for 
mammary morphological changes using whole mounts.  On PND 19, 22, 28, 35, and 56 
mammary glands from the remaining control animals, BPAF and BPS and were removed, 
dissociated, and sorted using flow cytometry based on the epithelial markers EpCAM and CD49f 
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to obtain the basal/myoepithelial and luminal populations.  Sorted cells were transplanted into 
cleared fat pads of 3-week old recipient female mice using limiting dilution, assessed for gland 
regeneration 6-8 weeks later, and the mammary repopulating unit frequency (MRU) determined. 
Whole mammary glands from a subset of each group were assessed for Wnt1, Wnt5a, Lrp5, and 
Notch1 expression. The percentage of MaSC was greatest at PND 22, but was significantly 
decreased at PND 35 following treatment with both chemicals. Neither BPAF nor BPS altered 
percent progenitor or stromal cells at any time during puberty compared to controls. Transplant 
regeneration yielded pubertal (PND 22-56) MRU frequencies of 1/1099-1/6988 (vehicle) 
compared to 1/4123-1/31997 (BPAF) and 0-1/20901 (BPS). Lrp5, Wnt5 and Notch1 gene 
expression were significantly decreased at PND 22. Taken together these data suggest that 
pubertal morphological changes associated with prenatal BPAF and BPS exposure are not driven 
by increased pubertal MaSC and progenitor populations. Lineage tracing of fetal MaSC may 
reveal different results. 
 
INTRODUCTION 
Breast cancer is a complex and heterogeneous disease that remains the second leading 
cause of death in women in the U.S. with < 25% of the cases resulting from heredity and genetics 
[1]. Established factors such as age, sex, ethnicity, and parity also alter a woman’s risk for breast 
cancer, but other factors like lifestyle choices, high breast density, and incidental/accidental or 
occupational exposure to chemicals may further compound an individual’s susceptibility. Breast 
cancer is a disease that targets the epithelial fraction of the gland, and these cells also respond to 
many environmental and chemical exposures. Therefore, great interest lies in understanding the 
associations between disease risk and communication of the breast epithelial and stroma that 
occur across a lifetime and may be modified by early life influences from these non-heritable 
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factors. The mechanisms that drive these events are at the forefront of mammary biology and 
breast cancer research and are critical to prevention/intervention, diagnosis, and treatment.   
The mammary gland is an intricate tissue that involves extensive crosstalk between 
multiple cell and tissue types including adipose tissue, endothelial, stromal, immune, and 
epithelial cells. Normal mammary gland development occurs at a rate comparable to other organs 
and tissues but remains in a quiescent state until puberty. Mammary gland growth is reactivated 
prior to other aspects of puberty (i.e., first estrus or menses). In rodents, neuronal excitation and 
inhibition initiate pubertal development to initiate the release of gonadotrophin releasing 
hormone (GnRH) [2]. Influences from both trans-synaptic and glia to neuron pathways rely on 
the kisspeptin peptide, an excitatory amino acid, to become activated. Kisspeptin neurons have 
been found to expressed and regulated by the gonadal steroids estrogen receptor alpha and beta 
(ERα and β), progesterone receptor (PR) and androgen receptor (AR). When these gonadal 
steroids are released by the ovaries they signal the kisspeptin neurons [3]. As a result, the level of 
neuronal activity through gamma amino butyric acid and opioid peptides is reduced. In response 
to estradiol and progesterone release from the ovaries and GnRH activation, puberty is initiated 
and estrogen receptors in the epithelium and stroma of the mammary gland are increased causing 
increased terminal end buds (TEBs) and lumen formation, stromal remodeling, and ductal 
elongation. The TEBs are highly mitotic terminal ends [ex., terminal end buds (TEB) in mice and 
terminal ductal lobular units (TDLU) in girls]. Cap cells occupy the basal surface of the TEBs 
and have been interpreted to represent a pluripotent stem cell population that are capable of 
undergoing differentiation into ductal and myoepithelial mammary cell types [4]. Several studies 
have identified and characterized the pubertal mammary stem cell (MaSC) and progenitor cells 
in the mouse mammary gland [5-10]. Although spikes in fetal- and pregnancy-induced MaSC 
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exist, it is unclear whether these are the same populations that peak during puberty, since they 
perform unique functions during each phase of development [11-14]. Regardless of 
developmental stage, there is mounting evidence to support the concept that mammary 
carcinogenesis originates from a MaSC population or cancer stem cell population (CSCs) [5, 15-
17]. These cells often have longer life spans with retained proliferating capabilities that results in 
a higher mutation rate probability [18]. Accumulation of mutations and aberrant signaling in the 
pathways associated with stem cell maintenance and differentiation are thought to be at the root 
of tumorigenesis [19-22]. The stage at which mutations occur may also dictate the tumor 
subclass (i.e. basal-like, luminal, ERRB2+) [23] and gaining a better understanding of these 
events will play a pivotal role in both diagnosis and treatment of a resulting cancer. 
Bisphenol A (BPA) is one of the very few chemicals that has been extensively studied for 
effects on the developing mammary gland. Used in the production of plasticizers, epoxy resins, 
dental sealants, thermal receipt paper, and canned food linings, BPA is also an established 
endocrine disruptor. Several studies have linked BPA to neuroendocrine and neurobehavioral 
effects, reproductive tract abnormalities, and altered mammary gland development with 
progression to mammary carcinogenesis in rodent models [24-28] . Women involved in the 
manufacturing of plastics and food canning were found to have an increased breast cancer risk 
when factors including age of menarche, years of employment in the industry, parity and other 
lifestyle risks were considered [29]. Compared to case controls from the same area, women who 
manufactured plastics and food canning had significant odds ratios of 2.68 and 2.35, 
respectively, and premenopausal women were also found to have a higher estrogen receptor 
status of their tumors, suggesting a link between their breast cancer subtype and exposure to 
estrogenic chemicals. While it cannot be ruled out that these women may have been exposed to 
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other monomers including phthalates or polybrominated diphenyl ethers, these data suggest that 
there is an association between exposure to bisphenols and breast cancer risk.  
Perinatal and pubertal exposures to BPA in rodent models have been linked to an 
increased number of TEBs, enhanced ductal extension and branching points, and increased 
sensitivity to estradiol in ovariectomized females [30-32]. Developmental BPA exposures also 
increased the incidence of pre-neoplastic and neoplastic lesions, while decreasing the time to 
tumor formation [28, 33-35]. Additional efforts have been undertaken to understand BPA’s 
effect on the rodent mammary transcriptome and epigenome [30, 36], and only recently has the 
MaSC and progenitor cells been implicated as potential targets. Perinatal BPA exposure has been 
shown to increase total cell populations without altering individual population counts, increase 
progesterone expression in luminal cells, and induce genes involved in stem cell function [37]. 
Three-week peripubertal BPA exposures in Balb/C mice increased MaSC populations by 6 wk, 
delayed the increase of luminal progenitor cells seen at 4 mo, and decreased the time to 
neoplasm formation in DMBA induced transplant cells [38]. Taken together, there is a risk of 
altering the trajectory of cells involved in tumor formation during critical periods of 
development, such as puberty, when MaSC are more abundant.  
In recent years, several structurally similar bisphenol analogues, including Bisphenol AF 
(BPAF) and Bisphenol S (BPS), have been detected in foodstuffs, dust and water and recovered 
in human samples [39-41]. Both chemicals have been shown to induce proliferative effects in 
vitro and in vivo and were also estrogenically comparable or enhanced compared to BPA [42-
44]. Our group has shown that early life exposure to BPAF and BPS altered early pubertal 
mammary gland development that persisted into adulthood (Chapter 3). BPAF and BPS 
increased numbers of TEB, prolonged the presence of TEBs (3 mo), and increased the incidence 
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of preneoplastic and neoplastic lesions without altering pubertal onset or serum steroid hormone 
levels (i.e. estradiol, progesterone, DHEA, and testosterone).  Although similar to BPA in its 
effects on the mammary gland, the definitive mechanism(s) and cellular pathways remain 
undefined and unexplored for these bisphenol analogues. From our experience ER, PR, and AR 
expression in the mammary gland during time points when hyperplasia, inflammation and 
neoplastic lesions were present remained unchanged. Therefore, it is possible that the 
mechanisms driving the changes later in life are independent of classical estrogen signaling and 
that many of these changes may be occurring much earlier in development. Still, with the 
increasing similarities between BPA, BPS, and BPAF it is possible that they have many similar 
or overlapping mechanisms, including the role of the MaSC. 
Although the MaSC have been implicated as potential targets for tumor initiation only a 
handful of studies have attempted to draw a connection between this population and BPA [37, 
45, 46]. In this study, CD-1 female offspring that were prenatally exposed to BPAF, BPS or 
vehicle control were evaluated during puberty to define the normal MaSC population, determine 
whether changes in this and other mammary cell populations correspond with previously 
reported morphological alterations and investigate potential pathways that may be involved. In 
this study the MaSC population was greatest at PND 22 in mice exposed to vehicle and both 
bisphenols, with no significant differences between groups. This population of cells also had a 
decreasing trend throughout pubertal development regardless of chemical treatment. This 
decrease resulted in a reduction of successful transplants and MRU frequency. Assessment of 
stem cell maintenance and renewal genes, Wnt1, Wnt5a, Lrp5, and Notch1 revealed no changes 
or significant reductions at only PND 22. Overall, our data suggests that although there is clear 
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evidence that perinatal BPAF and BPS exposure increase epithelial cellularity that this may not 
facilitated by a larger pubertal MaSC population. 
 
MATERIALS AND METHODS 
Animals  
Timed pregnant CD-1 mice were obtained from Charles River Laboratories (Raleigh, 
NC).  Upon arrival, animals were weighed and randomly assigned to the vehicle or a treatment 
group.   All dams were acclimated to the animal facilities a minimum of 2 days prior to dosing.  
Pregnant dams were individually housed in polypropylene cages and received AIN-93G feed 
(Harlan Laboratories) and tap water ad libitum. Bisphenol contamination in the animal 
environments was minimized as previously described (Chapter 2).  Animal facilities were 
maintained on 12:12 hr light-dark cycles, at a controlled temperature (20-24ºC) with 40-60% 
relative humidity.  All animals were treated humanely and in accordance with the protocols 
published by the National Institute of Environmental Health Sciences Animal Care and Use 
Committee. 
 
Chemicals and Dosing 
 BPAF was obtained from 3B Pharmachem International Co. Ltd (Wuhan, P.R. China) 
and BPS was obtained from Sigma Aldrich (St. Louis, MO). Purity for both chemicals was ≥ 
97.5%, as previously confirmed (Chapter 2). Chemicals were dissolved in sesame oil (Jedwards, 
International, Inc., Braintree, MA) daily and administered to the animals by blind allocation in a 
volume of 10 µl solution/g body weight or pure sesame oil for vehicle control animals.  
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Experimental Design 
Timed pregnant CD-1 dams were oral gavaged twice daily between gestational days 10 
and 17 (GD 10-17) with vehicle (sesame oil), BPAF (5 mg/kg) or BPS (0.5mg/kg). Three 
separate dosing blocks were designed to retrieve an adequate amount of mammary epithelial 
tissue for the transplant studies. Except for Block 2, each block of exposed dams included 
vehicle n=4-9, BPAF 5 mg/kg n=9-12, and BPS 5mg/kg n = 9-12. These single doses of 
bisphenol analogues were chosen as they promoted significant increases in pre-neoplastic lesions 
and were also dose groups in which neoplastic lesions were evident in previous studies (Chapter 
3). Gavage was twice daily to avoid episodic doses that would be cleared from the body by the 
next day (Chapter 2). The latter half of fetal growth was targeted as the mammary bud develops, 
forms its first stalk, and produces a lumen during the chosen exposure period [47]. CD-1 dams 
gave birth on the eve of GD 18 and postnatal day 1 (PND 1) was considered the next day. All 
litters were equalized to 10 pups on PND 3 with as many female pups as possible per litter. On 
PND 19, 22, 28, 35, and 56, the left and right 4th and 5th inguinal mammary glands of female 
offspring were excised for cellular dissociation and sorting.  These glands are the preferred 
choice for carmine stained whole mount assessment and are not intermixed with muscle, unlike 
the thoracic glands. All animals greater than 22 days old were collected in the stage of diestrus 
when the stem cell populations have been shown to be at their maximum [48]. Mammary glands 
that were not collected for dissociation were snap frozen in liquid nitrogen and stored at -80oC 
for future use. 
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Mammary gland dissociation and stem cell enrichment 
The dissociation protocol was adapted and modified from Prater et al. [49] . Briefly, 
excised mammary tissues were washed in 70% ethanol to eliminate contamination. For each 
block, 4-10 animals/dose group from different litters were euthanized to obtain the 4th and 5th 
inguinal glands. Higher animal numbers were used during earlier collections (PND 22) due to 
less epithelial tissue per gland. Tissues were digested in a solution consisting of collagenase-
hyaluronidase (1X-final concentration) (Sigma Aldrich, St. Louis, MO), DMEM/F-12 (Life 
Technologies, Grand Island, NY) and gentamicin (50 µg/ml) and incubated at 37 ºC for 14-16 hr 
The cell pellet was collected by brief centrifugation at 450 x g for 5 min (Thermo Scientific 
Sorvall Legend XFR centrifuge, Langenselbold, Germany). Red blood cells were lysed using 
Ammonium Chloride solution (Stem Cell Technologies, Cambridge, MA) and cleaved by 
successive trypsin (Life Technologies) and Dispase/DNase I (Stem Cell Technologies) washes 
(37 ͦ C). Cells were then washed in 10 ml of 4o C HF [Hanks’ Balanced Salt Solution (500 
ml)/HEPES (10 mM)/fetal bovine serum (2% FBS)], filtered through a 40 µm cell strainer and 
centrifuged. 2 ml of HF were added to the pellet after the removal of supernatant and the cells 
were counted on a Z2 coulter particle count and size analyzer (Beckman Coulter, Indianapolis, 
IN).  
Stem and progenitor cell enrichment was performed using the EasySep Mouse Mammary 
Stem Cell Enrichment Kit (Stem Cell Technologies) per the manufacturer’s instructions. This kit 
helps to separate mammary epithelial cells from other cells through a process known as negative 
selection. In this case, non-epithelial cells become bound to the tube and removed from the 
epithelial enriched supernatant. Briefly, 100 µl of the EasySep mouse enrichment epithelial 
cocktail was added to the cell suspension acquired from dissociation and incubated on ice for 15 
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min, followed by two additional 15 min incubations with 1) EasySep Biotin selection (200 µl), 
then 2) EasySep magnetic nanoparticles (100 µl). HF (100 µl) was added to the mixture to bring 
the volume to 2.5 ml and placed in the EasySep Magnet (Stem Cell Technologies) for 5 min. 
With the tube still in the magnet, the enriched cell suspension was transferred to a new tube and 
placed on ice. To ensure that all or at least most the epithelial population was isolated, the tube in 
the magnet was removed and HF (2.0ml) was added, gently triturated to mix the contents, and 
returned to the magnet for another 5 min to remove all the undesired populations. The cell 
supernatant/suspension in the magnet was poured into the tube with the supernatant/suspension 
from the first separation until a total volume of 4.5 ml was achieved; the enriched cell suspension 
was centrifuged at 350 x g for 5 min. The HF media was discarded and 2.5 ml of cold new HF 
was added to the cells and placed in the magnet to select out any remaining non-epithelial 
populations. The transferred cells were centrifuged and recounted.  
 
Cell Staining and Flow Cytometry   
The cell pellet was suspended in 3 ml of cold HF with 10% normal rat serum 
(Invitrogen), incubated on ice for 10 min and 1.7 ml of cold HF was added to stop the reaction 
and bring the total volume up to 5 ml. It should be noted that due to limited antibody, we were 
only able to stain a select number of cells. Preliminary studies showed that 10-20 million cells 
provided an adequate number of each sorted population. To ensure that one population was not 
overrepresented, the cell suspension was vigorously triturated and then distributed into 5 ml 
polystyrene tubes at a density of 1.0-2.0 x 107 cells for the flow sorted sample and stained with 
EpCAM and CD49f (Table 4-1). A total of 6 tubes are prepared for individual cell titrations at a 
concentration of 0.5-1.0 x 106 cells and included one tube for 1) cells that received no staining, 
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2) cells stained with propidium iodide stain (PI) to measure cell death, 3) Isotype Control 
(EpCAM), 4) Isotype Control (CD49f), 5) CD49f, and 6) EpCAM.  All tubes were incubated for 
30 min covered on ice and washed with HF (4 ͦ C) followed by a 5 min centrifugation at 450 x g. 
The supernatant was poured off from each tube and each cell pellet was re-suspended in 500 µl 
of HF. Prior to FACS sorting, PI (5 µl/1 x 106 cells) was added to its designated tube. 
 Stained cells were sorted on a BD FACSAria II (BD Biosciences, San Jose, CA). Briefly, 
sorted cells were gated on PI- to obtain a viable population, and then by forward scatter (FSC) 
and side scatter (SSC). Cells were then gated by SSC high vs. SSC width followed by FSC high 
vs. FSC width to obtain single cells as cell clumping can inhibit proficient sorting. To separate 
the basal, luminal, and stromal populations from one another the samples were sorted per their 
fluorescence in the fluorescein isothiocyantate (FITC) and Allophycocyanin (APC) channels. 
Luminal cells were identified as EpCAMhighCD49fmed, stromal cells were EpCAM-CD49, and 
basal/myoepithelial cells were EpCAMmedCD49fhigh. The highest 20% fluorescing cells within 
the basal population contained the mammary repopulating unit cells (MRU) (Figure 4-2). FACS 
Diva Software 6 was used for data acquisition and analysis. All cell populations were collected 
in HF pre-coated chilled 1.7 µl microcentrifuge tubes. Cells were recounted and centrifuged at 
450 x g for 5 min to form a pellet.  The pellet was then re-suspended into a trypan blue 
(10%)/PBS (65%)/Growth Factor Reduced Matrigel (25%) mixture and diluted into cell 
concentrations that ranged from 1-500 cells/µl for transplants. 
 
Mammary Transplantation and MRU Frequency Analysis 
Three-week old female CD-1 mice were obtained from Charles River Laboratories. 
Animals were pre-operatively anesthetized with isoflurane gas and received 0.1 mg/kg 
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buprenorphine HCl (i.m.) for pain. During fat pad clearing and cell transplants, all recipient 
animals received a constant flow of isoflurane gas at 2.5% with oxygen to ensure they remained 
sedated. Briefly, a small incision was made around the nipple where the fat pad was retrieved 
using blunt forceps. The mammary gland was cauterized between the 4th and 5th inguinal glands, 
caudal to the lymph node (reference point) to ensure that all endogenous epithelial tissue from 
the recipient’s 4th and 5th gland was removed. Transplanted cells were injected in the fad pad of 
the recipient’s 4th gland. The trypan blue/PBS/Growth factor and cell population mixture was 
injected into the cleared fat pad in a volume of 10 µl with stem cell concentrations from 1-500 
cells/µl (10-5,000 total cells/transplant). Three to five mice per cell concentration were 
transplanted for each chemical or vehicle (total of all mice = 20-25 per block). The skin was 
sutured and recipient mice were placed on a heat pad until they awoke. Once mice were appeared 
normal they were returned to regular cages lined with Diamond soft recovery bedding (Envigo, 
Madison, WI). Transplant animals were given the same diet as the animals used for mammary 
harvesting. Animals were monitored daily for the first week following surgery and once weekly 
thereafter. Mammary glands from transplant animals were recovered 6-7 weeks later, as 
described above. Glands were placed on a charged microscope slide, fixed in Carnoy’s solution, 
stained with carmine alum, cleared in xylene, mounted with Permount (Sigma Aldrich) solution, 
and coverslipped.  
Transplant examples are shown in Figure 4-1. Successful transplants consisted of 
epithelial tissue that grew in a concentric direction and appeared to not be a result of endogenous 
epithelium. Transplants were considered failures if the fat pad was improperly cleared leaving 
epithelial tissue or unilateral growth. Each successful transplant for vehicle or BPAF/BPS 
treatment were recorded and entered into L-Calc software (https://www.stemcell.com/l-calc-
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software.html) to determine the mammary repopulating unit frequency (MRU). Frequency is 
calculated from the total of successful transplants and total number of attempted transplants 
using a Poisson distribution. 
 
RNA preparation and RT-PCR               
Snap frozen mammary tissues were immediately placed in Trizol (Sigma Aldrich), 
homogenized at 6.0 m/sec for 40 sec. and incubated on ice for 5 min (3x). The Trizol supernatant 
was transferred to a clean microcentrifuge tube and spun for 10 min to remove the fat layer. The 
clean supernatant was then extracted for RNA per the manufacturer’s recommended protocol and 
purified with the Qiaqen RNA Mini Kit (Qiaqen, Germany) and DNase I treatment. RNA was 
quantified with a Nano Drop 2000 (Agilent, Germany). One microgram of RNA was reverse 
transcribed using the High Capacity cDNA reverse transcriptase kit (Applied Biosystems, Foster 
City, CA) and amplified in a Bio-Rad thermocycler (Bio-Rad, Hercules, CA), per the 
manufacturers recommended setting. cDNA was mixed with Taqman (Applied Biosystems) 
Universal PCR Master Mix, No AmpErase UNG (2x), Taqman 20x gene expression assay mix 
(Wnt5a, Wnt1, Notch1, and Lrp5, Table 4-2) and RNase free water. Transcripts were measured 
on a Quantstudio 7 Flex (Applied Biosystems) and analyzed in Excel. All data output was 
recorded as a threshold value (Ct) and fold change was calculated using 2-ΔΔCt. Briefly, all 
samples were normalized to the reference gene (Cdkna1) and ΔCt was calculated using the 
formula Δtarget gene Ct – Δreference gene Ct. Samples with Ct values ≥ 35 or with a duplicate 
standard deviation of ≥ 0.5 were omitted from analysis. 
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Statistical Analysis 
The dam is considered the unit of measurement; therefore, if two animals were retrieved 
from the same dam then the average of their measurements was used in the analyses. All data is 
represented as the mean ± SEM. FACS sorted fraction data is represented as the number of sorts 
completed. A student’s t-test was performed to determine statistical significance (p ≤ 0.05). Fold 
change was calculated using Microsoft Excel 2010 and graphs were constructed in GraphPad 
Prism v7.  
 
RESULTS 
 Identifying the MaSC population in CD-1 females during normal pubertal development. 
Normal pubertal mammary gland development in CD-1 mice occurs just after the third week of 
life when the HPGA becomes active. Estrogens from the ovary and potentially the mammary fat 
pad itself promote epithelial proliferation within the cell, while progesterone increases lateral 
ductal growth. During puberty, duct ends form the highly mitotic TEBs, which house the MaSC 
population. Using mammary gland whole mounts, normal development was observed from pre-
puberty to mid-puberty (Figure 4-3A). At PND 19, both 4th and 5th inguinal glands were entering 
the time of rapid growth, however, TEBs were not typical and very few secondary branches were 
present. By PND 22, TEBs were easily identifiable and much more branching had occurred even 
though there was still a significant gap between the two glands. Vaginal opening, an outward 
sign of puberty in mice, occurred within a couple of days of this breast development stage 
(Chapter 3). At 5 weeks of age (PND 35), ductal growth had increased exponentially; 4th gland 
growth either approached or surpassed the lymph node and the distance between the 4th and 5th 
glands decreased to the point that they had grown together and ends had differentiated. Because 
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the glands grew together, contact inhibition occurred and TEBs become terminal ducts. Ducts 
that had grown to the edge of the fat pad had persistent TEBs. Assessment of these glands for 
TEB count showed a linear increase in the number of TEBs from PND 19-28 but slightly 
decreased by PND 35, which may reflect the changes that occurred due to 4th and 5th glands 
growing together (Figure 4-3B). 
 Prior to determining the effects of BPAF and BPS on the MaSC population, it was 
necessary to characterize the specific cellular populations during normal pubertal development in 
control CD-1 mice. To confirm that basal cells were indeed the population that contained the 
stem cells, mammary transplants were conducted using basal, luminal, and stromal cells (luminal 
and stroma data not shown). Stromal cells did not re-constitute any glands (0/3) whereas luminal 
cells did (2/4), and basal cells reconstituted a gland in 14 out of 37 transplants. The high 
percentage of luminal reconstitution is because only four transplants were conducted. More 
transplants would have adjusted for this discrepancy. Three to twenty five females per treatment 
group were euthanized depending on the postnatal age evaluated (PND 19, n = 15; PND 22, n= 
10-15; PND 35, n= 9-20; and PND 56, n = 3-10). It should be noted that following FACS 
sorting, a subset of each cell population was removed from the sample and isolated in Trizol for 
future PCR analysis. PND 19 animals did not contain many epithelial basal cells because they 
have not entered puberty and therefore required more animals to acquire more cells.  
 MaSCs were successfully sorted via FACS by gating the viable mammary cell sample 
with EpCAM APC and CD49f FITC. The basal population was identified by 
EpCAMmedCD49fhigh (Figure 4-2) and the 20% highest fluorescing cells within this population 
are considered to contain 70-80% of the mammary repopulating unit cells (MRU) [49, 50]. This 
population is capable of both self-renewal and differentiation. A quantification of this population 
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in control animals revealed that at PND 19 approximately 13% of the mammary population 
consisted of basal cells (Figure 4-4). Within three days, the population had increased by 3-fold to 
40%. Following this peak there was a precipitous decrease in the population to almost pre-
pubertal percentages and this trend continued into adulthood (PND 56). 
Mammary transplants from the sorted basal cells collected from PND 19-56 were 
conducted in three separate blocks as previously mentioned to determine the MRU frequency in 
CD-1 pubertal females. Within each block, four collection and transplant time-points were 
attempted where approximately 3-5 animals per cell concentration were transplanted into 
recipient mice (~20-25 animals/time-point/block). Although basal cells were detected by FACS 
at PND 19, those cells were unable to reconstitute a gland at any cell concentration. Therefore, 
the MRU frequency for PND19 was unable to be calculated. Further analysis at PND 19 was 
discontinued. The highest frequency achieved was at the next collection time point (PND 22), 
which was also the collection point where the highest percentage of basal cells was collected. 
During this time 1/2,159 basal cells was calculated to effectively reconstitute a mammary gland 
in control animals. With increased age, this ratio decreased considerably by approximately 3-4 
fold. A comparison of MRU frequencies found in CD-1 mice in this study and mouse strains 
previously reported is shown in Table 4-3. Compared to the outbred CD-1 mouse, the FVB and 
C57Bl/6 mouse could reconstitute the mammary gland at much lower frequencies (ex. 1/100-
1/200) at postnatal ages that spanned from 8-12 weeks old [51], an age similar to 56 d within our 
study that provided inefficient reconstitution results. 
 BPAF and BPS effects on the MaSC Population and MRU frequency. We previously 
reported that when pregnant dams were exposed to BPAF and BPS the mammary glands of their 
female offspring had accelerated development compared to vehicle controls (Chapter 3). At PND 
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20, mammary glands from BPAF exposure showed increased branching density, number of 
TEBs, TEBs/area of mammary gland, and longitudinal growth that persisted into early adulthood 
(PND 56). Similarly, BPS glands were significantly more developed than controls as shown by 
the developmental qualitative scores. Other pubertal indices, such as timing to vaginal opening 
and first estrus, were unchanged relative to controls. Those significant developmental increases 
in epithelial structures led us to isolating the MaSC fraction of the mammary glands from 
females prenatally exposed to BPAF and BPS by flow cytometry to assess whether these cells 
were contributing to increased branching and development. MaSC counts (%) were greatest at 
PND 22 for control, BPAF and BPS (33±18.5%, 29.5±11.3% and 26.9±18.3%); however, no 
significant differences in cell populations were observed between treatment and control animals 
(Figure 4-5). Overall, between PND 28 and 56, the fraction of basal cells per total cell number 
decreased in all groups including control. At PND 35, % BPAF and BPS basal cell counts 
statistically decreased compared to controls. Surprisingly, the lowest basal cell counts were 
obtained at PND 28 and 35 for BPAF and BPS. When the luminal and stromal cell fractions 
(consists of endothelial and immune cells and fibroblasts) were evaluated, they were also 
unchanged following early life exposure to BPAF and BPS. Luminal and stromal cell counts at 
all time-points were typically greater than the basal compartments, except for BPAF at PND 22. 
Luminal counts ranged from 9-40% for BPAF, and 26-40% for BPS, and were greatest at PND 
56 for both chemicals. Stromal compartment fraction ranged from 33-67% for BPAF, and 36-
61% for BPS, peaking at PND 28. 
 Using limiting cell dilutions, basal mammary epithelial cells from control, and BPAF 
(n=20-25 females/time-point/block) and BPS (n=20-25 females/time-point/block) exposed 
females were transplanted into the cleared fat pads of 3-week old female recipient CD-1 mice to 
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establish the MRU frequency and determine if differences between vehicle and treatment groups 
existed (Table 4-4). Similar to quantitative basal cell counts, MRU frequency in the control 
group was greatest at PND 22, decreased by PND 35 and maintained at the same level until PND 
56. We expected the MRU population in BPAF and BPS groups to increase since we had 
observed increased TEBs and growth in the whole mounts (Chapter 3), however, frequencies 
were decreased to 1:4,123 at PND 22 for BPAF (vs. 1/2,159 in the controls) and could not be 
calculated for BPS due a lack of successful gland re-constitutions. The inability of basal cells 
from bisphenol-exposed mammary tissue to reconstitute glands caused MRU frequencies to 
continue to decrease with increased pubertal age and were at least 3-4x less compared to 
controls. 
 Pubertal BPA exposure has previously been shown to alter the MaSC population in 
female Balb/C mice [38]. Immediately following the last exposure, the animals experienced an 
increase in the % of basal cells and % of MaSC as measured in frequency of total epithelium. 
Because of these findings, a similar mechanism was hypothesized to occur following BPAF and 
BPS exposure, as these chemicals have also been shown to stimulate mammary gland growth 
and branching in our previous studies (Chapter 3).  
During development, MaSC rely on critical genes to regulate stem cell maintenance, 
renewal, and luminal differentiation but these same genes are also thought to play a critical role 
in mammary carcinogenesis. Therefore, exposure to chemicals such as BPAF and BPS may have 
the capability of altering this population in several ways including 1) increasing the MaSC 
population, 2) altering critical genes that can drive the cells increased differentiation, or 3) exert 
genotoxic effects that can develop into mutations and drive cancer formation. Wnt5a, is found in 
the TEB and involved in directing branching morphogenesis but was significantly decreased at 
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PND 22 following BPAF and BPS treatment (Figure 4-6), even though these exposures increased 
the number of TEB at this age (Chapter 3). We also investigated Wnt1, a gene involved in stem 
cell renewal, and it was similar to vehicle expression. In the canonical Wnt/β catenin pathway, 
co-receptors LRP5/6 are involved in normal mammary gland development and required for stem 
cell activity [52]. Interestingly, expression of LRP5 was significantly decreased in glands from 
BPS females, but not BPAF-treated animals, at PND 22 at a time when basal cell counts were 
greatest for both chemicals. At other times, expression levels of LRP5 were similar to controls. 
Lastly, Notch1 and the Notch signaling pathway are also involved in stem cell maintenance and 
differentiation [53, 54]. When decreased, these pathways encourage the growth of the MaSC 
populations and breast cancer progression. Significant decreases in Notch family genes were 
observed in both bisphenol groups at the earliest time point (PND 22; Figure 4-6). 
 
 
DISCUSSION 
 
Early life exposures to BPA, BPAF and BPS are reported to cause advanced mammary 
morphological changes that manifest prior to puberty and lead to the increased risk of developing 
preneoplastic and neoplastic lesions (Chapter 3 and [28, 33, 34]). BPAF and BPS have been 
shown to be agonists for the estrogen receptor alpha [42, 55], however, the effects from 
bisphenol exposure that are observed in the mammary gland may not be solely due to classical 
estrogen signaling. In this study, we investigated alternative means by which uncontrolled 
proliferation may have been manifested, namely through increased basal cell (MaSC-containing) 
populations in BPAF- or BPS-exposed mammary tissue. Using prenatal bisphenol analogue 
exposures previously shown to induce inflammation, epithelial proliferative lesions, and 
neoplasia during adulthood (Chapter 3), it was determined that BPAF and BPS decreased or had 
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no effect on the MaSC or progenitor populations in the pubertal and young adult mammary 
gland. MaSC populations rose to their peak levels around the time of vaginal opening, and were 
maintained at lower levels into adulthood, just like that seen in untreated controls. Overall, these 
data suggest that the number of pubertal MaSC may not be critical in manifesting BPAF- and 
BPS-induced lesions in later life, even though the MaSC is known to be critical in epithelial 
expansion during puberty [56].   
The CD-1 mouse (an outbred strain) was chosen for our studies because BPAF and BPS 
were shown to induce multiple abnormalities in the mammary gland of this strain in a previous 
study (Chapter 3), although most transplant studies are conducted in inbred mouse strains. A 
recent study that examined the effects of perinatal exposure to BPA in C57Bl/6 females revealed 
that total epithelial cell populations were increased following exposure, however, individual cell 
populations (basal, luminal and stromal) remained similar between treatment and control [37]. 
We similarly observed no changes in the cell populations (specific cell fraction/total of isolated 
cell populations) in treated and control mammary tissue, nor were total isolated cell numbers 
changed (data not shown) following dissociation or FACS sorting. Dissociation of the mammary 
gland is a harsh process. If the method is precisely followed, it would be expected that the ratio 
of living to dead cells would remain constant, but this may not always be the case. In a different 
study, the MaSC from BPA-exposed Balb/c mouse mammary glands were increased (6 weeks) 
compared to controls following pubertal exposure, but those changes were not sustained in 
glands obtained in later collections (2 and 4 mo) [38]. Disparate findings between studies [35, 
36] may be attributed to differences in BPA’s effects in various mouse strains, as well as dose or 
timing of exposure.  
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Another reason that we may not have seen effects of BPAF and BPS on MaSC 
populations is that we were looking at the wrong time. Basal and MaSC increases were only 
observed following the last day of a BPA pubertal exposure (6 wk) in previous studies of Balb/C 
mice [38], which suggests that BPA and possibly BPAF and BPS effects on these populations are 
short-lived. Considering that these chemicals were administered between GD 10 and 17 and 
mammary collections and transplants were not performed until 3-5 weeks later could mean that 
we had already missed the window for these changes. It also implies that these chemicals may 
have a much greater effect on the fetal mammary stem cells rather than the pubertal stem cells. A 
recent study using mammary glands harvested from CD-1 embryos identified and characterized a 
fetal MaSC population that peaks during late embryogenesis and may closely resemble specific 
human breast cancer subtypes [14].  
When assessing a stem cell capability to self-renew and differentiate, the gold standard is 
to conduct mammary transplants, where the cell population of interest is injected into the cleared 
fat pad of a syngeneic pre-pubertal mouse.  A successful transplant confirms that the cells within 
that population have stem cell characteristics. When this population was transplanted into 
recipient mice using differing concentrations of stem cells within an appropriate range, we 
determined the MRU frequency or exact number of stems cells required to fully reconstitute a 
gland. We became proficient at these methods prior to attempting transplants of treated animals. 
Multiple ages were used to isolate stem cells in each treatment group, as we wanted to explore 
whether prenatal exposures to BPAF and BPS would increase the MaSC fraction as postnatal age 
increased; this would have explained why we reported increased epithelial structures (TEBs and 
branching density, Chapter 3) in a previous study. It was hypothesized that an increase in this 
population by these chemicals would also increase the number of positive gland reconstitutions 
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and MRU frequency. Contrary to this theory, BPAF decreased MRU frequencies compared to 
controls and this trend continued into early adulthood (PND 56). We also could not have 
predicted that BPS transplants conducted at PND 20 and 35 were going to be unsuccessful, thus 
prohibiting us from determining the MRU and any changes from controls. One explanation for 
this outcome could have been due to the decrease in basal cell populations at PND 28. 
Considering that approximately 70-80% of the MRU population is located in the highest 
fluorescing 20% of the basal fraction [57], the fact that this population is decreasing over time 
would suggest that there are also fewer MRU-type cells. We should also highlight that the CD-1 
model may have also been instrumental in the lack of changes observed. Cells from outbred 
strains may be more easily rejected during transplantation due to differences in the immune 
response because of genetic variability. Future studies should perform transplant studies in an 
inbred strain to assess whether lack of changes are due to chemical exposure or strain 
differences, as that could not be determined in this study. 
Several genes and pathways that regulate MaSC renewal and differentiation are also 
critical for mammary tumor formation. Two common pathways regulating stem cells include the 
canonical Wnt/β catenin and Notch pathways. In one study, the MMTV-Wnt-1 in transgenic 
mice increased the epithelial cellularity and percentage of cells in the basal fraction compared to 
the control. Following basal fraction transplants of both strains the MMTV-Wnt-1 mouse 
increased the MaSC frequency from 1/86 (control) to 1/57 (MMTV-Wnt-1) [8]. Wnt5a has also 
been shown to be expressed in luminal ERα cells and the TEBs [21]. The increased number of 
TEBs following BP analogue treatment that was observed in prior studies (Chapter 3) would 
suggest a possible increase in this gene. In contrast to our expectations, Wnt5a was significantly 
decreased at PND 22 and unchanged at all other time-points. Similarly the Wnt co-receptor Lrp5 
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was decreased at PND 22 in BPS-treated samples, but unaffected for BPAF and BPS throughout 
the rest of pubertal development. MaSC are highly enriched in Lrp5 and the decrease could 
suggest a decrease in the ability of the MaSC to self-renew. Although we did not observe any 
changes in the Wnt ligands and receptors we cannot eliminate the potential role of other Wnts on 
these populations; this includes Wnt4 which is greatly influenced by progesterone and solely 
expressed in luminal cells [37, 58]. Previous findings have shown that serum progesterone was 
significantly increased in 3-week old BPAF (5 mg/kg) exposed females (Chapter 3). Therefore, 
paracrine mediated effects should not be discounted as a possible mechanism for BPAF and BPS 
induced mammary changes and will require further studies to confirm. Notch ligands are also 
found in the MaSC, while the Notch receptors are in the luminal/progenitor cells [53]. Analysis 
of the Notch1 receptor in whole mammary glands showed statistically decreased levels only at 
PND 22 for both chemicals. Decreased signaling through Notch1 has been shown to alter 
transcription by decreasing interaction with Cbf-1, resulting in the increase of the MaSC 
populations [53]. An important note to make about our observations is that they were conducted 
in whole mammary glands versus FACS sorted epithelial and stromal populations. Expression 
from whole glands may have masked subtle changes due to the several cell types that comprise 
the mammary gland. It is recommended that an assessment of gene expression changes in FACS-
sorted populations should be conducted at these time points. 
In addition to understanding the effects of endocrine disruption on the MaSC and luminal 
cells these studies sought to successfully identify the MaSC population in the CD-1 outbred 
strain. To date, no published reports exist for this strain and are likely due to the genetic 
variability associated with outbred strains. However, numerous reports have used the CD-1 
mouse to report significant effects of BPA on the mammary gland [26, 59] making them an 
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important starting model system. More importantly, inbred strains that have identified the MaSC 
population have solely focused on late puberty to early adulthood populations. Since early 
pubertal mammary gland alterations following BPAF and BPS perinatal exposure were observed 
in CD-1 females, this study sought to use the same strain to assess the potential mechanisms of 
action. Basal cells accounted for approximately 30% of the total cell population at 3 weeks old 
compared to ≤ 20% of the population prior to puberty and during weeks 4-7. This early increase 
may be due to the surge of ovarian hormones that begin to circulate to stimulate mammary gland 
growth. Following enrichment with CD49f and EpCAM, MRU frequencies in the control CD-1 
pubertal mouse were shown to range from 1/942-1/7354. 12-week old FVB mice enriched for the 
same markers had an MRU frequency of 1/100, while an 8-week gland enriched for 
CD24+CD29hi had a MRU frequency of 1/200 [51]. Study comparisons reveal that in addition to 
differences in strain that timing and enrichment markers will highly influence MaSC 
populations. Therefore, great consideration should be taken when choosing a strain to assess 
basal and luminal properties. 
This study is the first to explore the relationship between the MaSC and alterations 
associated with early life BPAF and BPS exposure. These findings suggest that the pubertal 
MaSC population may not be the direct target of early bisphenol exposure, at least not at the 
concentrations that were explored and considering our study design. In fact, the bisphenol 
treatment decreased the MaSC populations and the ability to repopulate the mammary gland in 
transplants. Indirect signaling from other cells (i.e. cytokines, adipocytes and fibroblasts) are also 
critical for normal and altered mammary development and further exploration of their roles will 
be invaluable.  
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Table 4-1: Flow Cytometry Antibodies Needed for Cell Fraction Sorting 
Antibody Dilution 
EpCAM CD326 Alexa Fluor 647 Anti-mouse 1:4000 
CD49f Alexa Fluor 488 Anti-human/mouse 6.25 µl/ 1.0 x 106 cells 
Alexa Fluor 488 Rat IgG2a, κ Isotype Control Antibody 6.25 µl/ 1.0 x 106 cells 
Alexa Fluor 647 Rat IgG2a, κ Isotype Control 1:4000 
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Table 4-2: MaSC-Related Gene Primer List 
Gene Identifier Vendor 
Wnt5a   Mm00437347_m1 Taqman 
Wnt1 Mm01300555_g1 Taqman 
Notch1  Mm00627185_m1 Taqman 
Lrp5  Mm01227476_m1 Taqman 
Cdkna1  Mm04205640_g1 Taqman 
  
  
 
Table 4-3: Mouse Strain Comparison of MRU Frequency in Controls 
 FVB (per gland) FVB (per female) C57Bl/6 (per female) CD-1 (4 glands/female) 
Age (weeks) 12 8 8 3-5 
Total Epithelial 520,000 ~2,000,000 900,00 N/D 
MRU 20,000 N/D N/D N/D 
CFC 80,000 N/D N/D N/D 
Lin- Population EpCAMCD49f CD24+CD29hi CD24+CD29hi EpCAMCD49f 
MRU/Total Cell 1/100 1/200 N/D 1/942-1/7354 
Reference Stingl/Watson [51] Visvader/Lindeman [51] Visvader/Lindeman [51] Tucker/Fenton 
MRU- Mammary repopulating unit 
CFC – Colony forming cells 
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Table 4-4: MRU frequency following transplants of isolated MaSC from bisphenol analogue 
exposed mammary tissue 
Exposure PND 22 (n) PND 35 (n) PND 56 (n) 
Control 1/2159 (29) 1/7354 (22) 1/6988 (15) 
BPAF 5 mg/kg 1/4123 (28) 1/6237 (25) 1/31997 (20) 
BPS 0.5 mg/kg 0 (26) 0 (31) 1/20901 (32) 
n= total number of animals that received transplants. MRU frequency = (# positive transplant 
outgrowths/total # of attempted transplants)x + (# positive transplant outgrowths/total # of 
attempted transplants)x+1, where x =cell concentration transplanted 
 
  
 
 
A)                                                                                     B)  
 
            
 Figure 4-1: MRU Transplantation Analysis. Representative images of whole mounts showing: A) Successful MaSC transplant where 
growth originates from a central region and bi-directionality of ductal branching and B) Unsuccessful transplant where no epithelial 
tissue is present post-transplantation.  
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Figure 4-2: Representative Fluorescent Activating Cell Sorting (FACS) of isolated mammary cells stained with EpCAM and CD49f. 
EpCAMhighCD49fmed (green) = luminal cells (Lum1), EpCAMmedCD49fhigh (pink; Basal) = basal/myoepithelial cells, EpCAM-CD49 
(yellow) = stromal. The highest 20% fluorescing cells (blue) within the basal population contains the mammary repopulating unit cells 
(MRU). 
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A)             B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3: Peripubertal development in the untreated CD-1 female mouse mammary gland.  A) Representative control mammary 
whole mounts showing progression of growth through puberty and B) Terminal end buds per gland. n=number of animals per time-
point. Mean ± SEM.
PND 22 
PND 28 
PND 35 
PND 19 
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Figure 4-4: Mammary basal epithelial cell counts in control CD-1 female mice following FACs quantification (Peri-pubertal; PND 
19-56). PND 19 (n=2), PND 22 (n= 3), PND 28 (n=4), PND 35 (n=7), and PND 56 (n=5). N= number of FACS sorts at each time-
point.  
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A)        B)                   C) 
 
 
 
 
 
 
 
 
Figure 4-5: FACS sorted mammary cell fractions from control, BPAF or BPS early life exposure mice; evaluated over the course of 
puberty from PND 22-56. Quantitated fractions shown as a percentage of total isolated cells: A) Luminal, B) Basal, and C) Stromal. 
PND 22: Control (n = 2) BPAF (n = 3) and BPS (n= 3), PND 28: Control (n =4) BPAF (n = 3) and BPS (n = 3), PND 35: Control (n 
=7) BPAF (n = 3) and BPS (n = 3) and PND 56: Control (n = 5) BPAF (n= 3) and BPS (n= 3) where n= number of individual FACS 
sorts completed. All data are presented as the mean ± SEM. % cells were determined by # of cells per population/total # cells. 
Statistical significance was determined by student’s t-test; (p ≤ 0.05). 
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Figure 4-6: Whole mammary gland gene expression of stem and progenitor markers following prenatal exposure to BPAF (n=3) or 
BPS (n=3). These tissues were taken from animals used for cell fractionation shown in Figure 4-5. All data are presented as the mean 
± SEM. Fold induction changes calculated relative to controls (shown as 1.0 on each graph) and all data was relative to the 
housekeeping gene Cdkn1a which does not change in expression over this time-frame in the mammary gland. N= 3-4. Statistical 
significance determined by student’s t-test (p ≤ 0.05). 
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CHAPTER 5 
Effects of prenatal exposure to BPAF and BPS on mammary gland gene expression in the CD-1 
mouse 
 
OVERVIEW 
 Bisphenol AF (BPAF) and Bisphenol S (BPS) are endocrine disruptors used to produce 
fluoroelastomers, plastics and epoxy resins. Similar to BPA, prenatal exposure to these 
chemicals altered pubertal mammary gland development and increased inflammation and 
proliferative epithelial hyperplasia, producing tumors in mid-life (Chapter 3). These studies 
explored gene signatures produced by BPAF and BPS at concentrations shown to induce 
morphological changes as early as PND22, aiming to determine early life markers of later life 
disease. Pregnant CD-1 mice were exposed to vehicle (sesame oil), 5 mg/kg body weight BPAF 
or 0.5 mg/kg body weight BPS via gavage from gestation days 10 to 17. Female offspring were 
euthanized at postnatal day 20, 34 and 55 and the mammary gland was collected. Whole genome 
microarray analysis was performed on glands collected at PND 34 and genes from selected 
pathways were validated by RT-PCR, using RNA from glands from all time-points, so that 
temporal gene expression could be determined. BPAF exposure altered expression of 44 genes, 
many of which were associated with immunity (B cell development and antigen presentation), 
but expression levels of evaluated genes were all unchanged compared to age-matched controls. 
BPS altered expression of over 400 transcripts that were involved in mitochondrial dysfunction, 
circadian rhythm, and the TRK/Rac signaling pathways. RT-PCR analysis of RNA from tissues 
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collected between PND 20 and PND 55 confirmed changes in all (Aco2, Uqcrc1, Arntl, Nr1d1, 
Per3, c-jun, and Pi3k) but one gene (Map2k7) identified by the microarray. Gene signature 
changes were also evaluated for the family of estrogen receptors (Erra, Errg, Esr1, Esr2) and 
several genes involved in inflammation and apoptosis (Bax, Bcl2, and Il-6), but were all similar 
to controls, with the exception of Errg at PND 34. This nuclear receptor was downregulated by 
BPS exposure. Evi5 (BPS) and Tscc2d1 (BPAF), two genes involved in epithelial cancer 
formation were also altered at PND 34. These data suggest that several mechanisms are 
responsible for early pubertal mammary gland changes; they include mitochondrial and circadian 
genes, and genes involved in cancer formation. Although no single pathway was related to 
pathology outcomes, these stated pathways may all contribute and manifest in gland 
malformations that eventually lead to pre-neoplasia and cancer.  
 
INTRODUCTION 
 Bisphenol A (BPA) is a high volume production chemical that is incorporated into 
plasticizers, epoxy resins, thermal receipt paper and measured in many consumer products 
including foodstuff and beverages due to leaching from containers [1-3]. As a result, it is 
ubiquitous within the environment and has been detected in over 90% of urine [4] and serum [5, 
6] samples collected from the general U.S. population. BPA was also detected in maternal serum, 
amniotic fluid, placenta, fetal sera, and umbilical cord [7-10] and breast milk [11-13], and it can 
traverse the placenta resulting in fetal exposure. Exposure to BPA during perinatal and 
peripubertal development and the resulting health effects have been a prime focus of this 
research field. The current lowest observed adverse effect level (LOAEL) is set at 50 
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mg/kg/bw/d and the no observed adverse effect level (NOAEL) is at 5 mg/kg/bw/d based on two 
multigenerational studies that used high BPA exposures [14, 15]. Regulatory guidelines were set 
according to systemic and offspring toxicity, however, reproductive toxicity, was not calculated 
as a factor when determining the margin of safety. The margin of safety for both humans and 
adults was deemed as “adequate” and safe at the current levels occurring in foods. Therefore, 
based on these data the EPA proposed a recommended daily intake for BPA of 0.05 mg/kg/d. 
However, several low dose in vivo rodent studies have linked BPA to abnormal reproductive 
development, fertility, neurobehavior, liver function, tumor formation, and pubertal mammary 
gland development that decreased the timing to and incidence of proliferative and neoplastic 
lesions during adulthood [16-25]. The 2010 decision by the FDA to ban BPA in baby bottles and 
formula packaging products [26], and a separate voluntary discontinued use by manufacturers 
agreement, has resulted in the replacement of BPA in products with chemicals that are 
structurally and estrogenically similar to BPA, including Bisphenol AF (BPAF) and Bisphenol S 
(BPS). 
 BPAF is moderately produced and used in the production of fluoroelastomers and 
consumer electronics [27]. The six fluorine atoms increase its thermal stability in many products 
but may consequently increase its persistence within the environment. Exposure to the general 
population is primarily through oral ingestion, although it may be transdermally absorbed and 
inhalation exposure to contaminated dust may occur [28-30]. Occupational exposure to BPAF in 
the molding and casting industry was reported, with nearly half of the ~4300 workers exposed 
identified as women [31]. The disposition and pharmacokinetics of BPAF are similar to BPA 
where it is readily absorbed, metabolized by conjugation, and quickly excreted [32]. However, it 
has been recovered in human urine samples at much lower percentages than BPA [33]. More 
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importantly, BPAF is more estrogenic than BPA in numerous assays, and it has a greater affinity 
for the estrogen receptor beta (ERβ) [34]. Therefore, the use of this chemical may create 
concerns like BPA, especially since very little is known about its affects at low exposures. 
 A sulfonyl group is situated in between the two phenolic rings, in place of the bridging 
carbon and methyl groups of BPA, to produce BPS. Many products including thermal receipts, 
currency bills, foodstuff and beverage containers, and epoxy resins contain BPS, leading to 
human exposure [3, 28, 35, 36]. In a study conducted by the CDC, urine from convenience 
samples of adults collected between 2000 and 2014 were tested for a series of bisphenols to 
determine exposure trends. BPS was detected in the urine in all collection years and increased in 
detection rate from 25% (2000) to 74% (2014) [33]. BPA remained the highest recovered 
bisphenol in urine in all years, but an increasing trend of BPS detection in the general population 
could suggests that exposure to BPS is also on the rise. In a recently published study, BPS was 
detected in human maternal and cord serum making that the first human confirmation of 
transplancental transfer [37]. Perinatal exposure in mice altered maternal behavior and produced 
alterations in the brains of F0 and F1 generations [38]. In addition to being estrogenic, BPS was 
found to be adipogenic in murine 3T3-L1 preadipocytes and female human primary adipocytes 
[39, 40]. Collectively, these new findings propose a role for BPS to induce affects in endocrine 
regulated tissues, especially when exposure is early in life. 
 Mammary gland effects following early life, human relevant, exposure to BPA are well 
documented in rats and mice. The mammary gland is only a rudimentary ductal structure during 
late gestation and early perinatal development. During puberty, the ovarian hormones estrogen 
and progesterone influence mammary epithelial structure, as well as endogenous hormones and 
growth factors, for promotion of ductal elongation and side branching, led by TEBs. TEBs are 
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highly mitotic structures and are the targets of transformation because they contain the mammary 
stem cell population [41].  Early life exposure to BPA led to morphological changes during 
pubertal development that included increased TEB formation, ductal extension, and branching 
points as well as a reduction in apoptosis [20, 24, 42]. These early life changes resulted in pre-
neoplastic and neoplastic lesions in mammary glands [43, 44].  
BPAF and BPS accelerated pubertal mammary development and induced preneoplastic 
and neoplastic lesions following prenatal exposures in CD-1 mice (Chapter 3). BPAF has been 
recovered in elution fractions of human abdominal and breast adipose tissue [45]. The 
estrogenicity and anti-adrogenicity [34, 46-49] of these chemicals are postulated to regulate 
certain endocrine tissues (i.e. mammary glands, ovaries and testes, etc.) by binding to the 
estrogen receptor (ER), androgen receptor (AR) or through non-genomic binding [50]. Liver 
injury following BPA exposure has been attributed to increased oxidative stress and reactive 
oxygen species (ROS) generation [51, 52]. However, in the mammary gland, the mechanism(s) 
leading to accelerated development and neoplastic formation are still poorly understood. This 
may be due to factors that include the complexity of the mammary gland and continuous changes 
in morphology that occur during different stages of development. For BPAF and BPS, these 
mechanisms have yet to be explored and one could assume that similar tissue challenges may 
arise. 
 To identify genetic and signaling alterations during pubertal mammary development 
which may act as early biomarkers to predict risk of later life abnormalities, tissues prenatally 
exposed to BPAF and BPS doses previously shown to significantly produce proliferative lesions 
and inflammation (Chapter 3) were evaluated by microarray and RT-PCR. Postnatal day 34 
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(PND 34) mammary glands were assessed by whole genome microarray and candidate genes 
were validated by RT-PCR of mammary gland RNA isolated at PND 20, 34, and 55. 
 
MATERIALS AND METHODS 
Animals 
 Timed pregnant CD-1 mice were obtained from the National Institute of Environmental 
Health Sciences (NIEHS) in-house breeding facility. This animal stock was originally obtained 
from the Charles River R16 facilities (Raleigh, NC). Dams were weighed, randomly assigned to 
a treatment group, and individually housed in polypropylene cages previously screened for 
estrogenicity. San-Chip Hardwood bedding (PJ Murphy Forest Products, Inc. Montville, NJ) was 
supplied in all cages. Dams received AIN-93G chow (Harlan Laboratories, Indianapolis, IN) and 
tap water ad libitum in bottles that were screened for estrogenicity prior to being given to each 
animal. All procedures and handling were in accordance with the NIEHS Institutional Animal 
Care and Use Committee. Animal rooms were maintained on a 12:12 hr light-dark cycle at a 
controlled temperature of 20-40 ͦ C with 40-60% humidity. Precautions were taken for exogenous 
bisphenol contamination as previously described in Chapter 2. Dams were weighed daily prior to 
dosing. Any dam that produced a litter of ≤ 4 pups was excluded from all analysis. 
 
Chemicals 
 BPS (≥ 97.5 % pure) was purchased from Sigma Aldrich (St. Louis, MO) and BPAF 
(≥99.0% pure) was obtained from 3B Pharmachem International Co. Ltd (Wuhan, P.R. China). 
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Chemical purity was confirmed by the NTP chemical contract laboratory prior to dosing. Dosing 
solutions were prepared daily by dissolving the chemicals into pure sesame oil (Jedwards, 
International, Inc., Braintree, MA) followed by gentle vortexing (VWR, Scientific Products, 
Radnor, PA). All daily solutions were prepared in glass vials to reduce bisphenol contamination. 
All animals were administered sesame oil (vehicle), BPAF or BPS by blind allocation in a 
volume of 10 µl solution/g body weight. 
 
Experimental Design 
 Following a 2-3 d acclimation period, timed pregnant dams (n=9-10) were administered a 
twice daily oral gavage of vehicle control, BPAF (5 mg/kg) or BPS (0.5 mg/kg) due to the 
chemicals’ short half-lives and to ensure that the chemicals were not completely cleared prior to 
the next dosing day (Chapter 2). Exposure occurred between gestational days 10 and 17 (GD 10-
17; the period when rudimentary mammary placodes form and a critical timing of chemical 
exposure on the developing mammary gland). In a 14-month developmental study, accelerated 
mammary development and mammary lesion incidences (i.e. tumors, hyperplasia, and 
inflammation) were highly observed in female offspring from these two dose groups (Chapter 3). 
Animals gave birth on the eve of GD 18 and the next day was deemed postnatal day 1 (PND 1). 
Litters were culled to 10 pups on PND 3 and on PND 20, 34 and 55 the inguinal mammary 
glands from both sides of the animal were removed from the female offspring, placed in 
RNALater (Invitrogen, Waltham, MA) at 4˚ C overnight and frozen at -80˚C for future use. 
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Total RNA isolation 
 Mammary tissues from PND 34 were homogenized in Trizol Reagent (Ambion, 
Carlsbad, CA) in 2 ml Lysing D Matrix RNase/DNase free tubes (MP Biomedicals, Eschwege, 
Germany) that contained sterile 1.4 mm ceramic spheres. All samples were homogenized on a 
MP Fast Prep-24 5G (MP Biomedicals, Santa Ana, California) at 6.0 m/sec in repeated 40 s 
intervals followed by 5 min on ice until no tissue was visible. The supernatant was transferred to 
a clean microcentrifuge tube and the remainder of the extraction was performed per the 
manufacturer’s protocol (i.e., 200 µl chloroform, 500 µl isopropanol, and 1 ml 75% ethanol). 
RNA clean-up and DNase I digestion was completed using the RNeasy Mini Kit (Qiagen, Hilen, 
Germany). Total RNA quantification was performed on a NanoDrop 2000c (Thermo Scientific, 
Wilmington, DE) and RNA integrity was measured using the RNA 6000 Nano Kit and the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) per the manufacturers 
‘protocols. Samples with a RNA integrity number (RIN) ≥ 7.9 were considered acceptable for 
microarray analysis. 
 
Microarray Preparation and Data Analysis 
 Five mammary glands each from vehicle, BPAF and BPS were chosen for analysis and 
processed on an Affymetrix Mouse Genome 430 2.0 platform (Affymetrix, Santa Clara, CA) by 
the NIEHS Molecular Genomic Core Laboratory (RTP, NC). Differentially expressed probe sets 
between experimental groups were determined using analysis of variance (ANOVA). For each 
time point, probe intensity data from GeneChip® Mouse Genome 430 2.0 arrays were read into 
the R software environment (http://www.R-project.org) directly from .CEL files using the R/affy 
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package [53]. Data quality was assessed using image reconstruction, histograms of raw signal 
intensities, and scatterplots of normalized data. Normalization was carried out using the robust 
multiarray average (RMA) approach [54] to form one expression measure per probe set per 
array. Briefly, the RMA approach adjusts the background of perfect match (PM) probes, applies 
a quantile normalization of the corrected PM values and calculates final expression measures 
using the Tukey median polish algorithm. Gene expression measures were expressed in the fixed 
effects ANOVA model  using Yi = μ + GROUP + εi  [55] where Yi represents log2 
transformed expression data, μ is the mean for each array, GROUP is a 3 level factor identifying 
each experimental mouse group (untreated vehicle control, BPAF and BPS), and εi is random 
error. A modified F-statistic incorporating shrinkage variance components [56] was used to 
perform pairwise contrasts of interest (vehicle vs. BPAF and vehicle vs. BPS). P values were 
calculated by permuting model residuals 1,000 times using the R/maanova package [57]. False 
discovery rate (FDR) values were estimated in R using the p.adjust function based on the 
Benjamini-Hochberg step down procedure [55]. Unless otherwise noted, significant changes 
were determined at the FDR threshold of 0.1-0.2. Affymetrix probe sets were mapped to genes 
using Ingenuity Pathway Analysis (IPA) (Redwood, CA).   
 
RT-PCR 
 Total RNA was extracted from frozen mammary tissues (3-5 tissues/treatment/time-
point) in the exact fashion as the tissues prepared for microarray analysis. Briefly, glands were 
isolated with Trizol reagent, then purified and precipitated, following DNase I treatment, using 
an RNeasy Mini Kit. RNA quantity and integrity were performed using the methods described, 
with a quality cut-off above RIN ≥ 7.9. One microgram of RNA was reversed transcribed using 
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the High capacity cDNA synthesis kit (Applied Biosystems, Foster City, CA) and amplified in 
the Thermocycler (Bio-Rad) per the manufacturers’ instructions. Briefly, cDNA was mixed and 
prepared with Power SYBR PCR master mix (2x) (Applied Biosystems) and mouse primers 
identified by IPA or reference genes and measured on a QuantStudio 7 Flex (Applied 
Biosystems). Transcript analysis was performed on Quantstudio Real-Time PCR Software and 
Microsoft Excel 2010. Only samples with a CT value of ≤ 35 or standard deviation between 
duplicates of ≤ 0.5 were included in the final analysis. Fold change was calculated using 2-ΔΔCt. 
Briefly, the reference gene (RPL19) for each sample was averaged for each treatment group and 
normalized for each sample within the same group for each target gene to obtain the average 
delta CT (ΔCT). ΔΔCT was calculated using the formula ΔCT –Δvehicle. All results are 
represented as the log fold change. 
 Reference and target genes were purchased from Integrated DNA Technologies and 
include: Nr1d1, Per3, Arntl, PikK, Map2k7, c-jun, Uqcrc1, Aco2, Erra, Errg, Esr1, Esr2, Bax, 
Bcl2, Il-6, Evi5, Rnf168, B3galt5 and Tsc22dl. Mouse homologs for HLA-A (H2-Q4) and HLA-
DRB5 (H2-Eb1) were identified by NCBI (https://www.ncbi.nlm.nih.gov/nucleotide/) and the 
locus with the greatest homology to the human form was used to design the primer. The forward 
and reverse primers were input into the IDT PrimerQuest tool 
(https://www.idtdna.com/Primerquest/Home/Index). Primers with an amplicon length of ~100 
base pairs and GC content of ~50% were chosen. A description of all primers used in this study 
is illustrated in Table 5-1. 
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Statistical Analysis 
 Unless noted, all analyses are represented as the mean ± SEM and the dam is considered 
the unit of measurement. All analyses are a comparison between vehicle control and chemical 
treatment and were calculated using at student’s t-test (two tail) where p ≤0.05 is considered 
statistically significant. All RT-PCR samples were run in duplicates for each gene. If the 
standard deviation of the duplicates was ≥ 0.5, the entire sample was removed from the analysis. 
All graphs were constructed in GraphPad Prism 7. 
 
RESULTS 
 To correlate the morphological changes observed following prenatal exposures to BPAF 
and BPS with potential genes and mechanistic pathways, a genome-wide microarray was 
performed on mammary gland RNA from vehicle control, BPAF (5 mg/kg) and BPS (0.5 mg/kg) 
treated, PND34 CD-1 mice. The principal component analysis (PCA) for vehicle, BPAF and 
BPS are illustrated in Figure 5-1 and shows distinct separation between treatment groups for 
most of the tested samples. 
 
 Early BPS exposure alters genes involved in the circadian clock and mitochondria. 
Approximately 39,000 mapped transcripts were identified in the microarray. Once duplicate 
genes were removed and a single probe for each gene was accounted for, ~20,400 genes were 
used in the analysis. Filtering with an FDR ≤ 0.10 (10 %) returned 114 genes that were 
significantly altered between vehicle and BPS treatment. Ingenuity Pathway Analysis (IPA) 
ranks the Top Networks based on the number of altered genes from the data set and showed that 
BPS treated glands were highly associated with 1) developmental disorders, neurological 
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disease, and DNA replication, recombination, and repair (24 genes), 2) cell morphology, 
assembly, and organization (22 genes), and 3) lipid metabolism, small inflammatory response, 
and cellular function and maintenance (15 genes). A list of the top 10 up and down regulated 
genes is shown in Table 5-2. The Top Cellular and Molecular Functions identified were cell 
cycle and movement, DNA replication, recombination and repair and lipid metabolism (Table 5-
3). When a less stringent FDR (≤ 0.20) was applied to the data set, the number of genes 
increased to 422. Similar to the 0.1 FDR analyses, the Top Networks included cellular assembly, 
DNA replication recombination and repair, RNA post-transcriptional modification and lipid 
metabolism. The Top Molecular and Cellular Functions included energy production, lipid 
metabolism and RNA post-transcriptional modification (Table 5-3). The increased gene set also 
showed that the Top Tox lists were mitochondrial dysfunction, fatty acid metabolism and 
increased transmembrane potential of mitochondria and mitochondrial membrane.  
 Several canonical pathways that contained overlapping genes were identified. Three 
pathways that were likely associated with mammary gland changes were further investigated and 
included mitochondrial dysfunction, circadian rhythm and neurotrophin/TRK/Rac signaling. 
Analysis of the circadian pathway showed up-regulation of Period (Per3), Rev-ERBα (Nrid1), 
Dec, and Creb (Figure 5-2). Alterations in mitochondrial genes mostly occurred in the inner 
membrane where Complex I-IV of the electron transport chain takes place (Figure 5-3). These 
genes included NADPH dehydrogenases (NDUF), succinate dehydrogenases (SDHA-D), 
cytochrome bc1 (Uqcrc1 and CYTB), and cytochrome c oxidase (COX3). Several other genes 
located in the outer membrane and in the mitochondrial matrix were activated and included 
Aconitase 2, GPD21 and ATP5A1. Map2k7 (-1.367) and PTPN11 (-1.70) expression were 
downregulated and associated with the Rac and Neurotrophin/TRK pathways. 
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 Upstream regulators were also predicted based on gene expression changes from the data 
set and are assigned an activation (≥2) or inhibition (≤ 2) z-score. Based on p-values, the top five 
predicted upstream genes associated with inflammation/immunity, mitochondrial dysfunction 
and cancer were selected. The genes with an FDR ≤ 0.10 were tumor protein 53 (TP53), nuclear 
protein 1 (Nupr1), aryl hydrocarbon receptor nuclear translocator like 1 (Arntl), and Period 2 
(Per2) (Table 5-4). Z-scores were only assigned to Nupr1 (1.00) and TP53 (z- score =0.48), but a 
definitive prediction could not be determined due to the scores. Top upstream predicted genes 
evaluated with an FDR ≤ 0.2 included the transcriptional regulators estrogen related receptor 
alpha (Errg), beta-estradiol, lysine demethylase 5A (Kdm5a), peroxisome proliferator alpha 
(Pparα), peroxisome proliferator co-activator 1 alpha (Ppargc1a, Per1 and Per2). Pparα and 
Ppargc1a were predicted to be activated due to positive z-scores (2.80 and 2.46, respectively), 
whereas Kdm5a was predicted to be inhibited (z-score -3.05). Noteworthy was the fact that other 
members from the PPAR family (Pparγ and Pparδ) were all upregulated and predicted to be 
activated (z-score = 2.77-3.02), and insulin receptor (Insr) and insulin receptor substrate 1 (Irs1) 
were also predicted as activated (data not shown). Fibroblast growth factor 21 (Fgf21), a known 
biomarker for mitochondrial disease was predicted to be activated. Rb1 is downstream of Kdm5a 
and functions to inhibit cell cycle progression, but also functions to drive cells toward a 
differentiated state. Cells that don’t express Rb1 experience decreased oxygen consumption and 
altered mitochondria function [58]. In this data set, Rb1 had a positive z-score and was 
considered to be activated. 
 RT-PCR was completed on a select number of genes from each identified pathway as 
well as other genes from the Top Ten altered list. PND 34 glands were first considered in the 
validation effort, followed by RNA from tissues acquired on PND 20 and 55 (Table 5-5). The 
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PCR analysis confirmed that Aconitase (Aco2) and ubiquinol-cyctochrome c 1 (Uqcrc1) were 
both significantly up regulated at PND 34, but were unchanged at PND 20 and 55. Validation of 
circadian clock genes revealed that nuclear receptor subfamily 1 group D member 1 (Nr1d1) was 
increased at PND 34 and 55, whereas Period (Per3) was increased at PND 34, but no other time 
points. Aryl hydrocarbon receptor nuclear translocator like (Arntl), a downstream target of Nr1d1 
and Per3, was significantly reduced at PND 20. Selected genes that are common to the 
Neurotrophin/TRK and Rac pathways were also evaluated by PCR. Pi3k was increased at PND 
34, whereas Map2k7 was unchanged at all time-points. c-jun was not changed on the microarray, 
but at PND 20 was decreased. Ecotropic viral integration site 5 (Evi5) is a GTPase activator 
involved in cell proliferation and linked to adenocarcinoma and epithelial cancers; it was 
increased at PND 34, but decreased in the microarray. The family of estrogen receptors were 
assessed since BPS is estrogenic and previous studies showed that nuclear receptor expression 
was unchanged in late adulthood (Chapter 3). Estrogen receptor alpha and beta (Esr1 and Esr2) 
and estrogen related receptor gamma and alpha (Errg and Erra) were analyzed by PCR at all 
time points; expression in treated and control glands were similar. Fischer et al. [59] showed that 
following prenatal BPA exposure that genes involved in immunoregulation were altered in the 
mammary gland. Although changes in the microarray were not apparent, we were interested in 
determining if we would observe individual genes changes with PCR since we saw increased 
histopathological findings of inflammation from our previous 14 mo. study (Chapter 3). The 
cytokine Interleukin-6 (Il-6) and two master regulators of cell death, B-cell lymphoma-2 (Bcl2) 
and Bcl2 like protein 4 (Bax) were analyzed. Interestingly, none of these genes were significantly 
different between treated and vehicle control glands evaluated at exposure to PND 20 and 55.  
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 Early BPAF exposures results in transcriptional alterations in the immune system. The 
same analysis was performed on mammary glands from BPAF exposed mammary glands. When 
samples were filtered using a FDR ≤ 0.10 (10%) only 6 genes were altered (Table 5-6). Selective 
Top Networks identified by IPA included metabolic disease, lymphoid tissue structure and 
development, and cancer. Since there were a limited number of genes identified many of the Top 
Cellular and Molecular Functions were linked to cell cycle maintenance, structure and cell to cell 
signaling (Table 5-7). To increase our pool of candidate genes, the FDR was broadened to 0.20 
(20%) and increased the number of altered genes to 44. This change identified inflammatory 
disease and response (20 genes) and cell cycle/interaction (17 genes) in the Top Cellular and 
Molecular Functions. In addition to the top functions that were determined at a FDR ≤ 0.1, 
energy production and cellular growth and proliferation were identified once the FDR was 
increased. Top Tox lists genes included PXR/RXR/RAR activation and AHR signaling. 
 Many of the altered genes were clustered into canonical pathways that involved immune 
regulation including antigen presentation, OX40 signaling and B cell development. The four 
genes related to these pathways were major histocompatibility complexes I and II, specifically 
HLA-A, HLA-DRB5, HLA-DMB, and HLA-A. All play a role in T4 and T8 antigen presentation 
and activation. HLA-A was the only gene found upregulated (4.61); HLA-DMB (-3.25), HLA-
DRB5 (-6.85), and HLA-E (-2.26) were all downregulated.  
 A list of selective predicted upstream regulators is illustrated in Table 5-8. Very few 
genes were assigned a z-score prediction with the exception of myeloid differentiation primary 
response 88 (Myd88), a member of the death domain superfamily that is associated with several 
neoplasia’s and lymphoid diseases. Myd88 was downregulated and predicted to be inhibited (z-
score = -2.16). Genes involved in the inflammatory response with significant p-value overlaps, 
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but not given a prediction, included Il10ra, Il6, Il1b, and Ifng (z-score = -1.98, -1.32, -0.70 and -
0.99). The endocrine related gene Erbb2 and chemical beta-estradiol (z-score = 0.15 and -0.53) 
were also considered to be potential upstream regulators.   
 Similar to BPS, select genes of interest from pathways identified by IPA were evaluated 
by RT-PCR. Mammary glands from PND 34, as well as PND 20 and 55, were analyzed to 
establish if the genetic changes were persistent. Selected genes and their expression levels can be 
found in Table 5-9. Genes involved in B cell development and antigen presentation were 
evaluated. The microarray identified the human HLA homologs; however, human primers do not 
amplify mouse tissues. Therefore, mouse homologs were identified by the NCBI database and 
validated using primers with a similar genetic sequence. H2-Q4 was run for HLA-A and H2-Eb1 
for HLA-DRB5. At PND 34, H2-Eb1 expression was unchanged, unlike its downregulation that 
was observed in the microarray. Although significance was not achieved at PND 20 and 55, H2-
Q4 trended towards significance (p = 0.06-0.07). Statistical changes were not observed at any 
time-point for H2-Q4. Beta-1,3-galactosyltransferase 5 (B3galt5) and TGF-β stimulated clone 22 
domain family 1 (Tsc22d1) were within the top up and downregulated genes within the 
microarray and both play a role in diseases associated with adenocarcinoma, squamous cell 
carcinoma and carcinomas (Table 5-6). Tsc22d1 was upregulated at PND 20 and unchanged at 
PND 34, although it was downregulated in the microarray. By PND 55, expression trended 
toward down-regulation (p = 0.07). B3galt5 expression was unchanged at PND 34, although it 
was down-regulated in the array (-1.28). Studies that have confirmed BPAF as estrogenic also 
prompted us to evaluate the family of estrogen receptors [34, 48]. Estrogen related receptor alpha 
(Erra), estrogen receptor alpha (Esr1), and estrogen receptor beta (Esr2), were not altered 
between PND 20 and 55. Estrogen related receptor gamma (Errg) was significantly upregulated 
 209 
 
at PND 34. The cytokine Interleukin-6 (Il-6) and two master regulators of cell death, B-cell 
lymphoma-2 (Bcl2) and Bcl2 like protein 4 (Bax) were analyzed. Interestingly, none of these 
genes were significantly different from vehicle controls during PND 20 and 55. Il-6, Bax and 
Bcl2 were unchanged at all time-points. 
 
DISCUSSION 
 Previous studies within this lab have identified increased TEBs, longitudinal growth and 
branching density that progressed into inflammation, hyperplasia and adenocarcinoma in 
mammary glands following prenatal BPAF and BPS exposure (Chapter 3). However, the 
mechanism in which this occurs has not been explored and still poorly understood in BPA 
exposed mammary glands. In this study, mammary glands from low dose prenatal exposure to 
BPAF and BPS were evaluated to understand mechanistic changes that were related to early 
morphological changes. Changes in immunoregulatory genes including HLA-A (H2-Q4) and 
HLA-DRB5 (H2-Eb1) and a membrane bound estrogen receptor, Errg, were identified as 
possible mediators of effect in BPAF exposed mammary glands. In glands from BPS treated 
mice, genes involved in the circadian rhythm, mitochondrial dysfunction and TRK and Rac 
signaling were of interest. These data suggest that the dynamics of multiple gene signaling 
events are likely leading to the morphological alterations that affect later life pre-neoplastic and 
neoplastic mammary lesion development.  
 Interestingly, the number of genes that were identified as statistically altered by BPAF 
were ~8x (44 genes) lower (FDR ≤ 0.20) compared to changes observed in the BPS treated 
mammary glands (~400 genes). Animal to animal variability is the likely cause of this, as many 
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of the BPS samples clustered more closely to one another on the PCA, compared to BPAF 
glands where some samples were more like vehicle glands. If this is the case, then potentially 
increasing the sample size or excluding animals that were like controls may increase the number 
of altered genes. However, mammary glands following BPA exposure have also been shown to 
produce limited transcriptional changes [42, 60]. 
 Since only a small number of genes were changed following BPAF exposure, limited 
pathways that involve these same genes were identified. These pathways included antigen 
presenting B-cell development, and OX40 signaling, and involved genes associated with the 
major histocompatibility complexes I and II (MHC). HLA-A is a part of the class I complex. 
When bound to CD8 this complex presents cytosolic proteins to CD8+ cytotoxic T lymphocytes. 
We chose the H2-Q4 mouse homolog for validation because it shared 69% homology with 
human HLA-A. Downregulation of this class of genes in primary tumors, including breast tissue, 
are thought to promote tumor metastasis [61], because the tumor cells are able to evade immune 
targeting. HLA-A, however, was up-regulated in the microarray, but was unchanged with PCR. 
HLA-DRB5 and HLA-DM5 are a part of the complex II class and were both downregulated in 
the microarray. MHC complex II genes are found on many cell types including epithelial cells 
and are responsible for presenting extracellular proteins to CD4+ T cells by phagocytosis. PCR 
analysis of the HLA-DR5 homolog H2-Eb1 showed no changes at PND 34, but exhibited a 
downregulated trend toward significance at PND 20 and 55. If this trend were to become 
significant during later development, then toxic cells may be able to successfully evade immune 
surveillance, increasing potential risk for tumor progression.  
 Several pathways involved in normal and abnormal mammary development and cancer 
were identified following BPS exposure. Genes from the circadian rhythm pathway were altered 
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(Figure 5-3). Bhlhe40, Nr1d1, and Per3 were all upregulated in the microarray. We chose to 
evaluate Nr1d1, as well as Per3, and Arntl, which are downstream of Nr1d1. Per3 and Nr1d1 
validated the microarray findings, and Arntl was significantly downregulated at PND 20 and 55. 
Women who work night shifts have increased breast cancer risk, thus this group of circadian 
rhythm genes may have impact on cancer development [62, 63]. Camacho et al. also showed that 
at EE2 (5.0 mg/kg), but not BPA, caused decreased expression of Clock, a transcription regulator 
that dimerizes with Arntl, in the mammary gland. 
Over 15 genes related to mitochondrial dysfunction were altered in BPS-treated 
mammary glands including Aco2 and Uqcrc1 (Figure 5-4). Aco2 is an enzyme that catalyzes 
citrate to isocitrate and has been shown in several studies to play a role in prostate cancer. Under 
normal conditions it is inhibited, but in cancer it is restored and increases citrate oxidation and 
decreases fatty acid oxidation [64, 65]. In the microarray, Aco2 was upregulated in both the 
microarray and by PCR (1.90). Similarly, Uqcrc1 a component of the ubiquinol-cyctochrome c 
complex III was also upregulated in the microarray and via PCR (1.53). This gene is involved in 
catalyzing electrons from ubiquinone to coenzyme Q 10, and mutations in the mitochondrial 
DNA of the cytochrome bc1 family have been linked to breast cancer [66]. Therefore, early 
dysfunction of these genes could suggest a mechanism for the phenotypes observed in later life. 
The TRK and Rac pathways share many similar genes and are involved in cancer formation 
because they signal downstream to drive transcription of c-jun. c-jun is overexpressed in MCF-7 
cells and involved in breast cancer metastasis [67]. Map2k7 and Pi3k were downregulated in the 
microarray. These genes and c-jun were chosen for PCR validation. Contrary to the microarray, 
Pi3k was upregulated at PND 34 and c-jun was significantly reduced at PND 20 and 55.  
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 BPA, BPAF, and BPS have all been identified as estrogenic due to their ability to bind to 
the estrogen receptor but only at concentrations much greater than 17β-estradiol therefore 
making them weak estrogens. Since these chemicals are estrogenic, and the mammary 
morphologies identified previously (Chapter 3) following exposure to these chemicals are similar 
to those produced by estradiol or EE2, it was thought that the mechanism for mammary effects 
were estrogen related. BPAF and BPS are agonists for ERα, but BPAF is considered a full 
antagonist for ERβ, and a predominant isoform has not been identified for BPS-related 
estrogenicity [34]. Therefore, we performed PCR on BPAF and BPS mammary glands with 
Erra, Errg, Esr1, and Esr2, even though the microarray did not show changes in these genes. 
BPAF has a greater binding affinity to ERα compared to ERβ [34], but is considered a full 
antagonist for ERβ and currently the preferential estrogen receptor for BPS binding has not been 
established. Our previous findings showed that following prenatal exposure to BPAF (5 mg/kg) 
and BPS (0.5 mg/kg) Esr1 expression was unchanged at 8 and 14 mo. (Chapter 3). Similar to 
adult mammary Esr1 expression, that in BPAF and BPS-exposed pubertal mammary glands was 
also unchanged. None of the other estrogen related genes were altered at any time-point except 
for Errg at PND 34 (increased 1.23 fold). These data suggest that effects of BPS and BPAF on 
the mammary gland may be indirectly mediated by the ERs, but no clear direct indication is 
apparent. Further testing will be required to determine this relationship. 
 We were also interested in the effects on BPAF and BPS on immune changes. As 
mentioned earlier, BPA exposure caused reduced expression of cytokines, chemokines, 
interleukins and leukocyte markers in the mammary gland [59]. This was also confirmed in rats 
by Camacho et al. [60] who showed decreased Ccl11, Ccl5, and Il4ra expression. In Chapter 3, 
BPAF and BPS caused inflammation in mammary glands that increased significantly with age, 
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and in some cases dose. Macrophages and leukocytes play a critical role in normal and breast 
cancer microenvironment [68, 69]. In our study, PCR was performed on BPAF and BPS exposed 
mammary RNA using a select number of genes from the Fischer et al. study [59], but Il6, Bax 
and Bcl2 expression were unchanged. However, several genes were altered in the microarray, 
and the three that were chosen may not have been a good representation for these chemicals or 
pathway. It should be noted that several cytokines (Ilb, Il1a, Il10ra, and Infg) were all predicted 
upstream targets by IPA due to changes in other genes involved in immune regulation and those 
genes were not tested by PCR. Therefore, immune dysfunction in the mammary gland following 
BPAF and BPS exposure should still be considered as a potential mechanism, especially since 
we observed increased inflammation that was detected in cycling animals and persisted over time 
in previous studies. 
 Finally, we wanted to explore genes that played a role in cancer initiation, promotion, or 
progression. BPS exposure resulted in downregulation of Evi5 and Rnf168 in the microarray. 
Evi5 was the only gene changed in PCR analyses and was upregulated, contrary to the 
microarray findings. Evi5 is a GTPase activator that whose role in the cell involves proliferation 
and cell formation. When Evi5 was ectopically expressed in hepatocellular carcinoma cells, 
tumor migration and invasion were reduced [70]. Tsc22d1 and B3galt5 were both downregulated 
in BPAF-exposed glands in gene arrays, but were unchanged when PCR was performed at 
PND34. Tsc22d1 was however, upregulated at PND 20. Tsc22d1 works as a tumor suppressor by 
inhibiting Ras/Raf activation. These conflicting findings between the microarray and PCR 
expression will require a further look at protein expression levels to determine Evi5 and Tsc22d1 
roles in BPAF and BPS treated mammary gland, and possibly an evaluation of these genes at 
time points closer to when pre-neoplastic lesions and adenocarcinoma were developing in our 
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prior studies. Both genes have also been implicated in epithelial cancers and adenocarcinoma. It 
should be noted that several other genes that play a role in cancer were identified by both 
treatments, and will be evaluated in the future. 
 When comparing bisphenol induced transcriptional changes between different studies it is 
important to note that the amount and developmental time period (i.e. prenatal, pubertal or 
adulthood) of exposure may result in different gene signatures.  When transcriptional analysis of 
mammary glands from BPA (250 µg/kg/bw/d) prenatally (GD 9- PND 1) exposed rats were 
performed only a small number of gene changes were observed at PND 4 (alpha-lactalbumin), 
that were unchanged at PND 21. It was not until PND 50 that most the gene changes were found, 
and they included genes involved in cell cycle regulation [71]. Similarly, Moral et al. [42] 
showed that when rats were exposed to BPA (25 or 250 µg/kg) between GD 10 and 21 that a 
small set of genes from female offspring mammary glands were altered at PND 21, and less at 
PND 35, but many gene changes from both dose groups were observed at PND 50, and in the 
highest dose at PND 100. However, increased TEBs were observed as early as PND 21. These 
data suggest that while morphological changes occur very early during puberty that possibly the 
greatest effects don’t occur until well after these changes have occurred. Very few gene changes 
were observed in the mammary gland at PND 34 following BPAF exposure even when the FDR 
was increased and even fewer changes were observed in a microarray that was completed using 
mammary tissue from littermates at PND 20. Therefore, it is quite possible that if we had 
performed transcriptional analysis at time points later than PND 34, and closer to the times we 
saw phenotypic responses that we may have observed additional changes.  Future transcriptional 
studies should be performed at later time-points. 
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 This first study of the gene changes induced in the mammary gland of prenatally BPAF- 
and BPS-exposed mice during early life stages indicates some of the latent health effects that 
were detected in previous work (Chapter 3). Many of the cellular functions include changes in 
cell cycle and differentiation, as well as changes that are critical in breast cancer development 
(circadian rhythm and mitochondrial dysfunction), and as a result may serve as a precursor for 
abnormal mammary growth. Although only one time-point was assessed by microarray, PCR 
confirmed that some changes were sustained over time and could persist into later age. Further 
studies at different time-points will be necessary to confirm this, but many of these findings have 
also been observed following early life exposures to BPA and should warrant concern regarding 
human exposure and health outcomes.  
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Table 5-1: Gene Primer List 
Gene IDT Primers 
Per3   Mm.PT.58.12973804 
Nr1d1 Mm.PT.58.17472803 
Arntl  Mm.PT.58.11121936 
Pi3k  Mm.PT.58.5285167 
Map2k7  Mm.PT.58.28392891 
c-jun  Mm.PT.58.32691984.g 
Uqcrc1 Mm.PT.58.42202784 
Aco2  Mm.PT.58.6843105 
Rpl19 Mm.PT.58.12385796 
Bax Mm.PT.58.14012210 
Bc12 Mm.PT.58.7362966 
Erra Mm.PT.58.29487425 
Errg Mm.PT.58.28487522 
Esr1 Mm.PT.58.8025728 
Esr2 Mm.PT.58.43122172 
Il-6 Mm.PT.58.10005566 
 
Gene Forward Primer Reverse Primer 
H2-Eb1 CAGATGTGGCAGGACAATAGA  CCTTGAGCAGGCTGATTTAGA  
H2-Q4 CAGATCCTCCAAAGGCACAT CAGGATGATGTTAGCAGGGTAG 
  
  
 
217 
Table 5-2: Top 10 up and down regulated gene expression changes in mammary gland following BPS exposure  
 
 
 
 
 
 
 
 
 
 
 
 
 
BPS data was filtered with an FDR of 0.10. 
Molecule Gene Name Location Δ Fold  
FDR 0.10    
GSN gelsolin extracellular 190.79 
DBP D-box binding PAR bZIP transcription factor nucleus 3.360 
BHLHE40 Basic helix-loop-helix family member e40 nucleus 2.414 
ASPG asparaginase cytoplasm 2.385 
TEF TEF, PAR bZIP transcription factor nucleus 1.860 
PER3 Period circadian clock nucleus 1.843 
NR1D1 Nuclear receptor subfamily 1 group D member 1 nucleus 1.672 
NR1D2 Nuclear receptor subfamily 1 group D member 2 nucleus 1.669 
ACO2 Aconitase 2 cytoplasm 1.638 
PIM1 Pim-1 proto-oncogene, serine/threonine kinase cytoplasm 1.554 
    
ZNF397 Zinc finger protein 397 nucleus -2.348 
XIST X inactive specific transcript (non-protein coding) nucleus -2.223 
Ear3 Eosinophil-associated, ribonuclease A family, member 3 other -2.195 
Kctd12b Potassium channel tetramerisation domain containing 12b Plasma membrane -2.032 
CREBBP CREB binding protein nucleus -1.989 
APC APC, WNT signaling pathway regulator nucleus -1.978 
ARID4B AT-rich interaction domain 4B nucleus -1.973 
HDLBP High density lipoprotein binding protein nucleus -1.947 
UTRN Utrophin Plasma membrane -1.940 
LPP LIM domain containing preferred translocation partner in 
lipoma  
nucleus -1.928 
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Table 5-2: Top 10 up and down regulated gene expression changes in mammary gland following BPS exposure (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
BPS data was filtered with an FDR of 0.20. 
Molecule Gene Name Location Δ Fold  
FDR 0.20    
GSN Gelsolin extracellular 190.79 
UCP1 Uncoupling protein 1 cytoplasm 4.526 
Zfp945 Zinc finger protein 945 nucleus 3.443 
CIDEA Cell death inducing DFFA like effector A cytoplasm 3.412 
DBP D-box binding PAR bZip transcription factor nucleus 3.360 
COX7A1 Cytochrome c oxidase subunit 7A1 cytoplasm 3.218 
CPT1B Carnitine palmitoyltransferase 1B cytoplasm 2.988 
SLC27A2 Solute carrier family 27 member 2 cytoplasm 2.540 
BHLHE40 Basic helix-loop-helix family member e40 nucleus 2.414 
ASPG Asparaginase cytoplasm 2.385 
    
CP Ceruloplasmin extracellular -3.373 
RARRES1 Retinoic acid receptor responder 1 plasma membrane -3.086 
Rn18s 18s ribosomal RNA other -2.424 
ZNF397 Zinc finger protein 397 nucleus -2.348 
Ear2 Eosin-affiliated, ribonuclease A family, member 2 cytoplasm -2.334 
RAPGEF4 Rap guanine nucleotide exchange factor 4 cytoplasm -2.328 
XIST X- inactive specific transcript (non-protein coding) nucleus -2.223 
EAR3 Eosin-affiliated, ribonuclease A family, member 3 cytoplasm -2.195 
BPTF Bromodomain PHD finger transcription factor nucleus -2.191 
Kctd12b Potassium channel tetramerisation domain containing 12b nucleus -2.032 
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         Table 5-3: Top Cellular and Molecular Functions for BPS-exposed mammary tissue  
 The top molecular and cellular functions are based on p-values. FDR 0.10 (p-value range 2.85E-04 - 2.31E-02) and FDR 0.20  
 (P-value range = 6.04E-05 –2.80E-02)  
   
BPS (0.10 FDR) # Molecules BPS (0.20 FDR) # Molecules 
    
Cell Cycle 27 Energy Production 15 
Cellular Movement 14 Lipid Metabolism 40 
DNA Replication, Recombination, and Repair 19 Small Biochemistry 54 
Gene Expression 35 RNA Post Transcriptional Modification 20 
Lipid Metabolism  9 Cell Cycle 68 
 220 
 
Table 5-4: Predicted Upstream Regulators following BPS prenatal exposure  
BPS (FDR 0.10) Molecule Role Activation z-score p-value overlap 
TP53 Transcription regulator 0.479 3.15E-04 
NUPR1 Transcription regulator 1.00 1.62E-03 
ARNTL Transcription regulator ND 2.19E-03 
Sos Group ND 2.71E-03 
PER2  Transcription regulator ND 4.28E-03 
    
BPS (FDR 0.20) Molecular Role Activation  z-score p-value overlap 
KDM5A Transcription regulator -3.05 3.27E-05 
ARNTL Transcription regulator ND 2.19E-03 
Sos group ND 2.71E-03 
ESRRA Ligand-dependent nuclear receptor ND 2.62E-03 
TP53 Transcription regulator 1.47 1.16E-02 
PER2  Transcription regulator ND 4.28E-03 
PPARGC1A Transcription regulator 2.46 4.67E-03 
PER1 Transcription regulator ND 1.89E-02 
PPARA Ligand-dependent nuclear receptor 2.80 1.73E-02 
Selected predicted upstream regulators identified by IPA. Activation score ≤ 2 predicts inhibition and ≥ 2 
predicts activation. ND = no activation thus z-score could not be determined. Note: Predicted regulators 
are genes involved in cancer, circadian rhythm, estrogen receptor and the peroxisome proliferator family. 
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Table 5-5: Quantitative PCR of Candidate Genes (BPS) 
 PND 20 PND 35 PND 55 
Aco -1.11 ± 0.31 1.90 ± 0.21** 1.19 ± 0.25 
Uqcrc1 1.11 ± 0.21 1.53 ± 0.12** 1.06 ± 0.20 
    
Arntl -1.82 ± 0.26 ** -1.13 ± 0.12 1.79 ± 0.13 
NR1D1 1.38 ± 0.11 2.93 ± 0.06** 2.26 ± 0.13** 
Per3 1.56 ± 0.17 2.32 ± 0.30** 1.38 ± 0.32 
    
c-jun -1.48 ± 0.20* -1.35 ± 0.29 -1.34 ± 0.20 
Map2k7 -1.14 ± 0.22 1.08 ± 0.13 1.03 ± 0.09 
Pi3k -1.04 ± 0.18 1.49 ± 0.22* -1.10 ± 0.12 
    
Evi5 -1.00 ± 0.12 1.34 ± 0.09** 1.00 ± 0.11 
RNF168 1.05 ± 0.19 -1.00 ± 0.09 -1.15 ± 0.16 
    
Erra -1.12 ± 0.29 1.21 ± 0.12 1.40 ± 0.19 
Errg -1.16 ± 0.07 1.23 ± 0.10* -1.18 ± 0.27 
Esr1 -1.32 ± 0.29 1.16 ± 0.15 1.06 ± 0.19 
    
Il-6 -1.21 ± 0.28 1.49 ± 0.29 -1.34 ± 0.06 
Bax 1.02 ± 0.14 -1.08 ± 0.20 1.41 ± 0.15 
Bcl2 -1.04 ± 0.17 -1.02 ± 0.06 1.64 ± 0.26 
    
Data are represented as mean fold induction ± SEM. N= 3-5 samples/treatment 
per time-point. A student’s t-test was performed to determine 
statistical significance. † p = 0.06, * p< 0.05 and **p< 0.01.
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Table 5-6: Top 10 up and down regulated gene expression changes in mammary gland following BPAF exposure 
 
 
       
 
 
BPS data was filtered with an FDR of 0.10. 
Molecule Gene Name Location Δ Fold  
FDR 0.10    
SL35E2B Solute carrier family 35 membrane E2B Other 1.204 
HLA-DRB5 Major histocompatibility complex, class II, DR beta 5 Plasma membrane -6.853 
SFRP5 Secreted frizzled related protein 5 Plasma membrane -2.374 
TSC22D1 TSC22 domain family member 1 Nucleus -1.950 
B3GALT5 Beta-1,3-galactosyltransferase 5 Cytoplasm -1.281 
SNAPIN SNAP associated protein Plasma membrane -1.216 
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Table 5-6: Top 10 up and down regulated gene expression changes in mammary gland following BPAF exposure (cont.) 
 Molecule Gene Name Location Δ Fold 
FDR 0.20    
HLA-A* Major histocompatibility complex, class I, A Plasma membrane 4.607 
ELOVL3 ELOVL fatty acid elongase 3  3.439 
Zfp945* Zinc finger protein 945  3.063 
Tmsb4x Thymosin, beta 4, X chromosome  2.085 
ASPG Asparaginase  1.779 
Zfp40* Zinc finger protein 40  1.726 
SLC35E2B Solute carrier family 35 member E2B  1.204 
SIN3B SIN3 transcription regulator family Nucleus 1.179 
PPM1B* Protein phosphatase Mg2+/Mn2+ dependent 1B  1.131 
AKT3* AKT serine/threonine kinase 3 Cytoplasm 1.118 
    
HLA-DRB5 Major histocompatibility complex, class II, DR beta 5 Plasma membrane -6.853 
HLA-DMB Major histocompatibility complex, class II, DM beta  Plasma membrane -3.250 
RARRES1 Retinoic acid receptor responder 1  -2.952 
8030497I03Rik Riken cDNA 8030497I03 gene  -2789 
Zfp989/Znf41-ps* ZNF41  -2.714 
ITCH* Itchy E3 ubiquitin protein ligase  -2.464 
ZNF616* Zinc finger protein 616  -2.458 
SFRP5* Secreted frizzled related protein 5 Plasma membrane -2.374 
HLA-E* Major histocompatibility complex, class I, E Plasma membrane -2.258 
NRIP1* Nuclear receptor interacting protein 1 nucleus -2.192 
BPS data was filtered with an FDR of 0.20. 
 
 
 
 
  
 
 
Table 5-7: Top Cellular and Molecular Functions for BPAF-exposed mammary tissue 
BPAF (0.10 FDR) # Molecules BPAF (0.20 FDR) # Molecules 
    
Cell Death and Survival 1 Cellular Growth and Proliferation 18 
Cell Cycle 1 Energy Production 4 
Cellular Development 3 Cell Death and Survival 17 
Cellular Assembly and Organization 1 Cell Cycle 5 
Cell-To-Cell Signaling 2 Cell Morphology 12 
The top molecular and cellular functions are based on p-values. FDR 0.10 (p-value range = 2.94E-03 
 -3.68E-04) and FDR 0.20 (p-value range = 4.96E-02 – 4.13E-04)  
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Table 5-8: Predicted Upstream Regulators following BPAF prenatal exposure  
 
 
 
 
 
 
 
 
 
 
 
Selected predicted upstream regulators identified by IPA. Activation score ≤ 2 predicts inhibition and  
≥ 2 predicts activation. ND = no activation z-score determine.  
  
BPAF (0.10 FDR) Molecule Role Activation z-score p-value overlap 
B3GALT1 enzyme ND 3.68E-04 
COPS4 other ND 7.35E-04 
oxazepam chemical drug ND 7.35E-04 
AFP transporter ND 2.94E-04 
Map3k7 kinase ND 2.01E-02 
Beta-estradiol chemical ND 1.45E-02 
    
BPAF (0.20 FDR) Molecule Role Activation z-score p-value overlap 
B2M Transmembrane receptor ND 1.61E-05 
POR enzyme ND 3.96E-05 
MYD88 other -2.16 8.95E-05 
Beta-estradiol Chemical ND 5.45E-04 
ERBB4 Kinase ND 8.41E-04 
ERRB2 Kinase 0.152 2.25E-03 
EGFR Kinase ND 3.07E-03 
IL10RA Transmembrane receptor -1.98 4.32E-03 
IL6 cytokine -1.36 1.05E-02 
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Table 5-9: Quantitative PCR of Candidate Genes (BPAF) 
 PND 20 PND 35 PND 55 
H2-Eb1(HLA-DRB5) -2.50 ± 0.41†† -1.75 ± 0.40 -1.71± 0.23† 
H2-Q4 (HLA-A) 1.40 ± 0.50 1.54 ± 0.27 1.10 ± 0.25 
    
B3galt5 NA -1.43 ± 0.68 NA 
Tsc22d1 
 
1.24 ± 0.03** -1.16 ± 0.09 -1.44 ± 0.16†† 
Erra -1.58 ± 0.19  -1.04 ± 0.13 -1.27 ± 0.21 
Errg -1.54 ± 0.22 1.20 ± 0.14* -1.20 ± 0.23 
Esr1 -1.31 ± 0.16 -1.03 ± 0.08 -1.13 ± 0.25 
Esr2 -1.23 ± 0.17 -1.51 ± 0.19 -1.01 ± 0.01 
    
Il-6 -4.04 ± 0.62† -1.38 ± 0.43 -1.61 ± 0.49 
Bax -1.14 ± 0.16 -1.05 ± 0.11 -1.27 ± 0.11 
Bcl2 -1.29 ± 0.10 -1.06 ± 0.10 1.08 ± 0.28 
    
Data are represented as mean fold induction ± SEM. N= 3-5 samples/treatment 
per time-point. NA= Not analyzed. Genes with NA had low expression 
levels. A student’s t-test was performed to determine 
statistical significance. †† p = 0.07, † p = 0.06, * p< 0.05, and **p< 0.001. 
 
  
  
 
 
 
Figure 5-1: Principle component analysis of vehicle, 5 mg/kg BPAF and 0.5 mg/kg BPAF  
mammary gland gene expression changes at PND 34. Green dots = vehicle, red dots = BPAF  
and blue dots = BPS. N= 5 glands/treatment/time-point. 
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Figure 5-2: Circadian rhythm canonical pathway identified by IPA (BPS). All genes were upregulated except for CREB. Red = 
upregulated genes; Green = downregulated genes. Ingenuity Pathway Analysis (www. Ingenuity.com). 
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Figure 5-3: Mitochondrial Dysfunction canonical pathway identified by IPA (BPS). All genes were upregulated. Red = upregulated 
genes; Green = downregulated genes. Ingenuity Pathway Analysis (www. Ingenuity.com). 
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Figure 5-4: Antigen Presenting Pathway canonical pathway identified by IPA (BPS). All genes 
were downregulated. Green = downregulated genes. Ingenuity Pathway Analysis (www. 
Ingenuity.com). 
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CHAPTER 6 
Conclusions and Future Perspectives 
SUMMARY 
 The research from this dissertation serves as an initial step to address the current data 
gaps associated with bisphenol analogue exposures, specifically BPAF and BPS, and their effects 
on the mammary gland. These data describe the disposition and pharmacokinetics of these 
chemicals in a pregnant mouse model and confirm fetal bisphenol exposure, a known critical 
window of mammary gland development. This work is also the first to detail accelerated pubertal 
mammary gland development and progression to increased mammary hyperplasia, inflammation, 
and in some cases, neoplasia in the prenatally exposed offspring.  
Further investigation of the pubertal mammary gland shed light on potential molecular 
and cellular markers that were responsible for its advanced morphological development early in 
life, and sought to determine if they served as early predictors of disease formation. BPAF and 
BPS had little effect on stem and luminal cell counts and MRU frequency. These discoveries and 
the lack of changes in endocrine related genes led to the discovery of changes in genes involved 
in immunity, mitochondrial dysfunction, and circadian rhythm. BPA remains the most widely 
studied bisphenol because of its extensive use in many products and its inevitable exposure to 
humans and potential health effects. However, with the emergence of BPS, BPAF, and several 
other structurally similar chemicals being used in everyday products, undertaking this research 
was essential to inform the scientific and lay communities of their effects. 
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 In order to put this research into context of bisphenol exposure and human health impact 
it was necessary to use doses that were within human relevant levels. Serum BPS has only been 
reported in one study [1] and urinary data only serves as a biomarker of exposure. Therefore, 
bisphenol concentrations were chosen based on BPA risk assessment data. The current LOAEL 
for BPA is 50 mg/kg and therefore the recommended daily intake (RDI) for human exposure has 
been set at 50 µg/kg/bw/day. We chose a dose range of ≤ 50 mg/kg for BPA and a dose range of 
≤ 5 mg/kg for BPAF and BPS since we anticipated human exposure to these chemicals to be less 
than BPA. 
  Neonatal tissue measurements have confirmed BPA placental transfer [2, 3] and the 
effects associated with fetal exposure to BPA have been well documented in rodent studies [4-8]. 
Prior to beginning my thesis work, there were no studies that addressed BPAF and BPS transfer 
to the fetus, and to date there remains none. Therefore, before the effects of BPAF and BPS on 
the mammary gland could be determined, it was first necessary to confirm that the offspring 
were being exposed. Following a single dose exposure, BPA, BPAF, and BPS were all measured 
by mass spectrometry and were above the LOD in the amniotic fluid inferring placental transfer 
and fetal exposure. Following birth, male and female offspring had measurable levels of each 
administered chemical in their serum that continuously decreased between PND 3 and 5 and was 
often ≤ LOD in BPAF animals. Lack of decreases or an increase of chemical in serum over time 
would have indicated that at this early age that metabolizing enzymes necessary to clear the 
chemicals had little to no activity. One study showed the UGT2B1 and UGT1AG gene 
expression in livers from male and female C57Bl/6 neonates were much lower compared to their 
mothers [9]. When liver microsomes of neonates were exposed to BPAF (0.2 mM), BPA (0.2 
mM), or BPF (0.2 mM) the glucuronidation activity was significantly lower in both male and 
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females at GD 18.5 and did not reach maternal activity until PND 21. These findings may further 
explain data that were obtained in my study [10]. We confirmed that serum and urinary half-lives 
in all chemically exposed dams were < 24 hrs. This finding has been noted in human exposures 
regardless of route and amount of exposure, and in pregnant and non-pregnant disposition studies 
involving BPA [11-13]. Due to ethical reasons, we could not place pregnant dams into metabolic 
cages and therefore excreta were only collected at designated time points. Metabolic caging 
would have allowed collection of 24 hr fecal samples (for a more precise measurement), but 
possible contamination from urine would have confounded our measurements. BPA, BPAF, and 
BPS were recovered in dam urine and feces. Recovery of both BPAF and BPS were highest in 
the urine. Although cumulative excreta was not collected and calculated, a similar trend to what 
we reported was also noted in earlier rat and mouse disposition studies [14], and human urine 
measurements over a 14 year span [15]. The low recovery of BPAF in my study inferred either 
increased rapid excretion or distribution to target organs, including the mammary gland; a 
question left unanswered and of interest in future studies. Collectively, these findings proposed a 
twice daily dosing to eliminate the occurrence of episodic circulating exposures, and were 
adopted for all developmental studies.  
 In Chapter 3, potential BPA, BPAF, and BPS-induced mammary gland effects were 
assessed using an extended dosing schedule at concentrations which were not materno- or 
fetotoxic (Chapter 2). Prenatal exposure to BPA, BPAF, or BPS caused increased TEBs, 
branching density, and longitudinal growth of mammary epithelia during puberty (PND 20-56). 
All of these changes have previously been reported in prenatally BPA-exposed mammary glands 
[7, 16, 17]. Interestingly, TEBs were still present during early adulthood (3 mo.) in our mice, a 
time when they should be mostly differentiated. In a study reported at the 2016 EDC Gordon 
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Conference, chemically exposed mammary glands thought to exhibit TEB structures for longer 
than usual were sectioned, and the TEB were actually hyperplastic lesions (L Vandenberg, 
personal communication). Further histopathological evaluation of the glands in our mice, using a 
method developed to prepare H&E stains from whole mounts (Appendix I) [18], determined no 
epithelial abnormalities. However, the increased presence of these structures poses a concern and 
may increase susceptibility to developing proliferative lesions in later life; TEB contain the most 
mitotically active and carcinogen-sensitive cells in the gland. Between 3 and 14 mo., mammary 
glands from all treated groups demonstrated an increased incidence of inflammation and 
epithelial hyperplasia. Mammary adenocarcinomas were detected as early as 11 mo. and other 
tumors including carcinoma, squamous cell carcinoma and papillary carcinoma were apparent by 
14 mo. in BPAF 5 mg/kg and BPS 0.5 mg/kg mice. It should be noted that we did not anticipate 
observing adenocarcinomas; these tumors rarely occur spontaneously in CD-1 mice, especially at 
this young age (mid-life). While we saw significant changes in proliferative epithelial lesions and 
inflammation, had the study been powered with more animals to detect mammary tumors then 
we may have seen significant effects on cancer, also.  
Indices of pubertal maturation including timing of vaginal opening, first estrus, and 
cyclity patterning were all unchanged. Mixed findings on these measurements have been 
reported with BPA in other studies, depending on timing, route, and amount of exposure [19, 
20]. We observed increased serum estradiol and progesterone levels during early puberty which 
would provide an explanation for the accelerated development of the mammary gland. However, 
testosterone and DHEA was decreased between late puberty and early adulthood; a finding that 
often is associated with an increased risk to developing breast cancer in women [21]. Serum 
steroid hormone levels and gene expression of Esr1, Pgr, Gper1, and Ar were all unchanged at 
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14 mo., compared to control mice. Taken together, the morphological changes and progression to 
cancer formation, with the concomitant lack of changes in pubertal timing, serum hormone 
levels, and gene expression of classical nuclear receptors later in life, suggest a role for indirect 
endocrine signaling or changes in other pathways. It also suggests that BPA, BPAF, and BPS are 
causing permanent disruption in pathways during early mammary development. 
 To gain a better understanding of how bisphenol exposure accelerated pubertal mammary 
development and incidence of proliferative lesions, changes within specific mammary cell types 
were examined (Chapter 4). The mammary gland is comprised of several cell types including 
epithelial, adipocytes, immune, endothelial and fibroblasts, however, metastatic tumors arise 
from epithelial cells that comprise the ducts and lobules. Therefore, for this study, only 
mammary stem and luminal epithelial cells were examined; theorizing that increases in these cell 
populations may have been early markers of later life effects and may contain altered cells that 
go on to form tumors. Prenatal exposures to BPAF 5 mg/kg and BPS 0.5 mg/kg were chosen for 
these studies since they invoked significant deleterious mammary phenotypes over time in 
previous studies (Chapter 3).  
Neither BPAF nor BPS altered total epithelial counts or individual luminal and stromal 
counts. Notably, stem cell counts were greatest just prior to vaginal opening and first estrus at 
PND 22, the same period that TEBs, branching density, and serum estradiol levels were 
significantly increased. Throughout the remainder of puberty, this population was lower than 
PND 22 counts and was statistically decreased at PND 35 suggesting that BPAF and BPS further 
decrease the stem cell population with increased pubertal age. This decreased stem cell recovery 
likely attributed to my observed lack of gland reconstitution in the treated groups. We would 
suspect that since the same cell concentrations for each chemical were used during 
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transplantation that the reconstitution frequency would be similar. However, as previously 
mentioned, an overall decrease in basal cells would also be reflected in a decrease in MRU-cells 
since they are a sub-population of the basal cells. MRU frequencies were greatest at PND 22 
(control>BPAF) apart from BPS stem cells that could not re-constitute a gland at any pubertal 
time-point. Prior studies have shown that BPA exposure transiently alters the stem cell 
population and increases PR expression in luminal cells and tissues [22].There were 
approximately 3-7 weeks in between the final administered dose and when cell counts and 
transplants were initiated, and therefore we could have missed the critical window when many of 
these changes were taking place. We chose these times assuming permanent effects on the stem 
cell populations, and specifically thought that the wave of increased stem cells in puberty may 
drive the latent phenotypes previously seen (Chapter 3). More recent data has implicated the fetal 
mammary stem cell as the population that may endure the greatest changes following chemical 
exposure [23]. Still, this data helped define the pubertal MRU frequency range and defined the 
window for the stem cell wave of puberty in the CD-1 mouse, and expands on the knowledge 
that is already known in other strains [24]. 
 The final goal of this research was to narrow down the possible mechanism(s) for BPAF 
and BPS effects on the mammary gland (Chapter 5). The same concentration and time points 
used in Chapter 4 were used to address this research question. Glands from mice exposed 
prenatally were collected on PNDs 20 and 35 in Chapter 3 studies, and were evaluated by whole 
genome microarray to compare molecular changes. However, treated glands from PND 20 were 
not statistically different from control animals in microarray analyses using an FDR of up to 0.4, 
and were therefore not used for this comparison. PND 35 analyses provided more useful 
information. BPAF altered a handful of genes compared to BPS at FDR of 0.1 and 0.2, and all 
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changes involved genes that were associated with antigen presentation and B cell development. 
HLA-DRB5, a transmembrane receptor that presents extracellular proteins to CD4+ T cells, was 
downregulated which could promote an environment for tumor growth. In contrast HLA-A, 
which presents cytosolic proteins to CD8+ T cells, was upregulated. HLA-A has been associated 
with tumor metastasis, however, several alleles of this gene exist and some have been shown to 
have a protective effect against tumor formation [25]. Mouse homologs for both genes (H2-Eb1 
and H2-Q4) were evaluated using PCR, but neither were significantly changed vs controls. 
Interestingly, at PND 20 and 55, H2-Eb1 (HLA-DRB5) expression in bisphenol exposed 
mammary tissue approached significance but was unchanged at PND 35. BPS produced 
numerous changes in pathways involved in mitochondrial dysfunction, circadian rhythm, and 
Rac signaling; pathways shown to play a role in cancer formation or risk.  
Mitochondria are the energy source of the cell and alterations in its function have been 
implicated as a mechanism for several chemical toxicants [26, 27]. Aco and Uqcrc1 were 
increased in both the microarray and confirmatory PCR. We also selected genes from the list of 
top up and down regulated altered genes from both treatments and evaluated them by PCR. 
Although none of these genes were linked to a specific canonical pathway, several were chosen 
based on their role in epithelial cancers, neoplasia and carcinoma/adenocarcinoma formation, 
since this was one phenotype that we observed following prenatal exposure to BPAF and BPS. 
Rnf168, Evi5, B3galt5 and Tsc22d1 are all regulated by cytokines and chemokines and are 
involved in apoptosis, cell differentiation and proliferation. Rnf168 and Evi5 were downregulated 
by BPS whereas BPAF caused downregulation of B3galt5 and Tsc22d1. Only one gene from 
each chemical was significantly altered when assessed by PCR (Evi5 and Tsc22d1) and 
interestingly both genes were upregulated in contrast to the microarray. Because we did not 
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observe any nuclear receptor changes in the adult mammary gland, we wanted to determine if 
receptor changes in younger glands existed as a possible mediator of increased estrogen 
sensitivity, as all of these bisphenols possess estrogenic activity in vitro. Neither BPAF nor BPS 
altered Erra, Esr1, or Esr2 between PND 20 and 55, but Errg was significantly upregulated by 
BPAF at PND 35.  
Immunomodulatory genes were  also examined as potential mediators of effect in the 
mammary gland following bisphenols exposure, as they have been reported as modulators of 
BPA effect in the mammary gland [28], and we previously observed significant increases in 
inflammatory cells in mammary tissue following BPS and BPAF exposures (Chapter 3). Il-6, 
Bax and Bcl2 were unchanged after treatment with BPS and BPAF. This is an interesting 
observation, considering IL-6, IL1RN, IL1B, IL1A, and IFNG were all predicted upstream 
regulators for BPS. Future validation of the IL-1 cytokine family will be necessary to confirm 
these predictions. Taken together, these data suggest that there are likely several mechanisms 
that are causing BPAF and BPS induced mammary gland changes.  
One major limitation in these studies is that we used an outbred mouse strain that 
presented more variability than we could compensate for in our study design. These studies were 
designed to evaluate early life outcomes such as pup number, growth, and pubertal outcomes and 
we chose this strain knowing that it had been previously used to demonstrate significant effects 
of BPA in the mammary gland in other labs [REFs].  The study progressed to late life evaluation 
and cancer outcomes because of the significant changes seen in the pubertal mammary gland and 
the retention of TEB at 3 mo. Had we known some of these findings, we would have a priori 
increased the animal numbers and more carefully selected the time points for evaluation, 
focusing on fetal stem cell populations and late life outcomes in a well powered cancer study.  
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Also, we feel that the variability in this mouse line led to few gene changes seen in microarray 
studies and some of our ongoing analyses will assess for outliers in our data sets. Further studies 
should use an estrogen responsive inbred mouse line and more samples per treatment group in 
gene analyses, or possibly a more sensitive way to measure gene differences between the groups 
(other transcriptomic approaches).    
IMPACT OF FINDINGS 
 In my opinion, the bisphenol replacements BPAF and BPS are not as safe as previously 
considered, but the fields of research for these chemicals are still in their infancy and require 
additional animal studies to increase the weight of evidence for their removal from marketplace 
products. In 2008, the NTP nominated BPAF for further assessment, but has only published one 
report since that time. My work has addressed data gaps that exist in the current literature and 
knowledge of BPAF and BPS, and their effects on the developing mammary gland, and has 
validated previous BPA findings. Although developmental abnormalities have been observed in 
rodents at doses lower than the BPA NOAEL and LOAEL [29, 30], the FDA has noted that the 
decision to ban the use of BPA in baby bottles and formula packaging was attributed to 
abandonment and not safety [31]. The data presented here should be used by regulatory and risk 
assessment agencies to set BPAF and BPS exposure guidelines. Many of the established breast 
cancer risk factors include early exposure to estrogenic compounds and the early onset of 
puberty. BPA exposure as a risk factor for breast cancer is still heavily debated in the field [32, 
33].  Similar to BPA, both BPAF and BPS induced adverse morphological mammary changes 
well after the chemical insult was removed. Therefore, this data implies that following the first 
“estrogenic hit” the accelerated mammary phenotype manifested as a result of a second 
estrogenic hit from increased estradiol and progesterone serum levels either prior to puberty or 
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due to the estrous cycle. Decreased DHEA levels and changes in immune and mitochondrial 
functions likely compounded these risks. In the grand scheme of things, the experimental design 
and unique methods to generate this data will be useful to assess other bisphenol analogues as 
well as other suspected mammary toxicants. 
 
FUTURE PERSPECTIVES 
 As mentioned throughout this work the mammary gland is composed of many cell types 
that signal through paracrine, endocrine and autocrine factors. While many studies have focused 
on the effects of BPA on the mammary epithelium, it has also been shown to alter the stroma, fat 
pad and immune cells. Prenatal BPA exposure in mice caused a decrease in stromal BrdU 
incorporation by PND 30 [7], but was increased at 6 mo. of age in a different study [6]. 
Mammary glands from female offspring exposed to BPA (250 ng/kg) experienced decreased fat 
pad density, increased Bax-positive cells, and increased number of adipocytes per 1 mm distance 
of epithelium [34]. Genes associated with the fatty acid beta oxidation 1 pathway were 
significantly increased (ACAA2, ECHS1, HADHA, and SLC2742) in BPS-exposed mammary 
glands according to the microarray data in my studies. Several of these genes are regulated by 
the peroxisome proliferator activated receptor isoforms and many of these isoforms were 
predicted as upstream regulators in my Ingenuity Pathway Analyses (PPAR α, δ, γ, and 
PPARGC1A).  In mouse liver samples in on-going studies in our lab, changes in these pathways 
were linked to adverse changes in mitochondrial morphology, gene expression, and activity (S. 
Fenton, personal communication). Fatty acids are found within various tissues and are broken 
down by oxidation to produce cellular energy. A study of triple-negative breast cancer showed 
that fatty acid oxidation upregulation in a mouse model that overexpressed MYC was required 
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for tumor growth [35]. This leads us to believe that BPAF and BPS alters the mammary fat pad 
and in turn gland development. To test this theory in on-going work, BPAF and BPS treated 
mammary glands from PND 9 were collected from the littermates of animals from Chapter 5. 
This early time-point represents an important period when epithelial structures have not 
completely invaded the fat pad and ER expression is likely higher in stroma than the epithelium. 
Therefore, sections of adipose tissue and epithelial tissue will be used to test for expression 
pattern differences. 
 The effects of BPA on epigenetic modulation has been observed in several tissues but has 
only been reported for the mammary gland in two studies [36, 37]. The mammary glands of 
Wistar-Furth rats were examined at PND 4, 21 and 50 with BPA concentrations found to induce 
ductal carcinoma situ (250 ug/kg); results showed that pubertal mammary glands exhibited an 
altered epigenome [37]. Mammary glands from prenatally BPA exposed female Wistar Furth rats 
displayed widespread changes in DNA methylation at PND 4 and PND 21. Both hypo and 
hypermethylated loci were detected, especially at PND 21. However, the methylation pattern 
changes between control and BPA did not always remain similar for each time point. NCTR 
Sprague Dawley rats exposed to low (2.5-2700 µg/kg bw/day) and high (100,000 and 300,000 
µg/kg bw/day) BPA and EE2 (0.5 and 5.0 µg/kg bw/day) were also assessed for changes in 
global genomic DNA methylation in mammary tissue at PND 90, but no significant changes 
were detected [36, 38].  
Microarray analyses from Chapter 5 showed that DNA methylation and transcriptional 
repression signaling was a canonical pathway of interest. DNA methyltransferase 3A 
(DNMT3A), chromodomain helicase (CHD4), and AT-rich interaction domain (ARID4B) were 
all downregulated, and methyl Cpg binding (MECP2) was upregulated following BPS exposure. 
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DNA methyltransferases are ubiquitously expressed in normal human tissue but overexpressed in 
many cancers including the breast [39]. DNMT3A is overexpressed in approximately 3% of 
breast cancer cases [40] and sex specific differences in gene expression in the prefrontal cortex 
and hypothalamus following prenatal BPA exposure [41]. CHD4 is a part of the NuRD complex 
and can be regulated by ESR1. ARID4B is also known as breast cancer associated antigen gene 1 
and contains a similar antigen epitope to retinoblastoma binding protein 1 (Rb-1) an anti-
oncogene that binds to E2F to repress transcription of genes involved in the cell cycle [42]. The 
downregulation seen in our analyses could indicate that genes were signaled to continue 
proliferating. MECP2 is highly expressed in the brain and altered expression is associated with 
neurodevelopmental disorders and was increased by BPA in primary embryonic cortical neuron 
[43]. Contralateral glands from Chapter 5 have been preserved to analyze DNA methylation 
status in the near future. 
 Because this data is novel and potentially useful for regulatory bodies, it will be 
necessary to repeat these studies to determine their effects in other strains/species. The OECD 
421 Reproductive and Development Toxicity screening tests, suggest that rats are the 
recommended species and mice can also be used [44]. Our CD-1 disposition data (Chapter 2) 
was very similar to the disposition in B6/F1 mouse and Sprague Dawley rats reported by the 
NTP [14]. Therefore, we believe that these and other rodent models will be good models to test 
the effects of BPAF and BPS on mammary gland development. Currently our lab is undertaking 
a BPAF transcriptomic study from Harlan Sprague Dawley dam and offspring exposed between 
GD 6 and during lactation to PND21. Multiple endocrine related tissues have been collected and 
we anticipate that this data will help to identify and explore important pathways of interest. 
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 The overarching goal of this project was to understand the chemical toxicity of BPAF and 
BPS in the mammary gland. Cancer development was not an expected outcome, and 
demonstrates the importance or further assessing these chemicals for latent disease susceptibility. 
Exposure to these chemicals, combined with well-established non-heritable breast cancer risks 
that include breast density, age at first period, and the emerging obesity epidemic in younger 
children, may further increase one’s susceptibility for developing cancer. It has already been 
reported that women working in canning facilities, that use resins to line the cans, are at an 
increased risk for breast cancer [45]. Making these connections to the bisphenols will require 
more epidemiological studies that will be able to track development over a lifetime, but also 
determine the serum concentrations in human populations to design better human relevant animal 
studies. We anticipate that BPAF and BPS effects will be brought to the forefront of bisphenol 
research and these data will influence the undertaking of similar studies with other bisphenol 
analogues. We anticipate these studies will be influential for regulatory and risk assessment 
decisions. 
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APPENDIX I 
Preparation of high quality hematoxylin and eosin-stained sections from rodent mammary gland 
whole mounts for histopathologic review1 
OVERVIEW 
 Identifying environmental exposures that cause adverse mammary gland outcomes in 
rodents is a first step in disease prevention in humans and domestic pets. ‘Whole mounts’ are an 
easy and inexpensive tissue preparation method that can elucidate typical or abnormal mammary 
gland morphology in rodent studies. Here we propose procedures to facilitate the use of whole 
mounts for histological identification of grossly noted tissue alterations. We noted lesions in 
mammary whole mounts from 14-month old CD-1 mice that were not found in the contralateral 
gland hematoxylin and eosin (H&E)-stained section. Whole mounts were removed from the slide 
and carefully processed to produce high quality histological sections that mirrored the quality of 
the original H&E-stained section in order to properly diagnose the unidentified gross 
abnormalities. Incorporation of this method into testing protocols which focus on low-dose 
human relevant chemicals and endocrine disruptors will increase the chances of identifying 
lesions in the gland and reduce the risk of false negative findings. This method can be especially 
invaluable when lesions are not always palpable during the course of the study or visible at 
necropsy, or when a single cross-section of the mammary gland is otherwise used for detecting 
lesions.  
INTRODUCTION 
 Whole mounts are an invaluable tool used primarily in rodent studies to illustrate the 
progression of normal or chemically-altered mammary gland epithelial growth, development, 
                                                          
1 This chapter was previously published in Toxicologic Pathology. Tucker, DK., Bouknight, SA, Foley, JF. and 
Fenton, SE. (2016). Preparation of High-quality Hematoxylin and Eosin-stained Sections from Rodent Mammary 
Gland Whole Mounts for Histopathologic Review. Toxicologic Pathology 44(7), 1059-1064. 
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function, and disease. When collected during various stages of development, the whole mount 
provides information regarding 1) early development of mammary tissue before endogenous 
hormone changes, 2) pre- and peripubertal epithelial alterations in offspring as a consequence of 
chemical transfer through placental/lactational exposure 3) early signs of lactational impairment 
in dams when evaluated during mid-pregnancy, 4) influences of circulating endogenous hormone 
or endocrine disrupting chemical (EDC) exposures, and 5) gross pre- and neoplastic lesions that 
can be verified and properly diagnosed using histopathology [1]. The latter examples often 
involve tissues collected in adulthood at final necropsy in studies involving chemicals with 
known or suspected endocrine disrupting activities, although mammary tissue can and should be 
collected at other life stages.  
 Historically, rodent mammary glands were prepared and evaluated as a representative 
cross-section that included the skin and very little mammary epithelial tissue. Current 
recommendations [2] include using coronal or longitudinal sections to improve the ability to 
observe any abnormalities; the whole mount also provides an image of the entire gland and 
therefore is another acceptable technique of choice for histopathological evaluation of the 
mammary gland. The mammary whole mount is typically prepared from the inguinal 4th and 5th 
glands on one side of the animal. Glands from this region are easier to access compared to the 
thoracic glands thus preserving the glands natural architecture when spread onto a charged slide. 
One set of inguinal glands are mounted onto the slide, fixed, stained and covered with a 
coverslip, or sealed in a bag of methyl salicylate for temporary or permanent storage, and the 
contralateral gland may be processed for histology [2].  
 When using this approach, a comparative visualization of a whole mount along with 
H&E-stained sections prepared for histologic examination can provide an excellent appreciation 
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of the morphological and cellular alterations occurring in the tissue, especially in cases where a 
palpable tumor is not observed. However, acquiring and evaluating glands from both sides of the 
animal may not always be feasible (i.e. tissue required for RNA or protein analysis or due to 
insufficient funding), or gross abnormalities may occur asymmetrically. The latter was the case 
during the analysis of a current study where the abnormal findings in the whole mounts were 
disproportionately higher compared to the contralateral histopathology findings.  In response, we 
developed an inexpensive and streamlined protocol to examine H&E-stained paraffin sections of 
the original mammary gland whole mount using brightfield microscopy.  The development of a 
standardized protocol will facilitate tissue comparison between labs and may limit the need for 
additional tissues originally processed for H&E staining.   
 
MATERIALS AND METHODS 
Whole Mount and Contralateral Gland Preparation 
 Whole mounts were prepared by excising the 4th and 5th inguinal mammary glands from 
adult female Crl: CD1 (ICR) mice (CD-1; Charles River Laboratory, Raleigh, NC) in an on-
going study (collected at 14 mo of age) or from animals that failed to deliver healthy litters (for 
practicing sectioning and technique specifics). The whole mounted gland was sandwiched 
between parafilm (Bemis, Neenah, WI) and another glass slide with slight pressure applied to 
flatten the gland and increase the surface area for fixation and staining. Fixation (Carnoy’s), 
staining (carmine alum) and defatting (xylene) were performed as previously described in detail 
in Davis and Fenton [2].  
 The contralateral gland was removed and fixed in 10% neutral buffered formalin (Fisher 
Scientific, Fairlawn, NJ) for 48 hours and dehydrated in 70% ethanol to minimize adipose 
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distortion that can occur during sectioning. Within 48 hr. following fixation, samples were 
embedded in paraffin, sectioned at 5µm, and stained with H&E on an automated platform (Leica 
ST2050 Multistainer Workstation, Buffalo Grove, IL). H&E-stained sections were visualized on 
an Olympus BX41 (Olympus Scientific Solutions Americas Corp., Waltham, MA), digitally 
captured on an Olympus DP70 camera and examined by a board certified veterinary pathologist 
(S.H.B.). 
Whole Mount to H&E Preparation 
 We recommend that before the sectioned tissue stages of this protocol are started, that 
high quality images of the intact whole mounts be taken for any future analyses. The first step in 
preparing mammary whole mounts for sectioning was removal of the glass coverslip. Each 
whole mount was placed in a glass Coplin jar and immersed overnight in xylene, followed by 
two additional fresh xylene soaks; 6 hr. and overnight, respectively. Covers fall off during this 
process. Slides were held perpendicular to the bottom of a glass petri dish containing xylene and 
the tissue was scraped from the slide with a sharp disposable razor blade beginning at the top of 
the slide. To ensure the tissue was removed intact, the blade was slowly and carefully pulled 
down the slide, parallel to the tissue. This allowed the gland to fall into the xylene at the bottom 
of the glass petri dish, minimizing air drying of the sample. The tissue was then placed in a 
histology cassette for processing. When necessary, larger glands were halved at the midline 
where the pad narrows and the tissues were placed into two separate cassettes, one labeled for 
the top half and the other for the bottom half. Since the tissue was thin, we do not advise placing 
both halves in the same cassette. The cassettes were held in xylene for up to 2 hr. before being 
placed on the tissue processor (Leica Microsystems TP1020, Chicago, IL). Glands were 
processed in xylene for 30 min. This step was repeated and followed by immersion in a 1:1 
261 
 
xylene: molten paraffin (30 min.). The cassettes were then transferred to the next station, which 
consisted of molten paraffin (1 hr.), followed by another incubation in molten paraffin (2 hr.). 
Processor settings included a temperature of 60°C and the vacuum on for all stations. See Table 
AI-1 for a summary of the tissue processing schedule. Finally, the mammary pad was embedded 
in paraffin with the flat surface down (side adjacent to the glass slide). Prior to sectioning, the 
paraffin blocks were incubated at -20°C for 1 hr. This step aided in obtaining quality sections for 
histopathology. Glands from animals not included in our study (small litters or gestation timing 
off the group average by more than 12 hr.) were sectioned at 4 µm (superior quality vs. a thicker 
section (6 µm); Figure AI-1) using a low profile blade (Sakura, Finetek, Inc. USA, Torrance, 
CA). All slides were incubated overnight at 37°C prior to an automated staining with H&E, as 
described above for the contralateral gland. Tissue de-staining was unnecessary, since very little 
of the whole mount carmine alum staining remained in the tissue sections.  
Scanning 
 High quality archival whole mount images were recorded to preserve intact structures for 
future assessments. Images were prepared by scanning the whole mount mammary gland glass 
slide on a flatbed scanner (Epson Perfection V750 Pro, Epson America, Long Beach, CA).  
 Digital images of H&E-stained slides were captured on the Aperio AT2™ slide scanner 
(Leica) using Imagescope™ software (v.12.1, Leica). White balance correction and image 
resizing were completed using Adobe Photoshop™ (Adobe Photoshop Creative Cloud 2014.0.0).   
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RESULTS 
 It is important to note that the intact mammary gland whole mount, displaced with xylene 
from the glass slide, is not optimized for sectioning in the traditional histologic sense. In the 
current situation, the whole mount was permeated with a heavy layer of mounting media, such as 
Permount (Sigma Aldrich), so that a coverslip may be placed over the thick mammary pad 
without the introduction of air bubbles. In developing this protocol, the whole mount paraffin 
blocks from animals not included in our study were originally sectioned at 6 µm. The sections 
appeared thick, piling up of cells was evident, and specific cellular detail was insufficient (Figure 
AI-1A). Tissue blocks sectioned at 4 µm yielded superior results with cellular features and 
stromal area infiltrates more easily discernable (Figure AI-1B). 
 This modification in tissue block sectioning is being used for a large on-going study.  The 
histopathology findings of the H&E-stained longitudinal sections from the contralateral gland of 
14 month old female CD-1 mice in our study were inconsistent with whole mounts collected 
from those same animals, and were found to contain mammary lesions. Two tissue samples with 
conflicting diagnoses were chosen to illustrate the effectiveness of this method; however, 
multiple abnormalities were identified and will be described elsewhere in detail.  Histopathologic 
evaluation of the original contralateral H&E-stained tissue section revealed a normal gland with 
no histologic findings. Normal mammary gland architecture consisted of ducts lined by a single 
layer of simple cuboidal epithelial cells and supported by a layer of myoepithelial cells. Ductal 
lumens were evident and the adipocytes were uniform throughout the sections (Two examples; 
Figure AI-2A and AI-3A). In contrast, gross visualization of the contralateral whole mount 
revealed abnormal gland architecture (Figures AI-2B and AI-3B; boxed area) characterized by 
increased opacity around ducts and stromal structures of the mammary gland. It was not possible 
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to determine whether these areas of opacity represented inflammatory, hyperplastic, or neoplastic 
changes without an examination of a representative H&E-stained section of the gland. 
 Results from examination of the sectioned, H&E-stained whole mounts are shown in 
Figures AI-2C, AI-2D, AI-3C, and AI-3D. Samples from one 14 mo old animal (Figure AI-2C 
and AI-2D) contained lesions diagnosed as perivascular inflammation; characterized by an 
increased number of perivascular lymphocytes that extended into the adjacent adipose tissue. A 
portion of the whole mount of a second virgin 14 mo old animal (Figure AI-3B) was 
morphologically similar to the appearance of the mammary gland during pregnancy (mid-
gestation) or to the mammary gland of male rats (Filgo et al., submitted), characterized by 
extensive lobular budding. A full evaluation of H&E-stained sections from the whole mount 
(Figure AI-3C and AI-3D) revealed lobular alveolar hyperplasia characterized by focal to 
multifocal enlarged lobules comprised of increased numbers of relatively normal alveolar 
epithelial cells. Alveolar epithelial cells were well differentiated, round, often vacuolated and 
formed a single concentric layer around ducts that typically contained proteinaceous fluid. Ducts 
were lined by a single layer of well-differentiated columnar epithelial cells. Alveoli and ducts 
were normally distributed and there was no evidence of adipocyte compression or cellular atypia.  
 
DISCUSSION 
 Histopathological evaluation plays an essential role in identifying abnormalities in the 
mammary gland that are not grossly obvious. This is especially important when evaluating low-
dose exposure to EDCs and chemical mixtures that approximate human exposure levels. Whole 
mammary gland mounts depict the intact morphological landscape and allows an accurate 
assessment of where and how many abnormalities are occurring. Use of both whole mount and 
264 
 
H&E-stained section evaluation is ideal, but not always practical; however, sole reliance on one 
method can potentially result in missing significant findings. This is especially true when a 
single H&E-stained mammary gland section is used for histopathological evaluation. 
 This sectioning method highlights the dual utility and benefits of the mammary gland 
whole mount.  In the two examples discussed, inflammation and lobular hyperplasia were 
identified in the H&E-stained representative whole gland mount section, but not in the H&E-
stained representative from the contralateral mammary gland.  This technique is applicable and 
effective at identifying and quantifying a range of abnormalities, especially in mammary glands 
of chemically treated or genetically modified rodents.  The regular evaluation of mammary tissue 
from mice and rats during various life stages of development (i.e. wean, puberty and early 
pregnancy) is highly recommended, due to its small tissue size and relatively low epithelial 
density. We anticipate that this method will 1) serve as a standardized protocol to reduce inter-
lab variability, 2) increase awareness within the scientific community of  the ease with which the 
mammary gland can be incorporated into studies at minimal added cost [3], and 3) stimulate 
collection of the mammary gland into chemical test guideline studies, which may or may not 
include evaluations (OECD TG443 and NTP) [4, 5], fail to focus on specific mammary gland 
developmental endpoints [6]or are not collected at all (OPPTS 890.1450, US EPA 2009 and 
OPPTS 890.1500 2009b) [7, 8].  
 Although it is probable that other histochemical and immunohistochemical staining may 
be applied to sections derived from whole mounts, it was beyond the scope of this work and 
further testing would be necessary to make these determinations. Furthermore, it may be possible 
to prepare smaller sections of abnormal tissue (i.e., punch-biopsy samples) in the same fashion as 
the whole gland; however, those technical variables were not tested and would require further 
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efforts. It is hoped that evaluation of the entire mammary gland using a combination of whole 
mounts and their representative H&E-stained sections will minimize the possibility of false 
negatives in a rodent study, and lead to increased awareness of environmental factors that 
adversely modify mammary development or function.  
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Table AI-1: Mammary Whole Mount Tissue Processing Schedule 
  
Process Temperature (◦C) Time (min) 
Xylene  37◦ 30 
1:1 xylene: molten paraffin 60◦ 30 
Molten paraffin 60◦ 60 
Molten paraffin 60◦ 120 
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Figure AI-1: Determining an optimal thickness to prepare mammary gland sections. Mammary 
gland sections of (A) 6 µm and (B) 4 µm thickness. Due to the increased clarity and cellular 
distinction in (B), the 4 µm thickness is preferred. Magnification 40x.  Mammary tissues were 
obtained from animals otherwise destined for euthanization. 
 
  
 
         
Figure AI-2: Mammary gland section of perivascular inflammation using the whole mount method.  Normal mammary gland section 
with no histopathologic findings, formalin-fixed H&E-stained, magnification 10x (A); Increased opacity around ducts and stromal 
structures (box) in the contralateral carmine-stained mammary whole mount (B); At low magnification, in the contralateral mammary 
gland H&E prepared from the whole mount (boxed area shown), there are clusters of mononuclear cells around the blood vessel and 
extending into the adjacent adipose tissue magnification 20x (C); Higher magnification illustrated that the inflammation is composed 
of perivascular lymphocytes; magnification 40x (D). Tissue samples are from a 14 mo. old female CD-1 mouse.  
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Figure AI-3: Mammary gland section of lobular hyperplasia using the whole mount method. Normal mammary gland section with no   
histopathologic findings, formalin fixed an H&E-stained, magnification 10x (A); Increased opacity around ducts and stromal 
structures (box) in the contralateral carmine-stained mammary whole mount. (B); At low magnification, in the contralateral mammary 
gland prepared from the whole mount (boxed area), there is enlargement of the lobule due to an increase in the number and size of 
cells (lobular alveolar hyperplasia); magnification 10x (C); Higher magnification illustrated enlarged lobules consisting of increased 
numbers of normal alveolar epithelial cells which were well differentiated and often vacuolated. Alveolar lumens often contained 
proteinaceous fluid; magnification 40x (D). Tissue samples are from a second individual 14 mo. old female CD-1 mouse.
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APPENDIX II 
The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal 
perfluorooctanoic acid (PFOA) exposure1 
 
OVERVIEW 
 Perfluorooctanoic acid (PFOA) is a known developmental toxicant in mice, with varied 
strain outcomes depending on dose and period of exposure. The impact of PFOA on female 
mouse pubertal development at low doses (≤1 mg/kg), however, has yet to be determined. 
Therefore, female offspring from CD-1 and C57Bl/6 dams exposed to PFOA, creating serum 
concentrations similar to humans, were examined for pubertal onset, including mammary gland 
development. Mouse pups demonstrated a shorter PFOA elimination half-life than that reported 
for adult mice. Prenatal exposure to PFOA caused significant mammary developmental delays in 
exposed female offspring in both strains. Delays started during puberty and persisted into young 
adulthood; severity was dose-dependent. In contrast, an evaluation of serum hormone levels and 
pubertal timing onset in the same offspring revealed no effects of PFOA compared to controls in 
either strain. Therefore, our data suggest that the mammary gland is more sensitive to the effects 
of early low level PFOA exposures compared to other pubertal endpoints, regardless of strain.  
INTRODUCTION 
 Perfluorooctanoic acid (PFOA) is an eight carbon member of the perfluoroalkyl acid 
family. Its use as a surfactant in various industrial and consumer products, as well as its ability to 
resist further degradation under extreme temperatures, has made it both persistent and ubiquitous 
within the environment resulting in the inevitable exposure to both humans and wildlife.  
                                                          
1This chapter was previously published in Reproductive Toxicology. Tucker, D.K., Macon, M.B., Strynar, J.M., 
Dagnino, S., Anderson, E. and Fenton, S.E. (2015). The mammary gland is a sensitive pubertal target in CD-1 and 
C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure. Reproductive Toxicology 54, 26-36. 
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 Serum PFOA levels in the general U.S. population have declined from 5.21 ng/mL 
(1999-2000) to 3.07 ng/mL over a decade (2009-2010) [1], potentially due to consumer 
awareness and a gradual phase out of PFOA production in the U.S. However, residents living in 
areas of elevated PFOA exposure (sites near manufacturing facilities) have serum levels 10-100 
times higher than the national average, and children aged 2-5 years demonstrated a geometric 
mean serum concentration of 600 ng/ml (as of 2006) [2]. Pubertal aged children from this area 
also experienced higher total geometric mean serum levels (<12 years, 77.6 ng/ml and 12-19 
years, 59.9 ng/ml) [3]. Exposure at these ages is mostly related to drinking water sources but 
may also be contributed to by the ingestion of contaminated dust, food sources and hand to 
mouth contact. PFOA exposure may also occur during gestation or shortly after birth, as PFOA 
was detected in human and rodent milk, rodent serum, urine, amniotic fluid and at relatively low 
levels in human cord blood [4-6]. These findings suggest that PFOA is not only capable of being 
transferred from mother to offspring due to its long half-life (3.8-4.4 years in humans [7]), but 
that the longer the exposure, the higher the potential is for increased serum PFOA levels in 
offspring. Parental exposures prior to conception may compromise embryonic development and 
continued placental and lactational [8] exposures may have deleterious effects on the developing 
fetus, newborn and infant. Early life exposures to PFOA may induce alterations in the 
epigenome, such as altered DNA methylation [9, 10], that have the potential to alter normal 
development and lead to adverse health outcomes in later life. 
 
 High dose exposures in adult rodents (≥10 mg/kg PFOA) have resulted in hepatotoxicity, 
tumors of the liver and pancreas and in pregnant adult mice, neonatal toxicity and mortality of 
their offspring [11-13]. Lower perinatal doses, however, have resulted in an array of reproductive 
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and developmental alterations in mouse offspring that have included advanced preputial 
separation in males, sex specific neurobehavioral differences [14] and impaired mammary gland 
development [15]. The mammary gland is a unique organ in that the majority of its development 
occurs postnatally. Although differentiation is not complete until late pregnancy, puberty 
demarks an exponential growth phase that is facilitated by various paracrine and endocrine 
factors including estrogen and progesterone and includes an increased mammary stem cell 
population [16-18]. Additionally, the highly proliferative terminal end buds (TEBs) lead the 
migration of the mammary epithelium into the fat pad resulting in the extensive ductal branching 
patterns of the gland. Exposures to endocrine disrupting chemicals (EDCs) during gestation or 
early life are especially of concern because they may affect the normal progression of mammary 
development that may not become apparent until puberty or later life. EDCs can disrupt normal 
functions by mimicking naturally occurring hormones, inhibiting hormone receptor binding or 
causing an abnormal inhibitory or stimulatory endocrine response [19]. High dose PFOA 
exposure has demonstrated these properties in the mammary gland by stimulating growth in the 
glands of peripubertal exposed C57Bl/6 female mice [20]. These effects were only apparent 
when the ovaries were present and also resulted in the upregulation of estrogen receptor alpha 
(ERα) expression within the gland. However, the mechanism for prenatal PFOA exposure on 
mammary gland development has yet to be determined, but it is evident that early exposures set 
in motion key alterations that may be exacerbated by circulating endogenous hormones. This 
could potentially further target the proliferating TEBs resulting in the increased potential for 
cellular transformations that may make the gland more susceptible to developing later life 
diseases, such as breast cancer [21, 22]. 
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 Full and late gestational exposure to low dose PFOA has been shown to induce stunted 
mammary epithelial growth in CD-1 female offspring, an abnormality that persisted into 
adulthood, which can begin as early as postnatal day (PND) 56 in some mouse strains. Macon  et 
al.  [15] reported adverse changes in female CD-1 mouse mammary gland development from 
0.01 to 1 mg/kg PFOA following a late gestation exposure, which is defined as a one-time daily 
oral gavage exposure between gestational days 10-17. Multigenerational effects have also been 
observed in CD-1 mice administered separate and combined oral gavage and drinking water 
exposure to 5 mg/L PFOA. All PFOA treated F1 females demonstrated reduced mammary 
development that continued until 63 days of age (young adulthood) [23]. Mammary development 
was also attenuated at weaning in F2 females that were never exposed to PFOA via placental 
transfer. Much higher oral exposures appear to be required for mammary effects in other strains, 
using peripubertal exposures. Yang  et al.  [24] reported striking differences among C57Bl/6 and 
Balb/c mice peripubertally exposed to ≥ 5 mg/kg PFOA. Peripubertal PFOA exposure 
significantly inhibited mammary growth at 5 and 10 mg/kg in Balb/c animals, whereas in 
C57Bl/6 mice stimulatory effects were reported at 5 mg/kg, but inhibitory effects predominated 
at 10 mg/kg. Mammary gland development was not altered in either strain following peripubertal 
exposures at 1.0 mg/kg suggesting that some mouse strains are more sensitive than others to 
PFOA effects and/or the effects in the mammary gland are highly dependent upon the timing of 
exposure (peripubertal vs. in utero).  
 PFOA has also been associated with changes in other pubertal developmental landmarks. 
Girls living in close proximity to PFOA-polluted areas have self-reported delays in menarche 
that were associated with increased serum PFOA levels [25]. Rodent models have also been 
assessed for similar hallmarks that include timing of first estrus, vaginal opening (VO) and 
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estrous cyclity, as the onset of cyclity occurs after VO and first estrus; VO and first estrus in 
prenatally exposed pups were slightly delayed at dose levels outside those that humans would be 
exposed to (20 mg/kg) and unchanged at the lowest dose tested (1.0 mg/kg) [13]. EDCs have 
been reported to elicit non-monotonic responses, wherein lower doses may produce changes not 
observed at higher doses [26]. To date, no study has examined the low-dose effects of PFOA on 
all pubertal events in prenatally exposed female mice nor determined how the mouse strain may 
influence any potential effects. Our goal was to provide a thorough evaluation of the low dose 
effects of PFOA exposure on the timing of critical pubertal events in the CD-1 and C57Bl/6 
female mouse including mammary gland development, VO and first estrus, in addition to the 
evaluation of serum steroid hormone and PFOA levels. These assessments may provide valuable 
information as to the most sensitive pubertal targets influenced by prenatal PFOA exposure, as 
well as indicate pathways that may be perturbed by other related toxicants during pubertal onset.  
 
MATERIALS AND METHODS 
PFOA 
Perfluorooctanoic acid (PFOA, ammonium salt; >98% pure) was obtained from Fluka Chemical 
(Steinheim, Switzerland) and 1, 2-13C2-perfluoroctanoic acid (13C2-PFOA) was purchased from 
PerkinElmer Life and Analytical Sciences (Boston, MA). PFOA dosing solutions were dissolved 
in de-ionized water (DI water) and freshly prepared daily.  
 
Animals  
 Timed pregnant CD-1 and C57Bl/6 mice were obtained from Charles River Laboratories 
(Raleigh, NC) on gestational day 0 (GD 0) when they were confirmed sperm positive. Upon 
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arrival, each dam was weighed and randomly assigned to one of five treatment groups, 
equalizing the mean starting body weight in each group. Pregnant dams were individually housed 
in polypropylene cages with microbarrier lids and received chow (LabDiet 5001, PMI Nutrition 
International LLC, Brentwood, MO) and tap water ad libitum. Animal facilities were maintained 
on 12:12h light-dark cycle, at a controlled temperature (20-24 oC), with 40-60% relative 
humidity. All animals were treated humanely and in accordance with the National Institute of 
Environmental Health Sciences Animal Care and Use Committee (ACUC).  
 
 Experimental Design 
 For space reasons, the studies in CD-1 mice were completed in three blocks (block 1 
n=97, block 2 n= 40, and block 3 n=26). Studies with the C57Bl/6 animals were completed in 
one block (n=41). For each experimental block, timed pregnant dams were orally gavaged daily 
with vehicle (DI water), 0.01, 0.1, 0.3 or 1.0 mg PFOA/kg/body weight (bw) between GD 1-17. 
A full gestation exposure design was chosen to recapitulate murine serum levels that have been 
established in previous experiments and were found to overlap with PFOA serum levels in 
residents living in heavily contaminated areas in the U.S. Dams were weighed daily to administer 
a dose volume of 10 µl/g bw. Parturition normally occurred on the eve of GD 18 and PND 1 was 
defined as the first day following parturition (usually > 0.5 days old). On PND 3, pup sex was 
determined and CD-1 litters were equalized to 10 pups per dam. If numbers permitted, each dam 
received 6-7 females and 3-4 males. Pregnancy rates in CD-1 females were >60% (block 1 =78% 
block 2 =67% and block 3 = 88%); however, the C57Bl/6 block yielded a much lower rate of 
approximately 27% (41/152). Regardless of treatment, C57Bl/6 dams produced litter sizes of 
between 5-8 pups. Any litters with an n<5 pups were excluded from these studies. On PND 21, 
277 
 
pups of both strains were weaned and all female pups were retained and housed 3-5 mice per 
cage in an effort to keep litter mates together. Male weanlings from controls were retained in 
order to circulate pheromones into the room that are known to assist in normalizing female 
cycling [27, 28]. Additionally, every 3-4 days (at cage changes) a small sample of bedding from 
the males was placed into each female cage.  
 
Necropsy 
 With the exception of PND 21 (sexually immature), vaginal lavage was performed on all 
females prior to necropsy to determine their stage of the estrous cycle. We attempted to necropsy 
females during the first day of estrus in order to minimize morphological and hormonal 
fluctuations caused by normal changes in the estrous cycle. Vaginal smears were acquired 
between 6 and 8 AM on the day of sacrifice and necropsied shortly thereafter (9 AM-12 PM) 
[29]. On PND 21, 35, and 56 for CD-1 mice (n=4-7 litters/treatment), and PND 21(n=2-6 
litters/treatment) and 61 (n= 3-9litters/treatment) for C57Bl/6 mice (fewer time points due to this 
strain historically having fewer pups per live birth and low pregnancy rates following plug 
identification) female pups were first weighed and then sacrificed using swift decapitation to 
obtain trunk blood for PFOA and hormone analysis. Mammary glands were collected from the 
fourth and fifth inguinal glands and prepared as carmine stained whole mounts. Body and liver 
weights were also recorded.  
 
Pubertal Endpoints 
 Pubertal maturation in females was assessed using VO and vaginal cytology to determine 
timing to first estrus in the estrous cycle. Visual assessment for VO started on PND 18 in CD-1 
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mice and on PND 23 in C57Bl/6 mice, as VO has been reported to begin as late as PND 30 in 
that strain [30]. Once VO occurred, daily vaginal lavage was performed using 1X phosphate 
buffered saline and a sterile eyedropper to obtain cells to determine the presence of cornified 
epithelial cells, the first indication of estrus [13, 31]. All samples were evaluated fresh daily on a 
Leica DM2000 light-microscope (Leica Microsystems). Body weights were taken daily and 
recorded on the day of VO and first estrus. Pubertal endpoints were only measured in CD-1 
block 1 (n= 7-8/treatment) and 2 (n=4-5/treatment) litters. Three to seven C57Bl/6 pups were 
evaluated per litter.  
 
Mammary Whole Mount Preparation and Analysis 
 The entire fourth and fifth mammary gland from each mouse was placed on a charged 
slide and flattened to the natural surface area. Each whole mount was fixed in Carnoy’s solution 
(EtOH, acetic acid and chloroform), stained in carmine alum and de-fatted in xylene [32]. For 
each collection, all samples were compared to age-matched animals within the same group and 
across other treatment groups [32]. Each gland was assessed and assigned a qualitative score on a 
scale of 1-4 (1=poor development and 4=best development) using a Leica Z16APO and DFC295 
light microscope and camera (Leica Microsystems Inc., Buffalo Grove, IL), respectively. 
Qualitative scoring criteria is based on, but not limited to, lateral and longitudinal epithelial 
growth, branching density, changes in epithelial growth, appearance of budding from ductal tree, 
number of differentiating duct ends and the presence or absence of terminal end buds. Each 
gland was scored by two individuals without knowledge of treatment and averaged to obtain a 
final score [15]. Approximately, 4-7 CD-1 females/treatment/block and 2-10 C57Bl/6 
offspring/treatment were scored. 
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PFOA Serum 
 Serum concentrations of PFOA were obtained using the methods reported by Reiner  et 
al. [33]. Briefly, 25-50 µL of serum from each individual was transferred to its own 15 ml 
propylene tube. A pre-determined amount of internal standard (13C2-PFOA) was added to 
approximate the midpoint of the calibration curve for the anticipated sample range. 0.1 M Formic 
acid was added to the sample to denature the proteins and it was vortexed. Cold acetonitrile (-
20C) was added to precipitate the proteins followed by vortexing and centrifugation at 2000 x g 
for 3 min. Supernatant from the acetonitrile mixture were placed in liquid chromatography vials 
containing ammonium acetate buffer (pH 6.5) (1:1). All samples were analyzed using a Waters 
Acquity Ultra Performance Liquid Chromatograph interfaced with a Waters Quattro Premier XE 
triple quadropole mass spectrometer (Waters Corporation, Milford, MA). Blank matrices were 
obtained using Pel-Freeze Biologicals CD-1 control mouse serum (Rogers, AR). At least six 
standards were used to generate the calibration curve with the coefficients of determination at 
0.99 or higher. Calibration curves were obtained by plotting the ratio of PFOA peak area to 13C2-
PFOA peak area vs. concentration and were fitted to a linear regression equation with 1/x 
weighting. The limit of quantitation (LOQ) was defined as the lowest point on the standard curve 
at which analysis may be reported with confidence. Quality control (QC) samples were 
interspersed throughout the analytical run and were run in duplicates for accuracy determination. 
Method accuracy and precision were determined by analyzing the QC samples repeatedly. 
Accuracy was calculated as the percentage of the concentration found compared with the 
theoretical concentration and the precision was calculated using the average relative standard 
deviation of the replicate analysis of the QC materials. Additionally, approximately 10% of all 
unknown samples were analyzed in duplicate for precision measurements. Each sample batch 
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run contained a calibration standard and a matrix and methanol blank that were prepared under 
the same conditions as the unknown samples. The LOQ for CD-1 serum samples ranged from 5-
100 ng/ml (Control=5 ng/ml, 0.01mg/kg=10 ng/ml, 0.1, 0.3 and 1.0 mg/kg=100 ng/ml). The 
LOQ for C57Bl/6 animals was 10 ng/ml. Samples that were below the LOQ were reported as the 
LOQ /√2 for statistical purposes. Serum PFOA was measured from at least one pup from each 
litter per treatment group in the CD-1 (n=5-10) and C57Bl/6 (n= 2-6) studies.  
 
Serum Estradiol and Progesterone Analysis 
 Serum estradiol and progesterone levels were measured using a commercially available 
assay kit (Meso Scale Discovery, Gaithersburg, MD). Coefficients of variation ≤ 20% were 
considered acceptable. Assays were performed in a multiplex format in 96-well, 4 spot plates 
that were pre-coated with estradiol and progesterone capture antibodies and 50 µl serum 
samples. Sandwich immunoassays were conducted by adding test serum followed by conjugated 
detection antibodies (anti-estradiol and anti-progesterone) containing an 
electrochemiluminescent compound. Electrochemiluminescence was detected using a SECTOR 
Imager 2400. Quantitation of estradiol or progesterone was based on the intensity of the emitted 
light. A rat serum sample of known concentration was also tested for QC purposes. Data from 
the Sector Imager was transferred to Excel worksheets for further analysis. The limit of detection 
(LOD) for estradiol was 5 pg/ml and 0.07 ng/ml for progesterone. 
 All unknown serum samples were analyzed in duplicate and standard curves for estradiol 
and progesterone were generated using calibrators supplied with the kit. Estradiol concentrations 
between 0 and 4 ng/ml and progesterone concentrations between 0 and 50 ng/ml were fitted to a 
sigmoid dose response curve and used to quantify the level of each hormone in test samples. 
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Serum samples from each treatment group were stratified across plates so that not all of one dose 
group was assayed on the same plate.  
 
Statistical Analysis 
 For all studies, dams or litters were considered the unit of measurement. Therefore, if a 
dam was represented by more than one pup, their values were averaged. Outlier values were 
determined by bodyweight and were calculated using GraphPad’s QuickCalc Grubb’s test 
(http://graphpad.com/quickcalcs/grubbs1/). Outliers were only removed when the animal 
presented as being moribund. When an individual animal was found to be an outlier within a 
specific end point, the data for that individual was removed from all data sets that it was 
contained in. Replicated experiments were treated as blocks and were analyzed using two-way 
analysis of variance (ANOVA) to determine block and treatment effects using Tukey’s post hoc 
test (p<0.05). A linear regression test was performed on the mammary glands to determine if any 
dose related effects existed. Serum PFOA, estradiol and progesterone levels were assessed using 
ANOVA followed by a Dunnett’s post hoc test. Graphs and tables were created using GraphPad 
Prism 6 (La Jolla, CA) and Microsoft Excel. All data are represented as the mean ± SEM. 
 
RESULTS 
 Internal PFOA burdens and liver enlargement. Serum PFOA concentrations in exposed 
female offspring were measured to determine the internal concentrations at which pubertal 
effects were being observed. PFOA levels were detectable in all exposed female offspring from 
both strains at PND 21 (Table AII-1). PFOA was undetectable in control mice of both strains. 
Serum PFOA concentrations increased in a dose dependent manner and were significantly 
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different at the two highest doses in the CD-1 females at PND 21 and 35 compared with control 
females. Detectable levels were measured in all treated animals at PND 35, however, by PND 56 
all animals experienced a 4-5 fold decrease in serum levels compared to littermates collected at 
PND 35, a decrease that was larger than expected, given the reported 15.6-21.7 d half-life of 
PFOA in adult CD-1 mice [34] following a single oral adulthood exposure [34]. By PND 56, 
serum PFOA levels were below LOQ in the 0.01mg/kg group and only statistically increased 
from control levels at 1.0 mg/kg. The same dose dependent trend observed at PND 21 in CD-1 
mice was also shown in the C57Bl/6 pups; however, differences were not significant, more than 
likely reflecting the fair amount of variability between mice in a small litter size, rather than 
treatment. Additionally, treatment with the same PFOA exposures in C57Bl/6 mice resulted in 
serum levels that were lower on average compared to those observed in the CD-1 strain of the 
same age. By PND 61 the C57Bl/6 animals in the three highest dose groups had measurable 
levels that were still above the LOQ threshold, however, these levels were ~10-100 fold reduced 
from those observed in their PND 21 litter mates. Taken together, these data suggest a faster rate 
of clearance of PFOA from the C57Bl/6 offspring and potentially a faster clearance in rapidly 
growing offspring than the 15.6-21.7 d half-life previously reported in adult CD-1 mice [34]. 
Based on our 1.0 mg PFOA/kg data and serum data collected previously [15], we estimated half-
life clearance in the CD-1 animals between PND 21 to PND 56 to be 7.3-8.9 days and C57Bl/6 
to be 6.0 days between PND 21 and PND 61. 
 
 Full gestation PFOA exposure (0.01 to 1 mg/kg) did not affect absolute body weight 
measurements in either CD-1 or C57Bl/6 female offspring (Tables AII- 2 and AII-3, 
respectively). Net body weight was defined as the liver weight subtracted from the body weight 
and was found to be significantly reduced in the highest dose group in CD-1 females (1.0 mg/kg) 
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at PND 21 and 35. This effect had little biological significance, as it resolved and net body 
weights were comparable to the control levels by PND 56. These finding are in agreement with 
the body weights observed at post weaning ages following a full gestation exposure to PFOA 
levels ≤ 1.0 mg/kg [13, 15]. No significant effects for net body weight were observed in the 
C57Bl/6 females. 
 Absolute liver weight differences in both strains were not significantly altered in 
comparison to their respective controls (Tables AII-2 and AII-3). CD-1 females in the 1.0 mg/kg 
dose group exhibited significantly elevated relative liver weights at PND 21 that recovered to 
normal levels by PND 35. As relative liver weights had returned to values similar to controls by 
PND 28 following a full gestational exposure in a previous study, our transient finding is thought 
to be biologically irrelevant [15]. C57Bl/6 mice did not demonstrate any significant relative liver 
weight changes at PND 21 or PND 61. Together these data confirm that liver effects resulting 
from early and low exposures are transient and may begin to dissipate during early puberty. This 
appears to correlate well with the higher internal body burdens in CD-1 mice that showed 
increased liver hypertrophy (relative liver weight) in 1 mg PFOA/kg bw weanlings compared to 
no effects seen in C57Bl/6 pups (Tables AII-2 and AII-3). 
 
 Pubertal Assessment. Pubertal onset in the female mouse is associated with an increased 
production of the steroid hormones estradiol and progesterone as a result of increased signaling 
from the hypothalamus and pituitary gland to the ovaries. Both hormones are critical for 
ovulation and uterine changes, as well as normal mammary gland development and sexual 
maturation [35, 36]. To understand the effects of prenatal PFOA on circulating steroids, serum 
was obtained from females in the stage of estrus, except at PND 21 where all hormone analysis 
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samples were from females that had not undergone VO. Figure AII-1A illustrates that estradiol 
levels in both strains were similar between PFOA treated and control mice. A similar lack of 
statistical difference for treatment effect was shown for progesterone (Figure AII-1B), however; 
progesterone levels were overall elevated in CD-1 animals at PND 56, in all exposure groups, 
compared to levels seen at PND 21 and 35. Progesterone levels in PFOA-exposed C57Bl/6 
females were comparable to control at both PND 21 and 61. 
 An assessment of the effects of PFOA on VO and first estrus are summarized in Table 
AII-4. Females from only two of the three CD-1 blocks were measured. Although all 
assessments were completed in an identical manner, it was necessary to assess each block 
separately due to block effect differences. VO occurred ~4 days later in block 2 compared to 
block 1, however, comparisons between the control and treatment groups within each block 
revealed no significant differences due to treatment. The reason for the block difference could 
not be determined. Timing to first estrus was also unchanged within each block. However, block 
1 females appeared to undergo their average first estrus 2-3 days following VO whereas it almost 
immediately followed VO in block 2 females, with the exception of the 1.0 mg/kg group (~2.5 
days timing to first estrus). Neither body weight at VO nor first estrus timing was changed by 
PFOA treatment in either block. The age of VO, day of first estrus and body weights at these 
times was also unchanged in the C57Bl/6 animals. The fact that no treatment related effects were 
observed in either strain implies that the differences in the normal timing of these events in each 
strain are likely a result of strain differences rather than PFOA exposure. 
 The effects of PFOA on mammary gland development were assessed by whole mount 
using factors that include lateral and longitudinal branching, the presence or absence of terminal 
end buds and branching density. However, these criteria were dependent upon the age of 
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development. Both CD-1 and C57Bl/6 strains exhibited developmental delays that were apparent 
at the lowest dose (0.01 mg/kg) and were significantly different from controls in CD-1 mice. As 
early as PND 21 we observed a dose dependent decrease in developmental scores in the CD-1 
animals with the highest dose group scoring ~1.2 points lower than control (Table AII-5). Score 
reductions were significant at PND 21 in the three highest dose groups (0.1-1.0 mg/kg); 
however, by PND 35 and 56 growth delays were obvious in all CD-1 treatment groups resulting 
in significantly lower scores. When a trend analysis was performed on the CD-1 glands the 
mammary scores were found to be inversely related to the dose (p<0.001), indicating that with 
increased dose the greater the developmental delays observed. Representative morphological 
evaluations of the CD-1 glands are illustrated in Figure AII-2. TEBs, lateral and longitudinal 
branching and secondary branching were all decreased with increased PFOA dose, resulting in a 
much smaller gland (Figure AII-2). By PND 35, in addition to the growth defects already 
described, PFOA caused a delay in the fourth and fifth glands growing together. Although, our 
evaluation of pubertal timing in both strains has established that C57Bl/6 animals reach sexual 
maturation at a later point than CD-1 mice, mammary glands were still evaluated on PND 21 to 
remain consistent throughout each block. We did note that control scores from both strains were 
very similar; it should be noted that scoring is based on the level of development compared to 
controls and may be based on entirely different criteria that can still result in similar scores 
across strains.  
 In the C57Bl/6 strain, only the 0.3 and 1.0 mg/kg developmental scores were significantly 
reduced from that of controls (Table AII-5), however a trend analysis also confirmed very 
similar trend as those seen in the CD-1 animals in which at higher doses greater delays were 
seen. The presence of TEBs was minimal at PND 21, considering that estradiol levels in both 
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strains at this time point were within the same range. However, significant defects in branching 
density due to PFOA exposure were visible in the 0.3 and 1.0 mg/kg PFOA groups at both PND 
21 and 61 (Table AII-5) . C57Bl/6 PFOA treated animals exhibited, at most, minimal budding 
and secondary branching with little to no lateral and longitudinal branching (Figure AII-3). At 
PND 61, the C57Bl/6 glands at the highest dose still had TEBs and internal budding throughout 
the fat pad; whereas at the same time point control glands were almost fully matured. This 
demonstrates that there are significant differences in the natural rate of mammary gland 
development in two different strains. Also, the impact of PFOA treatment on C57Bl/6 females 
was not as severe as that seen in CD-1 females and is likely due to differences in body burden, as 
serum PFOA levels were lower in C57Bl/6 than CD-1 across dose groups at the same ages. 
Regardless of those strain differences, the effects of PFOA on mammary gland development 
persisted in both strains through early adulthood. 
 
DISCUSSION 
 The objective of these studies was to determine the pubertal development effects of early 
life PFOA exposures, which produce serum concentrations in the CD-1 and C57Bl/6 female 
mouse that coincide with reported human blood PFOA concentrations in contaminated area, 
specifically evaluating for dose and strain-related effects. Perinatal low dose exposures to PFOA 
resulted in greater alterations in the pubertal mammary gland for both strains compared to all 
other measured pubertal endpoints. Mammary gland developmental delays were visible as early 
as PND 21 in both strains and were significantly different from controls at concentrations as low 
as 0.01 mg/kg in the CD-1 mouse. Our study suggests that at these low doses the strain 
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differences, in response to PFOA, are dose dependent. Given identical oral doses during the 
exact same window of exposure, both strains experienced delayed mammary development at 0.3 
and 1.0 mg/kg PFOA and lacked changes in the timing of other pubertal events. The CD-1 
mouse responded to lower doses of PFOA, demonstrating effects on mammary development at 
0.01 and 0.1 mg/kg, along with the higher doses. This is likely a reflection of the higher and 
longer circulating PFOA levels within the blood of the CD-1 mice. Although an increase in 
relative liver weight was evident in CD-1 mice and not the C57Bl/6 at 1.0 mg/kg PFOA 
exposure, we are unclear whether this observation was biologically relevant without having 
measurements from earlier time-points. From these data, we suggest that it is the peak serum 
PFOA concentration that regulates these effects (may have occurred between birth and within the 
first two weeks of life), rather than the serum PFOA level at the time of evaluation. This is 
further supported by earlier findings from Macon  et al.  [15] in which serum collected from a 
full gestation 1.0 mg/kg PFOA revealed that peak concentrations occurred at PND 14, rather than 
PND 7. To date, serum levels between PND 0 and PND 6 have yet to be reported for a full 
gestation study. In one study, where PFOA was administered once during late gestation (GD 17), 
pup serum concentrations peaked at PND 1 for all concentrations [5]. Therefore, the observed 
effects are likely a result of the in utero exposure, followed by exacerbation of effect from the 
exposure during lactation. 
In these studies, PFOA induced abnormal mammary gland development in both strains. This 
suggests that either the other pubertal end points measured have a much different dose response 
threshold or that the hypothalamic ovarian axes that govern the various processes differ in their 
response to PFOA. Full gestation (GD1-17) PFOA exposure studies have previously reported 
delayed mammary development at concentrations ≤ 3.0 mg/kg in the CD-1 mouse [15]. Our 
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current findings fully support and extend those previous observations with reduced 
developmental scores at the lowest dose of 0.3 mg/kg, and with an n that is 3-4 times that in the 
previous experiments. Previous changes were evident beginning on PND 7 and persisted until the 
last collection on PND 84. We confirm here the persistent mammary effects at lower doses and 
also determined through trend analysis that the severity of the effects increased with higher does 
in both strains (p <0.001). Macon and colleagues [15] also observed reduced mammary gland 
scores at PND 21 following a late gestation exposure (GD10-17) to PFOA in all concentrations 
including the 0.01 mg/kg dose. While they noted reduced mammary developmental scores 
following PFOA exposure, longitudinal growth measurements were only changed in the 1.0 
mg/kg group and the number of TEBs were significantly reduced in the 0.1 and 1.0 mg/kg 
groups. All other quantitative measurements, however, were similar to age matched controls. 
Studies comparing the effects of peri-pubertal PFOA exposure in C57Bl/6 and Balb/c have also 
shown differences by strain in mammary gland development [24, 37]. Although they found no 
significant effects at 1.0 mg/kg in either strain compared to control for ductal length, number of 
TEBs or stimulated terminal ducts, C57Bl/6 animals had an increased number of TEBs compared 
to the Balb/c at PND 56. Many of the glands from our C57Bl/6 highest dose group (1.0 mg/kg) 
also exhibited poor branching and differentiation; TEBs were very apparent at PND 61, in 
addition to the substantial number of long ducts with little to no branching. Zhao  et al.  [37] also 
evaluated serum PFOA in C57Bl/6 and Balb/c pups, and as concentrations increased, C57Bl/6 
mice were shown to have much lower serum PFOA levels compared to Balb/c females (≥5 
mg/kg). While we are aware of the fact that concentration plays a major role in the depth of 
effects seen, our data further supports that the excretion rate for PFOA varies amongst mouse 
strain, and plays a significant role in whether or not PFOA affects the mammary gland at the 
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lowest doses tested. The fact that we saw adverse mammary changes in the CD-1 mice at 0.01 
and 0.1 mg/kg suggests that this strain is the most sensitive to prenatal PFOA exposures for 
mammary gland developmental delays.  
 Puberty demarks a pivotal window of susceptibility for environmental exposures and the 
development of endocrine regulated tissues in both humans and rodents. During this period of 
development, upstream pulsatile increases from gonadotropin releasing hormone trigger sex 
hormones, such as estrogen and progesterone, to circulate at higher concentrations. In turn, other 
downstream cues are prompted that result in the occurrence of VO (rodents) or first menarche 
(humans), sexual maturation and rapid mammary gland development. Early exposure to EDCs, 
however, can alter the timing at which these processes occur or alter the morphological 
development altogether resulting in the increased risk of development of adulthood diseases, 
such as breast cancer [21, 22]. Since the onset of puberty is highly influenced by sex hormones, 
we were also interested in measuring circulating estradiol and progesterone to determine whether 
PFOA contributed to altered levels. Progesterone is involved in developmental branching [15, 
16, 20] and estradiol has both paracrine and endocrine roles in mammary development [15, 16, 
20]. We collected all post-pubertal animals on the same stage of the estrous cycle (first day of 
estrus) to minimize variability and found no difference in serum estradiol or progesterone in 
either strain in response to PFOA exposure. These findings are both supported and contrasted by 
the work of Zhao et al. [20]. C57Bl/6 mice exposed to 5 mg/kg during adolescence/puberty had 
no change in serum estradiol, yet were reported to have increased levels of progesterone. In a 
follow up study using PFOA doses of 2.5 mg/kg in Balb/c or 7.5 mg/kg in C57Bl/6 the same 
group of researchers were unable to see significant changes in progesterone due to an inadequate 
number of controls in each stage of the estrous cycle; however, they reported a significant 
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decrease in ovarian protein levels of StAR, CYP11A1, HSD3β1, HSD17β1, aromatase and 
PPARα, which are all involved in the biosynthesis pathway. Taken together, it appears that 
circulating levels of hormones have little, if any, effect on PFOA-induced decreases in mammary 
branching density. Thus, while other endocrine disruptors have been shown to alter estradiol and 
progesterone levels at much lower doses, we postulate that PFOA may alter mammary branching 
density through other endocrine related mechanisms that are specific to the mammary gland.  
 Evaluation of vaginal cytology is also a valid tool to identify the effects of toxicants, 
toxins or xenobiotics on the hypothalamic-pituitary-ovarian axis in rodents. In mice, VO is 
thought to denote the onset of puberty and is heavily influenced by increases in serum estradiol; 
however, it doesn’t necessarily reflect the onset of sexual maturity. In the untreated CD-1 mouse 
VO typically occurs around PND 23, although normal timing to this event can vary in other 
mouse strains. Neither strain in our study exhibited changes in timing of either VO or first estrus 
following prenatal exposure to PFOA. Body weights were unchanged at the time of these events, 
as well (Table AII-4). Lau  et al. [13] have shown a 3 day delay for VO and first estrus at 10 
mg/kg following prenatal exposure, and consistent with our findings, the 1.0 mg/kg group 
showed no effect. Serum levels were not reported in their study but it was implied that increased 
PFOA serum levels in rodents result in greater pubertal delays. Although no differences were 
observed between treated and control animals, there were marked differences between the timing 
of VO and first estrus in CD-1 controls compared to C57Bl/6 controls. This observation has been 
previously noted [29]. Inbred strain comparisons at puberty showed that C3H and DBA animals 
began VO at approximately PND 22-24, whereas C57Bl/6 mice were around PND 27 [29]. 
C57Bl/6 mice were also the last to exhibit cornification in that 3-strain comparison. Our data 
supports these findings and reinforces the idea that even in non-treated animals there appears to 
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be differences in genetic profiles between strains that govern the timing of these occurrences. 
This innate difference may also influence windows of sensitivity to chemicals. Variability within 
the outbred CD-1 strain was also apparent within our vaginal cytology data and thus the reason 
for representing it in two separate blocks. The different seasons during which these blocks were 
tested could have contributed to these differences, as it has been noted that VO tends to occur 
earlier in rodents born during the summer months compared to those born during winter [38]. 
Our animals in block 1 were born in mid-summer whereas block 2 females were born during 
early winter. Body weights at VO in both blocks were similar indicating that our second block 
required additional time to achieve the body weight necessary to begin these events.  
 Serum PFOA levels were measured in our studies to determine the internal doses 
required for pubertal changes, such as mammary gland development, and also confirmed our 
lab’s previous findings that internal exposures were within the range of serum PFOA levels 
reported in humans living in contaminated areas of the U.S. Children in the Ohio River Valley 
have been reported to have geometric mean (GM) serum PFOA levels as high as 600 ng/ml [2] 
and more recently, reports demonstrated levels of PFOA in children aged 12-19 even within the 
general population (GM: 1.81 ng/ml) that are comparable to those found in adults aged ≥20 (GM 
2.12) [39]. Most noteworthy from these findings are the fact that our PND 21 serum 
concentrations from the 0.01 mg/kg treated groups in both strains fell within the serum range 
reported in male and female participants aged <12 years old from the C8 Science panel (GM 
34.8 ng/ml) [3]. PFOA levels were elevated in a dose dependent manner and were within the 
same range at PND 21 in both strains, and were detectable in the three highest treatment groups 
on the final collection date in each strain.  
292 
 
 Interesting correlations between potential rodent and adolescent health impact may be 
realized if the half-life of PFOA following exposure during gestation is compared. With a half-
life of about 3 years in humans, by the time prenatal exposure had gone through three half-lives, 
a child would be around 9 or 10 years old (average age for Tanner Stage II; [40]). Similarly, in 
the prenatally exposed mouse pup with a PFOA half-life of 6-7 days (as calculated from our 
data), three half-lives would equate to PND 18-21 days old, which is also the time that the 
mammary tissue begins to develop. While there haven’t been any reports that have directly 
linked PFOA exposure to breast developmental timing in girls, new evidence suggests that there 
may be a correlation. Higher serum PFOA levels were associated with the length of time that 6-8 
year old girls had been breastfed [41] and their source of water and serum PFOA concentrations 
were highly correlated. In another study [42], breastfed girl’s experienced delayed onset of breast 
development in comparison to formula fed girls and was even more exacerbated by the length of 
time that they were breastfed.  
 Girls living in the Ohio River Valley area reported increased delays (self-reported) to 
menarche within the measured concentration ranges that were observed in our 0.01 and 0.1 
mg/kg group. This may indicate a lack of concordance between rodents and humans for other 
pubertal indicator endpoints following PFOA exposure. It has been well documented that the 
mode of action for these pubertal endpoints [43] are fairly different between rodents and girls 
and that VO and time to first estrus in rodents may not be translatable indicators for puberty 
timing in girls.  
 While most of organogenesis occurs during embryonic development, the mammary gland 
undergoes most of its growth during puberty. Still, exposure to excessive amounts of hormones 
or EDCs too early in life can have a permanent effect on the developing gland. Because 
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mammary alterations were documented following early low dose PFOA exposures in our study 
and by others [23], without altering other pubertal endpoints or liver: body weight ratios, implies 
that the mammary gland may be the most sensitive tissue to the prenatal effects of PFOA. This 
can also be said for other chemicals in which the mammary gland has been studied. Early 
exposure to human relevant levels of endocrine disruptors in rodents has led to both accelerated 
(Bisphenol A) and delayed mammary gland growth (TCDD and atrazine) that have presented in 
the form of an extended presence of TEBs [44], increased stromal and epithelial tissue and 
sensitization to estradiol [45-47]. Some of those chemicals, as well as PFOA [23, 48], have 
adversely affected the lactational capacity of rodents to nourish their litters. Dams [48] and their 
F1 offspring [23] demonstrate abnormal lactating gland morphology, decreased pup weight, 
and/or altered milk protein gene expression following exposure to PFOA during pregnancy. 
Studies using slightly higher exposures of PFOA [49] have also shown that the developmental 
effects of prenatal exposure had long-lasting effects; increased stromal hyperplasia and 
disorganized, scant mammary epithelium were reported in 18 month old PFOA-exposed mice.  
 The hypothesized mode of action for some of these chemicals involves either direct or 
indirect alterations to key receptors, such as ERα, or their corresponding signaling pathways. At 
least within the mammary gland PFOA has been shown to not directly bind to the ERα, nor 
cause a stimulatory effect in ovariectomized animals [20]. PPARα knock-out mice exhibited 
mammary effects following a peripubertal exposure indicating that PPARα may not play a 
predominate role in the mammary gland changes observed after PFOA exposure as those seen in 
rodent livers [20]. Work by Macon and colleagues (in press) suggest that post transcriptional 
changes may play a role in the observed mammary changes [50]. Pparα and γ expression were 
decreased in microarray validation studies, however, only Pparγ protein levels were increased. 
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Additionally, Pparγ molecular weight shifts were also found in Westerns, leading the authors to 
propose phosphorylating modifications. The stroma may play an important role, as lipid 
metabolism genes were also found to be altered. Therefore, we conclude that during early PFOA 
exposures post- transcriptional modifications in the gland itself may be responsible for the 
altered epithelium and microenvironment. Also, since PFOA was still present in the serum 5 
weeks following weaning, as a result of a lactational exposure, the effects may have been 
compounded and the peripubertal mechanism suggested by Zhao et al. [20] may have also taken 
effect. Regardless of the mechanism behind the outcome, each of these chemicals, including 
PFOA, has the potential to significantly alter the glands normal development, thereby increasing 
the gland’s risk to further environmental insults.  
 The few studies that have tried to correlate breast cancer risks to perfluorinated chemicals 
(PFCs) found that in a Greenland Inuit cohort the PFC levels were linear to the cancer risks [51], 
while a Danish cohort reported weak significance [52]. Whether PFOA directly causes cancer 
still requires additional evaluation, however, the delayed phenotype that it creates in the rodent 
ultimately leaves the gland more susceptible to other harmful exposures. Because of the potential 
for increased lifetime susceptibility to disease or dysfunction, pubertal assessments of chemical 
effect performed in rodent models should include an evaluation of the mammary gland. This 
suggestion has recently been echoed by the scientific community [53, 54]. It will also be 
necessary to evaluate for changes in breast development based on early life or cord blood PFOA 
levels in future epidemiological studies. 
 Although PFOA production and use in the USA is scheduled to be phased out by 2015 
[55], its lasting effects may continue to be seen well after this time due to its persistence within 
the environment and long half-life in humans. Because PFOA exposure occurs throughout the 
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lifetime in humans, it may be necessary to continue monitoring heavily exposed populations to 
determine if later life diseases arise. These studies confirm that the mammary gland is highly 
sensitive to low dose prenatal PFOA exposure. Our findings suggest that measures should be put 
in place to limit PFOA exposures in sensitive populations, especially in pregnant women and 
prepubescent females. Decreased exposure could potentially minimize early life effects as well 
as those that may persist throughout life to reduce the mammary glands susceptibility for later 
life diseases and dysfunction.  
 
  
 
Table AII-1: PFOA Serum Concentrations in pubertal CD-1 and C57Bl/6 mice 
 
 
 
 
 
 
 
 
 
 
 
Data presented as the mean ± SEM 
The LOQ for all C57Bl/6 animals were <10 ng/ml. Significance observed in comparison to control; *p≤0.05. 
CD-1 n= 4-12 
C57Bl/6 n= 2-6  
 Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n) 
CD-1        
PND 21 <LOQ (6) 74.8 ± 16.9 (10) 457.3± 91.0 (9) 904.8 ± 131.5 (10) * 3119.0 ± 396.4 (5) ** 
PND 35 <LOQ (11) 14.3 ± 2.3 (12) 61.7 ± 6.5 (9) 200.9 ± 32.2 (11) * 889.8 ± 117.5 (11) ** 
PND 56 < LOQ (5) ND 15.0 ± 5.0 (4) 46.2 ± 7.5 (6) 200.2 ± 21.1 (7)** 
 
C57Bl/6     
PND 21 <LOQ (2) 26.1 ± 19.0 (1) 247.1 ± 11.4 (2) 891.3 ± 528.7 (3) 2141.67 ± 666.8 (2) 
PND 61 <LOQ (6) <LOQ (2) 27.7 ± 10.4 (3) * 9.3± 2.2 (5) 22.0 ± 7.6 (5) 
296 
  
 
Table AII-2: Body and Liver Weights of Pubertal female CD-1 mice 
Data are represented as Mean ± SEM 
Net Body Weight= Body weight (g) – Liver Weight (g) 
Relative Liver weight = Body weight (g)/Liver weight (g) 
Significance observed in comparison to control; *p≤0.05 
n= 8-22 
 
 
 
 
 Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n) 
Body Weight (g)        
PND 21 11.9 ± 0.2 (20) 12.1 ± 0.2 (22) 12.5 ± 0.3 (22) 11.6 ± 0.3 (22) 10.9 ± 0.2 (21) 
PND 35 23.1 ± 0.3 (17) 22.9 ± 0.5 (16) 23.0 ± 0.4 (14) 22.2 ± 0.3 (17) 21.8 ± 0.4 (16) 
PND 56 26.6 ± 0.8 (9) 27.7 ± 0.7 (14) 27.6 ± 0.2 (8) 25.69 ± 0.83 (4) 28.5 ± 0.7 (9) 
Net Body Weight (g)     
PND 21 11.3 ± 0.2 (19) 11.5 ± 0.2 (22) 11.9 ± 0.3 (22) 11.1 ± 0.3 (22) 10.3 ± 0.2 (21) * 
PND 35 22.0 ± 0.3 (17) 21.7 ± 0.4 (16) 21.9 ± 0.4 (14) 21.1 ± 0.3 (17) 20.7 ± 0.3 (16) * 
PND 56 25.2 ± 0.8 (9) 26.3 ± 0.7 (13) 26.3 ± 0.2 (8) 25.6 ± 0.5 (10) 27.1 ± 0.6 (9) 
Absolute Liver Weight 
(g)      
PND 21 0.60 ± 0.02 (19) 0.62 ± 0.02 (22) 0.61 ± 0.02 (22) 0.59 ± 0.02 (22) 0.62 ± 0.02 (21) 
PND 35 1.16 ± 0.03 (17) 1.14 ± 0.04 (16) 1.13 ± 0.04 (14) 1.13 ± 0.02 (17) 1.13 ± 0.04 (16) 
PND 56 1.36 ± 0.05 (9) 1.35 ± 0.04 (13) 1.29 ± 0.03 (8) 1.22 ± 0.02 (10) 1.36 ± 0.07 (9) 
Relative Liver     
PND 21 0.051 ± 0.002 (19) 0.051 ± 0.001 (22) 0.049 ± 0.001 (22) 0.051 ± 0.001 (22) 0.057 ± 0.001 (21) * 
PND 35 0.050 ± 0.001 (17) 0.050 ± 0.002 (16) 0.049 ± 0.002 (14) 0.051 ± 0.001 (17) 0.051 ± 0.001 (16) 
PND 56 0.052 ± 0.002 (9) 0.048 ± 0.003 (13) 0.047 ± 0.001 (8)  0.046 ± 0.001 (10) * 0.048 ± 0.001 (9) 
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Table AII-3: Body and Liver Weights of Pubertal female C57Bl/6 mice 
Data are represented as Mean ± SEM 
Net Body Weight= Body weight (g) – Liver Weight (g) 
Relative Liver weight = Body weight (g)/Liver weight (g) 
N= 2-9 
 
 
 
 
 
  
 Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n) 
Body Weight (g)        
PND 21 8.4 ± 0.4 (6) 8.6 ± 0.1 (4) 9.5 ± 0.9 (2) 8.2 ± 0.7 (5) 7.5 ± 0.3 (5) 
PND 61 19.1 ± 0.3 (9) 19.8 ± 0.3 (5) 20.1 ± 0.5 (3) 20.1 ± 0.4 (9) 19.9 ± 0.5 (8) 
Net Body Weight (g)     
PND 21 8.0 ± 0.4 (6) 8.3 ± 0.03 (4) 9.1 ± 0.9 (2) 7.9 ± 0.6 (5) 7.1 ± 0.3 (5) 
PND 61 18.2 ± 0.2 (9) 18.8 ± 0.3 (5) 19.2 ± 0.5 (3) 19.2 ± 0.3 (9) 19.0 ± 0.4 (8) 
Absolute Liver Weight (g)      
PND 21 0.37 ± 0.03 (6) 0.43 ± 0.04 (4) 0.45 ± 0.03 (3) 0.38 ± 0.03 (6) 0.39 ± 0.01 (5) 
PND 61 0.93 ± 0.02 (9) 0.97 ± 0.03 (5) 0.90 ± 0.05 (3) 0.95 ± 0.05 (9) 0.89 ± 0.03 (8) 
Relative Liver     
PND 21 0.044 ± 0.002 (6) 0.049 ± 0.004 (4) 0.048 ± 0.001 (2) 0.045 ± 0.001 (5) 0.052 ± 0.001 (5) 
PND 61 0.048 ± 0.001 (9) 0.049 ± 0.001 (5) 0.045 ± 0.002 (3) 0.047 ± 0.002 (9) 0.045 ± 0.002 (8) 
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Table AII-4: Assessment of Pubertal Events following prenatal PFOA exposures 
 
 
 
 
 
 
 
 
 
 
 
Data are represented as Mean ± SEM 
CD-1 n= 4-11 
C57Bl/6 n=3-7 
  
 Control 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n) 
CD-1 (Block 1)         
Vaginal Opening 22.8 ± 0.7 (8) 24.1 ± 0.7 (11) 23.8 ± 0.9 (7) 25.7 ± 0.6 (7) 23.9 ± 0.7 (10) 
First Estrus 25.1 ± 0.6 (8) 26.7 ± 0.7 (11) 26.1 ± 0.9 (7) 28.2 ± 0.6 (7) 26.3 ± 0.6 (10) 
CD-1 (Block 2)      
Vaginal Opening 28.2 ± 1.4 (4) 27.7 ± 1.1 (5) 28.8 ± 0.4 (5) 28.1 ± 1.4 (5) 26.6 ± 0.9 (4) 
First Estrus 28.8 ± 1.2 (4) 29.8 ± 1.2 (5) 28.9 ± 0.4 (5) 29.2 ± 1.4 (5) 29.1 ± 0.4 (4) 
C57Bl/6       
Vaginal Opening  31.7 ± 0.8 (7) 31.2 ± 0.4 (3) 29.9 ± 0.3 (3) 31.3 ± 0.7 (5) 31.6 ± 0.6 (5) 
First Estrus 33.6 ± 0.9 (7) 32.9 ± 0.1 (3) 31.9 ± 1.0 (3) 31.7 ± 0.7 (5) 32.4 ± 0.8 (5) 
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Table AII-5: Mammary Gland Developmental Scores 
 
 
 
 
 
 
 
Data are represented as Mean ± SEM 
Significance observed in comparison to control; * p≤0.05, ** p≤0.01, *** p≤0.001 and  
**** p ≤0.0001. CD-1 n= 8-19 and C57Bl/6 n=2-10 
 
 Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n) 
CD-1         
PND 21 2.9 ± 0.1 (19) 2.4 ± 0.1 (22) 2.3 ± 0.1 (22)** 2.0 ± 0.1 (21)*** 1.7 ± 0.1 (21)**** 
PND 35 3.1 ± 0.1 (16) 2.3 ± 0.2 (17)** 2.2 ± 0.2 (14)** 2.3 ± 0.1 (16)** 1.9 ± 0.2 (14)**** 
PND 56 3.3 ± 0.1 (9) 2.3 ± 0.2 (13)** 2.5 ± 0.2 (8)* 2.2 ± 0.1 (10)** 1.9 ± 0.2 (9)**** 
     
C57Bl/6     
PND 21 2.9 ± 0.2 (7) 2.5 ± 0.4 (5) 2.1 ± 0.7 (2) 1.8 ± 0.3 (6)* 1.8 ± 0.2 (5)* 
PND 61 2.8 ± 0.2 (10) 2.2 ± 0.2 (5) 2.6 ± 0.1 (3) 2.1 ± 0.1 (10)* 1.7 ± 0.1 (8)*** 
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Figure AII-1: Effects of PFOA treatment on serum hormone levels. A) estradiol B) progesterone 
levels. All animals were sacrificed during estrus, with the exception of PND 21 when vaginal 
opening had not occurred. CD-1 litter/treatment group n=12-15 (PND 21), n=9-10 (PND 35) and 
n=8-10 (PND 56). C57Bl/6 litter n= 3-4 (PND 21) and n=3-9 (PND 61). Data presented as the 
mean ± SEM.  
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Figure AII-2: Whole mount assessment of early and late pubertal glands in CD-1 offspring. 
Representative image of control A) PND 21, F) PND 35, and K) PND 56, 0.01 mg/kg B) PND 
21, G) PND 35 and L) PND 56, 0.1 mg/kg C) PND 21, H) PND 35 and M) PND 56 0.3 mg/kg 
D) PND 21, I) PND 35 and N) PND56 and 1.0 mg/kg E) PND 21, J) PND 35and O)PND 56. 
CD-1 n= 4-11 litters/treatment group. 
 
  
 303 
 
Control 0.3 mg/kg 0.1 mg/kg 1.0 mg/kg 0.01 mg/kg 
A B C D E 
J F G H I 
PN
D
 6
1
PN
D
 2
1
 
Figure AII-3: Whole mount assessment of early and late pubertal glands in C57Bl/6 offspring. 
Representative image of  control A) PND 21 and F) PND 61, 0.01 mg/kg B)PND 21 and G) PND 
61, 0.1 mg/kg C) PND 21 and  H) PND 61, 0.3 mg/kg D) PND 21 I) PND 61 and 1.0 mg/kg E) 
PND 21 and J) PND 61. C57Bl/6  n=2-10 litters/treatment group. 
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APPENDIX III 
Table AIII-1. Premature animal deaths  
DOB ID Chemical Dose (mg/kg) Date Found Age Necropsy Findings/Cause of Death 
8/16/2013 8253 BPS 5 9/20/2014 13 mos. 
 8/16/2013 8257 BPS 0.5 9/19/2014 13 mos. 
 8/16/2013 8211 BPA 50 8/21/2014 12 mos. 
 8/16/2013 BPA 5 mg BPA 5 8/21/2014 12 mos. 
 8/16/2013 8266L BPS 0.05 1/13/2014 5 mos. 
 8/16/2013 8229 or 8231 BPAF 5 1/12/2014 5 mos. 
 8/16/2013 8206 Vehicle 0 5/30/2014 9 mos. 
 8/16/2013 8215 BPA 5 7/25/2014 11 mos. Opaque calcification throughout abdominal cavity 
8/16/2013 8226 BPA 0.5 7/15/2014 11 mos.  
8/16/2013 8205 or 8206 Vehicle 0 7/15/2014 11 mos. 
 
  
  
   DOB ID Chemical Dose (mg/kg) Date Found Age  
9/6/2013 8336R BPAF 0.5 9/24/2014 12 mos. 
 9/6/2013 8334L BPAF 5 9/26/2014 12 mos. 
 9/6/2013 8338L BPAF 0.5 8/15/2014 11 mos. 
 9/6/2013 8335 BPAF 5 8/25/2014 11 mos. 
 9/6/2013 No Info - - 9/26/2014 12 mos. 
 9/6/2013 8217 BPA 5 4/23/2014 7 mos. 
 9/6/2013 No Info - - 12/28/2013 3 mos. Fighting 
9/6/2013 No Info - - 4/1/2014 6 mos. 
 9/6/2013 8321B BPA 5 1/21/2014 4 mos. 
 9/6/2013 8362 BPS 0.5 8/7/2014 11 mos. 
 9/6/2013 8359RR BPS 0.5 3/14/2014 6 mos. Hepatosplenomegaly 
During the course of the study some animals from each block prematurely died and were not necropsied in time to determine cause of death or 
retrieve tissue due autolysis. These animals were not used in analysis involving the mammary gland, hormone, or hormone levels. They may have 
been used in pubertal timing endpoints (VO, estrus and cyclity). (-) no information was provided in animal health report.  
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